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Abstract: Zwei computerunterstützte Zugänge zum Studium von Modellproteinen werden vorgestellt:
Molekulares Docken zur Wirkstoffentwicklung und Moleküldynamik (MD)- Simulationen von Amyloid-
peptiden. Die Implementierung einer Hybridprozedur zum Absuchen des Konformationsraumes eines Lig-
anden verbessert die Qualität der Vorhersagen beim Docken deutlich bei geringer Rechenzeitzunahme.
Diese Prozedur wird verwendet, um grosse Bibliotheken von Verbindungen nach potenten Inhibitoren
der ￿-Sekretase zu durchsuchen; für einige Verbindungen wurde dann eine in vitro Aktivität im unteren
mikromolaren Bereich gemessen. Die Resultate der MD- Simulationen zeigen, dass es möglich ist, die
ersten Schritte der Amyloidaggregation bei physiologischen Temperaturen durch Verwendung von replica
exchange MD und impliziter Solvatation zu untersuchen. Im Einklang mit den Experimenten vermag der
nematische Ordnungsparameter die Tendenz zur ￿-Aggregationsbildung in korrekter Weise vorherzusagen
und amyloidogene von löslichen Peptiden zu unterscheiden. Dies hat zu einer neuen, generell anwend-
baren Methode zur Untersuchung der Aggregationseigenschaft von amyloidogenen Proteinen geführt.
Es zeigt sich, dass die ￿-Aggregationstendenz sehr heterogen ist mit Maxima (hot spots) und Minima
entlang der Sequenz der Proteine Amyloid ￿-Peptid, Amylin und der N-terminalen Domäne des Hefe-
Prions Ure2p. Zuletzt wird diese Methode verwendet, um eine Doppelmutante mit einer geringeren
￿-Aggregationstendenz zu generieren. Two computational approaches to study the behaviour of model
proteins are presented: molecular docking for drug discovery and molecular dynamics (MD) simulations
of amyloid peptide aggregation. In docking, the recognition between the receptor and the organic com-
pounds is mimicked by a simplified energy model and a searching procedure. The implementation of a
”hybrid procedure” to search the conformational space of the ligand is shown to improve the quality of the
predictions at a moderate additional computational cost. The strategy is applied to screen large libraries
of compounds against ￿-secretase and low-micromolar in vitro activity has been measured for several
molecules. The MD results show that it is possible to investigate the early steps of amyloid aggregation
at physiological temperatures by using replica exchange MD and an implicit treatment of the solvent.
In agreement with experimental data, the nematic order parameter correctly predicts the ￿-aggregation
propensity of a peptide sequence and discriminates amyloidogenic from soluble peptides. This has lead
to a novel approach to investigate the aggregation properties of amyloid polypeptides. The ￿-propensity
along sequence of the amyloid-￿ peptide, the human amylin, and the N-terminal domain of the yeast prion
Ure2p is found to be highly heterogeneous with maxima (aggregation hot spots) and minima. In the last
application, the approach is used to design a double-point mutant with lower ￿- propensity.
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Summary
Proteins are complex, high molecular weight organic compounds in-
volved in the most diverse and fundamental processes of the living organ-
isms. To carry out their function, proteins have to fold into a unique three-
dimensional structure, called the “native” state, that is exclusively deter-
mined by the amino acid sequence. The “native” state is the translation
of the genetic information and represents the meaning of the sequence in
the language of proteins. The statistical mechanic view of protein folding
describes the folding reaction as a diffusion of an ensemble of polypeptide
chains on a funnel-like energy landscape. Within this framework, the com-
plete description of the free-energy landscape of individual proteins repre-
sents a synthetic way to describe both thermodynamic and kinetic aspects of
protein folding and opens the way toward the breaking of the “protein code”.
Despite continuous development of innovative experimental techniques, the
determination of complete free-energy surfaces of individual proteins is not
yet feasible. Only the synergy between experimental and computational
strategies can supply information at the desired level of detail. Compu-
tational approaches to simulate the behavior of model proteins at atomic
resolution (in silico experiments) can be invoked. In the present thesis two
in silico experiments are presented: molecular docking for drug discovery
and amyloid peptide aggregation.
In molecular docking, the “virtual experiment” aims at the identifica-
tion of molecules able to bind the key regions of pharmacologically relevant
enzymes or macromolecules with high affinity and selectivity. The com-
putational approach mimics the molecular recognition between the target
receptor and small organic compounds on a computer by means of a sim-
plified energy model and a searching procedure. In this thesis, an improved
version of the fragment-based flexible ligand docking approach SEED-FFLD
developed in house is presented. The implementation of a “hybrid proce-
dure” to search the conformational space of the ligands significantly im-
proves the quality of the SEED-FFLD docking predictions at a moderate
additional computational cost. The docking strategy is tested on highly
flexible inhibitors of the human immunodeficiency virus type 1 protease,
human α-thrombin and the estrogen receptor β. The docking results indi-
cate that it is possible to correctly reproduce the binding mode of inhibitors
with more than ten rotatable bonds if the strain in their covalent geometry
(i.e., its bond angles and lengths) upon binding is not large. Hence, for
docking a limited set of compounds, strategies that allow for full flexibility
of the ligand, though computationally very expensive, should be preferred.
Thanks to the methodological development, the in-house docking procedure
has been recently applied to screen large libraries of compounds against
β-secretase, a very difficult target involved in Alzheimer’s disease. Remark-
ably, low-micromolar activity was measured in vitro for several compounds
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suggested by the docking procedure.
In the study of amyloid peptide aggregation, the ultimate goal of the
in silico experiment is to simulate fibrilization within a sample of amyloid
proteins and determine the complete free-energy surface for the oligomeric
system. The atomic detail of the simulation could provide a complete struc-
tural description of the molecular intermediates along fibrilization, which
are believed to be the most cytotoxic species. In vitro fibril formation is
a rather slow process and dependently on amyloid protein sequence may
take from several minutes to days. Such timescales are never accessible
by standard computer simulations. Moreover, amyloidogenesis is intrinsi-
cally cooperative and therefore several aggregating units must be included
in the model, thus dramatically increasing the possibility of statistical er-
rors. In the present thesis, the simulation results show that it is possible to
investigate the early steps of amyloid aggregation at physiologically relevant
temperature values by using efficient sampling procedures and simplified
energy models, such as the replica exchange molecular dynamics (REMD)
approach and an implicit treatment of the solvent. In agreement with ex-
perimental evidence, it has been shown that the nucleation process, i.e., the
formation of amyloid nuclei, can be interpreted as a condensation stage to-
ward disordered aggregates followed by an order transition. Therefore, the
simulation results were analyzed with two order parameters borrowed from
liquid crystal theory. Interestingly, it has been observed that the nematic
order parameter P2 averaged over the canonical ensemble effectively esti-
mates the β-aggregation propensity of a peptide system and discriminates
amyloidogenic from soluble peptides in agreement with the experiments.
From this operational definition of β-aggregation propensity, a novel in sil-
ico approach to investigate the aggregation properties of amyloid polypep-
tides has been derived. A novel strategy has been also designed to predict
the position dependence of the β-aggregation propensity along the protein
sequence, thus highlighting possible amyloidogenic stretches (the aggrega-
tion hot-spots). The β-aggregation propensity along the sequence of the
Alzheimer’s amyloid-β peptide has been investigated by multiple molecular
dynamics simulations of oligomeric systems of 7- and 11-residue segments
for a total of 0.31 milliseconds. The β-aggregation propensity is found to be
highly heterogeneous with a maximum in the segment V12HHQKLVFFAE22 and
minima at S8G9, G25S26, G29A30, and G38V39 which are turn-like segments.
Similar findings are obtained for the human amylin, a 37-residue peptide
which displays a maximal β-aggregation propensity at Q10RLANFLVHSSNN22
and two turn-like sites at G24A25 and G33S34. In the last application, the MD
approach is used to identify β-aggregation hot-spots within the N-terminal
domain of the yeast prion Ure2p (Ure2p1−94) and to design a double-point
mutant (Ure2p-N4748S1−94) with lower β-aggregation propensity.
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Zusammenfassung
Proteine sind komplexe organische Verbindungen von hohem Moleku-
largewicht, die an den unterschiedlichsten und fundamentalsten Prozessen
lebender Organismen beteiligt sind. Um ihre Funktion auszuu¨ben, mu¨ssen
sich Proteine in eine eindeutige dreidimensionale Struktur falten, den soge-
nannten nativen Zustand, welcher einzig und allein durch die Aminosa¨ure-
sequenz eines Proteins bestimmt ist. Der native Zustand ist die U¨bersetzung
der genetischen Information und entspricht der Bedeutung der Sequenz in
der Sprache der Proteine. Aus Sicht der statistischen Mechanik entspricht
die Faltungsreaktion einer Diffusion eines Ensembles von Polypeptidketten
auf einer trichtera¨hnlichen Energielandschaft. In diesem Zusammenhang
stellt die vollsta¨ndige Beschreibung der freien Energielandschaft eines Pro-
teins eine effektive Art dar, die thermodynamischen und kinetischen As-
pekte der Proteinfaltungsreaktion zu beschreiben und o¨ffnet den Weg zum
Knacken des ”Proteincodes”. Trotz stetiger Entwicklung von innovativen
experimentellen Techniken kann die vollsta¨ndige freie Energielandschaft zur
Zeit fu¨r kein einziges Protein bestimmt werden. Einzig die Synergie zwischen
experimentellen und computergestu¨tzten Strategien kann die Information im
gewu¨nschten Detail liefern. Computergestu¨tzte Simulationen des Verhaltens
von Modellproteinen in atomarer Auflo¨sung ko¨nnen dazu herangezogen wer-
den (in silico Experimente). In dieser Doktorarbeit werden zwei solcher in
silico Experimente vorgestellt: Molekulares Docken zur Wirkstoffentwick-
lung und die Aggregation von Amyloidpeptiden.
Im ersten Fall ist das Ziel der ”virtuellen” Experimente die Identifizierung
von Moleku¨len, die mit hoher Affinita¨t und Selektivita¨t an Schlu¨sselregionen
von pharmakologisch relevanten Makromoleku¨len binden. Der computer-
gestu¨tzte Ansatz stellt am Computer die molekulare Erkennung zwischen
anvisiertem Rezeptor und kleinen organischen Moleku¨len durch die Verwen-
dung von vereinfachten Energiemodellen und eines Suchverfahrens nach.
In dieser Doktorarbeit wird eine verbesserte Version des auf Fragmente
basierenden Ansatzes zum Docken von flexiblen Liganden namens SEED-
FFLD vorgestellt, welcher in unserer Forschungsgruppe entwickelt wurde.
Die Implementierung einer Hybridprozedur aus lokaler Suche und geneti-
schem Algorithmus zum Absuchen des Konformationsraumes eines Ligan-
den, verbessert die Qualita¨t der SEED-FFLD Vorhersagen deutlich bei nur
begrenzter Rechenzeitzunahme. Diese Strategie zum Docken ist an ex-
trem flexiblen Inhibitoren der Protease des menschlichen Immunschwa¨che-
Virus Typ 1, des menschlichen α-Thrombins und des O¨strogenrezeptors
β getestet worden. Die Resultate weisen darauf hin, dass es mo¨glich ist,
den Bindungsmodus von Inhibitoren mit mehr als zehn rotierbaren Bindun-
gen korrekt zu reproduzieren, falls die intramolekulare Spannung des In-
hibitors beim Binden nicht zu stark zunimmt. Aus diesem Grund sollten
fu¨r das Docken von einer begrenzten Zahl von Verbindungen Strategien
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bevorzugt werden, die eine vollsta¨ndige Flexibilita¨t der Liganden vorausset-
zen, ungeachtet der Rechenzeitzunahme. Dank der Weiterentwicklung der
Methode konnte unsere Prozedur zum Docken vor Kurzem benutzt werden,
um grosse Bibliotheken von Verbindungen nach mo¨glichst guten Inhibitoren
der β-Sekretase durchzusuchen - ein Enzym, das in der Alzheimerschen
Krankheit eine wichtige Rolle spielt und eine grosse Herausforderung an un-
sere Wirkstoffentwicklungstrategie darstellt. Bemerkenswerterweise wurde
fu¨r drei der von unserer Dock-Prozedur vorgeschlagenen Verbindungen eine
in vivo Aktivita¨t im unteren mikromolaren Bereich gemessen.
Das Ziel des zweiten in silico Experiments ist es, die Aggregation eines
Ensembles von Amyloidproteinen zu simulieren und die vollsta¨ndige freie
Energielandschaft dieses Systems zu bestimmen. Die atomare Auflo¨sung
dieser Simulationen ermo¨glicht eine vollsta¨ndige Beschreibung der Struktur
der wa¨hrend der Bildung von Fibrillen auftretenden molekularen Zwischen-
produkte, welche fu¨r die am meisten zytotoxischen Spezies gehalten wer-
den. Die in vitro Bildung von Fibrillen ist ein langsamer Prozess, der,
je nach Amyloidproteinsequenz, von einigen Minuten bis hin zu ganzen
Tagen dauern kann. Solche Zeitskalen liegen in keiner Weise im Bereich
von gewo¨hnlichen Computersimulationen. Ausserdem ist die Amyloidoge-
nese ein intrinsisch kooperativer Prozess und das Modell muss daher einige
aggregierende Einheiten enthalten, was jedoch die Wahrscheinlichkeit vom
Auftreten von statistischen Fehlern dramatisch erho¨ht. Die Simulations-
resultate, die in dieser Doktorarbeit vorgestellt werden, zeigen, dass es
mo¨glich ist, in silico die ersten Schritte der Amyloidaggregation zu un-
tersuchen, wenn effiziente ”sampling”-Methoden und vereinfachte Energie-
modelle, wie z.B. der sogenannte ”replica exchange molecular dynamics”-
Ansatz und die implizite Behandlung des Lo¨sungsmittels, verwendet werden.
Im Einklang mit experimentellen Daten konnte gezeigt werden, dass der
Nukleationsprozess, d.h. die Bildung des Amyloidkerns, als Kondensation
zu ungeordneten Aggregaten interpretiert werden kann, welche von einem
Ordnungsu¨bergang gefolgt wird. Die Simulationsresultate wurden daher
mittels zweier Parameter analysiert, die der Flu¨ssigkristalltheorie entlehnt
worden sind. Interessanterweise wurde beobachtet, dass der Mittelwert
des nematischen Ordnungsparameters P2 u¨ber das kanonische Ensemble die
Tendenz von Peptidsystemen β-Aggregate zu bilden auf effektive Art und
Weise abzuscha¨tzen vermag und, im Einklang mit experimentellen Daten,
amyloidogene von lo¨slichen Peptiden unterscheiden kann. Ausgehend von
der in silico Definition der β-Aggregationstendenz wurde ein neuer Ansatz
zur Untersuchung der Aggregationseigenschaften von amyloidogenen Pro-
teinen entwickelt. Die Strategie wurde so ausgelegt, dass Vorhersagen u¨ber
die Positionsabha¨ngigkeit der β-Aggregationstendenz entlang der Proteinse-
quenz mo¨glich sind und so eventuell vorhandene amyloidogene Segmente
ausfinding gemacht werden ko¨nnen. Die β-Aggregationstendenz entlang
der Sequenz des Alzheimerschen Amyloid β-Peptids ist (Aβ42) in mehreren
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Moleku¨ldynamiksimulationen - insgesamt 0.31ms Simulationszeit - von oligo-
meren Systemen von 7 und 11 Reste langen Segmenten untersucht wor-
den. Die β-Aggregationstendenz ist sehr heterogen mit einem Maximum im
Segment V12HHQKLVFFAE22 und mehreren Minima an den Positionen S8G9,
G25S26, G29A30, und G38V39. Letztere entsprechen schleifena¨hnlichen Seg-
menten. A¨hnliche Befunde werden fu¨r das menschliche Amylin beobachtet.
Amylin ist ein Peptid bestehen aus 37 Aminosa¨uren, das eine maximale
β-Aggregationstendenz fu¨r das Segment Q10RLANFLVHSSNN22 und die zwei
schleifena¨hnlichen Positionen G24A25 und G33S34 aufweist. Als letzte An-
wendung wurde der Moleku¨ldynamikansatz verwendet, um sogenannte hot
spots fu¨r die β-Aggregation in der N-terminalen Doma¨ne des Hefe-Prions
Ure2p (Ure2p1−94) zu identifizieren, und um die Doppelmutante (Ure2p-
N4748S1−94) mit einer geringeren β-Aggregationstendenz zu generieren.
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Chapter 1
Introduction
1.1 Protein Molecules
Proteins (in Greek piρωτνη = first element) are complex, high molecular
weight organic compounds essential to the structure and function of living
organisms. Chemically speaking, they are linear polymers of the same type,
built of various combinations of 20 building blocks, i.e., the natural amino
acids, and they differ only in the sequence in which the blocks are assem-
bled and the length of the polymeric chain. Hence, proteins constitute a
relatively homogeneous class of molecules. Despite the apparent simplicity
of their chemical structure, proteins are involved in the most diverse and
fundamental biological processes. Some of them, called enzymes, act as bio-
logical catalyzers and permit the occurrence of essential chemical reactions
under physiological conditions (i.e., aqueous solution, 37◦C, pH 7, atmo-
spheric pressure). Some others store and transport a variety of particles
ranging from macromolecules to electrons, transmit information between
specific cells and organs, control the passage of molecules across the cellular
compartments, defend the organism against intruders (antibodies), convert
chemical energy into mechanical energy and control gene expression. Thus,
if we aspire to understand how living organisms function, then we must first
understand the behavior of proteins. In order to carry out their biologi-
cal function, proteins have to fold into a unique three-dimensional structure
(called the “native” state) which is exclusively determined by the amino acid
sequence [1]. The “native” state of a protein is the translation of the genetic
information encoded in the sequence and from a semantic point of view, it
represents the meaning of the sequence in the language of proteins. In such a
fascinating language, the 20 amino acids are the letters of the alphabet and
the naturally occurring sequences “meaningful” words and sentences. The
semantic interpretation of the amino acid sequence is rather intuitive and
provides a simple description of most of the known properties of proteins
(see Fig. 1.1). As in any language, for example, only certain combinations
of letters are meaningful whereas random or incomplete strings often convey
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gibberish (a). Words and sentences have a sequence directionality which al-
lows them to be decoded (b) and they incorporate a certain robustness that
prevents them from being misunderstood even in case of accidental errors
(c). Moreover, sharing common portions (substrings) strings and sentences
can bring completely different messages (d). A few, instead, are degenerate
and potentially own multiple meanings which depend on the local context
(e). Finally, diverse strings with non detectable sequence identity share sim-
ilar significance and can be alternatively used in the same context (f).
IOMID
ODIIM
OIODM
IDIOM
DOMII
a) Meaningful sequences c)
e)
There’s no sense in it.
Education in its broadest sense.
Dogs have a keen sense of smell.
Sense
d)
ANIM
ANIM
ANIM
ANIM US
AL
ATION
ISTIC
Common substrings f)
Under/Beneath
Big/Large
Proteins are linear polymers.
s are linear polymers.Proteim
Proteims are liniar polymers.
Proteims are liniar polimers.
Prateims are liniar polimers.
Intrinsic robustness
Multiple meanings
b) Sequence directionality
ACID
ANIMAL
PROTEIN NEITORP
LAMINA
DICA
Synonym
Fig. 1.1: The semantic interpretation of protein sequences
All these properties are common to protein sequences. The latest re-
lease of the TrEMBL database (release 46.5, April 2005) contains 1,662,660
(∼ 106) unique protein sequences. Considering an average length of 200
residues per sequence, the total number of possible amino acid combina-
tions is 20020 (∼ 1046). Despite the rough estimate, this difference of 40
orders of magnitude indicates that naturally occurring sequences are a tiny
minority (a). Retro protein-folding experiments have revealed that retro
proteins are no more similar to their parent sequences than random se-
quences, despite having the same amino acid composition [2] (b). The
biological function of a protein has been shown to be more correlated to
the macromolecular geometry than to chemical detail [3]: when the global
three-dimensional structure and the active site of a protein are conserved,
considerable modifications of the sequence can be made without any loss of
function (c). Despite sharing short to medium sized subsequences, many of
these proteins do not present common folds nor do they accomplish similar
tasks (d). Certain sequences, like those from amyloidogenic proteins such
as transthyretin, the prion protein (PrP) and the human lysozyme, code
for folded structures with a high conformational plasticity that allows them
to refold into a stable “non-native” conformation under physiological con-
ditions. The information encoded is therefore degenerate and corresponds
to different “meanings” depending on the local context (e). Finally, protein
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structures are much more conserved than protein sequences [4]. Therefore,
sequences with low or non-detectable similarity can still promote the same
fold (f).
The semantic interpretation of the amino acid sequence suggests that
proteins are encoded in a proper language, the interpretation of which would
lead to an outstanding result: the solution of the mysteries of life and evo-
lution. If the language could be deciphered, in fact, the still missing link
between “protein sequence” and “specific function” would be discovered,
thus opening the way towards the understanding of biological processes at
atomic level. Molecular details of abnormal processes associated with severe
pathologies could be finally unveiled and highly specific and bio-compatible
molecules could be designed to deal with them. The breaking of the “protein
code” would promote the development of efficient strategies for treating and
preventing human disorders by means of drugs able to speak the language of
the pathogens. Unfortunately, the decoding process is far from trivial and
although the ultimate goal is very appealing, the “protein language” has not
yet been deciphered.
Protein
Sequence
Protein
Structure Activity
Biological
protein folding
DNA
Fig. 1.2: From protein sequence to protein function
As proteins must fold to fulfill their biological function, the relation be-
tween the amino acid sequence and the biological activity is clearly mediated
by the “native state”, the structure designed by evolution for the particular
task. Hence, to speak the language of proteins, i.e., to be able to develop
effective therapeutic strategies for treating human diseases, one must first
understand the link between protein sequences and protein structures: the
“protein folding” problem (see Fig. 1.2).
Protein Folding
Under physiological conditions, proteins fold to the native state rapidly and
reliably. To this purpose, protein sequences must satisfy two requirements:
one “kinetic” and one “thermodynamic”. The thermodynamic requirement
is that the three-dimensional structure of a protein in its physiological mi-
lieu (solvent, pH, ionic strength, presence of other components such as metal
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ions or prosthetic groups, temperature, etc.) corresponds to the global min-
imum of the Gibbs free energy. The kinetic requirement is that the dena-
tured polypeptide chain folds into the native conformation in a reasonable
amount of time. Given the huge number of degrees of freedom involved,
satisfying the kinetic requirement is not trivial. Even assuming only three
permissible configurations per residue, a medium sized chain of 100 amino
acids would be able to assume 3100 (∼ 1047) different conformations in solu-
tion. If only 10−11s were required to convert from one conformation into an-
other, the complete search of the conformational space would require about
1028 years [5]. Nevertheless, most proteins reach their native state in the
timescale of seconds or minutes. This puzzling inconsistency, better known
as the “Levinthal’s paradox”, has slowed down the understanding of protein
folding until a new era of experiments has shed light on the early events of
the process at atomic resolution. Thanks to great advances in both experi-
ments and theory, the classical “macroscopic” view of protein folding based
on simple phenomenological models was substituted by a “new view” that
describes folding as a statistical mechanics process. Macroscopic states of
the folding reaction (the folded, unfolded and intermediate states) have been
interpreted in terms of ensembles of individual conformations (microstates)
and the pathway concept of sequential events have been replaced by the
funnel concept of parallel events. In the new view, the folding process is
not described by the trajectory of a single molecule on a shallow surface
(Fig. 1.3, b) but by the diffusion of an ensemble of asynchronous chains on
a funnel-like energy landscape (Fig. 1.3, c). Or quoting K.A. Dill:
“During folding, the individual chains move on the funnel surface
and ultimately find their ways to the same native structure in
the same way that water flowing along different routes down a
mountainside can ultimately reach the same lake at the bottom.”
The new view of protein folding uses the concept of “free-energy surfaces”
and “folding funnels” to describe the folding reaction. These concepts cap-
ture the deep essence of the problem and interpret the universality of the
folding mechanism despite substantial differences among proteins. In partic-
ular, the interpretation of folding via free-energy surfaces provides a concise
and useful framework for studying such complex systems. Considering pro-
tein folding as a chemical reaction, the free-energy surface is the analogue to
the potential energy surface (PES) for simple chemical reactions [7]. In the
latter case, the PES describes the energy of interaction of the atoms involved
as a function of their position and provides the complete description of both
thermodynamics and kinetics of the reaction. A detailed knowledge of the
PES and the laws of dynamics enable the calculation of the trajectories along
which molecules move from reactants to products, the identification of the
transition state and the intermediates along the reaction pathways and the
determination of the overall rate constant [8, 9]. By analogy, a complete
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(b)(a) (c)
Fig. 1.3: Energy landscapes for protein folding: the Levinthal “golf-course”
(a), the “pathway” solution to the search problem (b) and the rugged funnel
with kinetic traps, barriers and narrow paths to the native state (c). N is
the native conformation. (Adapted from Dill and Sun Chan [6].)
description of the free-energy surface of a protein can provide the same in-
formation for the folding reaction. However, protein folding is a complex
process which involves a large number of degrees of freedom. Thus, the
relative free energy surface has a multidimensional character and includes a
multitude of local minima and transition regions. To obtain a meaningful
description of the accessible states and energetic barriers of the system, a
suitably defined progress variable has to be chosen. The projection of the
free-energy on to the progress variable, the value of which is obtained by
averaging over non-essential degrees of freedom, provides a simplified but
rather intuitive view of the mechanism which still accounts for the complex-
ity of the process, i.e., the existence of intermediate species “on” and “off”
the folding pathway, with the latter responsible for the heterogeneity of the
folding rates.
Indeed, free-energy surfaces are extremely valuable and their complete
description provides a unique tool for understanding the determinants of
many aspects of protein behavior including the stability of the native state,
the kinetics for folding and the mechanism of misfolding. They represent
a quantitative link between protein sequence and biological activity and
help in decoding the “language” of proteins. Experimentally, the complete
determination of free-energy surfaces for individual proteins is not feasible
yet, despite the continuous development of innovative techniques. Nowa-
days, only the synergy between experimental and computational strategies,
here referred to as in silico experiments, can provide the description of free-
energy landscapes at the desired detail. The relevance of computational
approaches to the comprehension of the language of proteins and their high
complementarity with experiments are discussed in the next section.
14
Whilst waiting for further progress in the interpretation of the protein
language, effective therapeutic strategies for treating human diseases can
be developed by focusing on the specific activity of proteins. Once a phar-
macologically relevant target has been identified, small molecules, that are
able to bind to its key or “active” regions and to hinder its biological func-
tion, can be researched. This alternative approach does not require any
knowledge of the folding mechanism and has proved very effective especially
when the three-dimensional structure of the target is available. In this field,
the synergy between experimental and computational strategies is very well
established and even “only-for-profit” pharmaceutical companies routinely
follow mixed procedures to discover new effective drugs. In particular, when
the crystal structure of the target is known, structure-based in silico exper-
iments can be designed to mimic the protein-ligand molecular recognition
patterns and estimate the binding affinities of electronic libraries of com-
pounds in a very fast and cheap way. A basic framework for computational
procedures used for “drug discovery” is also presented in the next sections.
1.2 In silico Experiments
Experimental Background
Thanks to recent advances in experimental techniques, substantial progress
has been made towards the understanding of the mechanisms lying behind
the structure and function of proteins. In particular, the determination
of three-dimensional structures of proteins and protein complexes by X-
ray crystallography and NMR spectroscopy has provided essential insights,
i.e., the location of the active site, information on the catalytic mechanism
and the possible conformational changes. Examples of recent spectacular
achievements include the determination of the structure of F1-ATPase [10],
the proteasome [11] and the ribosome [12, 13]. Although the total number of
solved structures (31,059 entries currently stored in the PDB database, May
2005) is continuously increasing, this number represents “only” about 2%
of all known protein sequences. Very accurate X-ray and NMR experiments
are, in fact, time consuming, not always successful and require a lot of
human expertise. In addition, their applicability is limited to some extent.
Moreover, both methods provide “only” a static picture of the problem, thus
neglecting not only important aspects of protein behavior involving non-
native structures [14] but also internal motions of the protein that are crucial
for the biological activity. Indeed, to capture these aspects, an accurate
description of the overall protein dynamics is required.
To this purpose, novel applications of established experimental tech-
niques have been tried to monitor the structural rearrangements of a polypep-
tide chain. However, it is never straightforward to obtain information at
atomic detail. To increase data resolution, mixed techniques have been pro-
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posed, which monitor different structural aspects at the same time. A good
example is the combined usage of far- and near-UV circular dichroism (CD):
while the former approach determines the average content of the secondary
structure, the latter monitors the packing of aromatic side-chains. Mixed
methods have provided a more global, though not yet complete, description
of protein conformational changes during folding [15].
The time resolution of the experiment is another problematic aspect.
Approaches limited to events on the millisecond range or longer, such as
standard CD, are not suitable to monitor rapid structural changes occurring
on nano to microsecond timescales. The development of novel methods
based on fluorescence and infrared sprectoscopy (IR) have extended the
range of available time-windows and successfully probed the early events in
protein folding [16, 17].
In a folding reaction, a highly heterogeneous ensemble of molecules, that
differ substantially in their structure and dynamics, is involved. For such
systems, characterized by a stochastic behavior, it is impossible to detect
the dynamics of individual molecules by ensemble-averaged measurements.
Therefore, standard experimental techniques cannot provide accurate in-
formation concerning molecular states (local minima of the free-energy sur-
face), especially far away from the native one. To overcome these difficulties,
novel techniques called SMD methods (single-molecule detection), have re-
cently been proposed [18, 19, 20]. SMD techniques, among which atomic
force microscopy (AFM), total internal reflection fluorescence microscopy
(TIRFM), optical-trapping nanometry, polarized fluorescence and fluores-
cence resonance energy transfer (FRET) are the most popular, can monitor
the time evolution of single biomolecules during their functional activity
and allow the detection of global movements and conformational changes.
SMD have been successfully applied to study the dynamic properties of
motor proteins [21], enzymes [22], RNA-polymerase [23] and cell-signaling
proteins [24, 25]. However, the rather low resolution of these experiments is
still a stringent limitation.
More detailed analysis of fundamental processes such as protein folding
and molecular docking requires monitoring the nature and the energies of
the interactions between individual atoms as a function of time. NMR spec-
troscopy and site-directed mutagenesis can partly supply this kind of infor-
mation. In the former approach, the proximity of specific pairs of atoms can
be detected through the measurement of nuclear Overhauser effects (NOEs).
The ensemble of conformations that satisfy the experimental distances is
then determined. In the latter approach, the properties of the wild-type
protein are compared with those of a series of mutants [26]. In summary, it
is assumed that a residue is involved in native contacts in the transition state
if a reduction in the size of its side chain upon alanine mutation destabilizes
the transition state as much as it destabilizes the native state. Within the
validity of this assumption, the method provides a structural description of
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the transition state ensemble (TSE).
Despite great progress, current experimental strategies are not sufficient
to provide a “complete” description of protein free-energy landscapes. As
pointed out, some techniques are too focused on the native state structure
and do not provide any information about the dynamics; others present
time or space resolution problems and cannot properly describe the time
evolution of the polypeptide chain, i.e., protein internal motions and con-
formational changes. Other methods supply information based on averages
over heterogeneous ensembles and thus lose much of the static and dynamic
detail.
Computational Approach
In an attempt to overcome the limitations described above, an alternative
approach would be to perform an experiment in silico: studying the behav-
ior of a model protein by means of a computational protocol. In principle,
by using an accurate atom-based model for the potential energy (a force
field) and solving the time-discretized form of Newton’s equation of motion
in the presence of the appropriate solvent, it should be possible to reproduce
the exact dynamics of a polypeptide chain and monitor the complete folding
trajectory at atomic resolution. If this were feasible, in silico experiments
could be used to address specific questions about proteins much more eas-
ily than the experiments themselves. However, computer simulations have
not reached this stage (yet) and, similarly to experimental techniques, they
suffer from stringent limitations. For a model protein of about 100 residues,
the complete folding transition in vitro takes about 1 ms. With the available
simulation protocols and computing power, monitoring the folding trajecto-
ries of such a protein would require more than 10 years. Moreover, current
force fields even in their most sophisticated forms are not accurate enough
to let a protein fold on a computer. Even if one could use a computer
several orders of magnitude faster than currently available processors, thus
solving the timescale problem, the model protein would never find its way
to the native state. Statistical errors related to timescales and sampling
of configuration space and systematic errors related to the inaccuracy of
the energy models dramatically reduce the applicability of such approaches.
Nonetheless, computer simulations can provide the ultimate details concern-
ing the motion of individual atoms as a function of time, which will never be
accessible from a sample in a test tube. In their range of validity, in silico
experiments are a valuable complement to experimental approaches. On the
other hand, experiments play a crucial role in defining that range of validity:
comparisons between simulation and experiments estimate the reliability of
the in silico results and provide useful criteria for improving the simulation
methodology. Hence, in vitro and in silico experiments should be considered
as complementary side views of the same problem and not mutually exclu-
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sive approaches. In the following, a series of notable examples highlight the
potential synergy between the two diverse approaches.
Role of solvent in protein dynamics: A particularly striking example is
provided by the resolution of the contentious question concerning the role
of solvent on the internal motion of proteins [27]. Experimentally, it has
not been possible to determine whether solvent fluctuations drive the inter-
nal motion of proteins. This question was addressed by a computational
study recreating a physical system which is not accessible in Nature. Molec-
ular dynamics simulations were performed with one part of the system (the
protein) at one temperature and the other part (the solvent) at a different
temperature. Protein atomic fluctuations calculated from the simulation
trajectories at either 180 or 330 K revealed that their magnitude is only
weakly dependent on protein temperature. In contrast, the fluctuations are
large when the solvent is at 300 K and small when the solvent is at 180 K,
independent of the protein temperature. This result demonstrates that the
temperature of the solvent, and thus its mobility, is the dominant factor in
determining the functionally important protein fluctuations under physio-
logical conditions.
Conformational change in the functional mechanism of GroEL: An-
other famous in silico experiment have been designed to find a pathway
between the open and closed conformations of the bacterial chaperonin
GroEL, which has been impossible to determine experimentally. GroEL
is supposed to assist the folding of about 10% of cytosolic proteins in Es-
cherichia coli. During its functional cycle, GroEL undergoes large conforma-
tional changes [28] that are regulated by the binding and hydrolysis of ATP
and involve the co-chaperonin GroES. In the absence of ATP and GroES,
the seven subunits of GroEL are in a “closed” conformation; in contrast,
they adopt an “open” conformation when bound to the cofactors. Since
the actual transition between the “open” and “closed” conformations oc-
curs in the millisecond timescale, a direct simulation of the overall motion
by molecular dynamics would not be possible. However, several methods
have been developed to follow the transition between two experimentally
determined states on shorter timescales. One of these, targeted molecular
dynamics (TMD), was actually applied to determine the transition pathways
of GroEL [29]. The computational results indicated that, in the absence of
GroES, the subunits adopt an intermediate conformation upon ATP bind-
ing. The simulations unveiled that the motion of the intermediate domain
induced by nucleotide binding triggers the larger movement of the apical
and equatorial domains. Subsequent cryoelectron microscopy results have
confirmed this prediction.
Protein Folding: In silico experiments have been successfully applied to
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study the reversible folding of structured peptides [30, 31, 32, 33]. Suitably
designed molecular dynamics simulations have reproduced the correct fold-
ing of a three-stranded β-sheet (beta3s) [31] and displayed multiple folding
pathways at atomic resolution [34]. The information provided by the simu-
lations, including the complete determination of the free energy landscape
and the description of the folding mechanism, could never be obtained ex-
perimentally. Since the fastest folding reactions require ∼ 10µs to complete,
folding a protein on a computer using brute force techniques is extremely
difficult (mainly due to statistical errors). Simplified models and effective
protocols that allow sampling at longer timescales are then required. A com-
mon approach for protein folding is to treat water molecules “implicitly” by
replacing them with a continuum dielectric. In this way, implicit solvation
models eliminate the solvent degrees of freedom and allow individual sim-
ulation runs to explore the microsecond timescale. For beta3s an implicit
model based on the solvent accessible surface area [35] was applied. Despite
the relative “inaccuracy” of the energy model, a statistically relevant anal-
ysis of the folding process of this 20-residue peptide could be performed.
So far, this kind of approach has only been successful with short peptides.
Despite the limited biological relevance, these systems are useful models to
investigate the general aspects of protein folding.
Structure determination of protein non-native states: Characterizing the
nature of partially folded states is crucial for understanding the thermody-
namic and kinetic behavior of protein molecules. Experimental approaches
used for protein determination involve three major steps: (i) the choice of a
technique to obtain data that can be interpreted in terms of structural pa-
rameters, i.e., atomic distances, dihedral angles, solvent exposure, etc.; (ii)
the selection of an appropriate energy model to represent the structure and
the energy of the molecule; (iii) the definition of an optimization technique to
select conformations that minimize the deviations from experimental data.
This approach has proved extremely successful for the description of the na-
tive state of protein (by X-ray or NMR) but rather inadequate for the char-
acterization of non-native states that are only partially or transiently struc-
tured (unfolded state or TSE). In the latter case, the main limitations arise
from the heterogeneity of the ensembles of conformations involved. A novel
and successful approach to characterize these elusive non-native ensembles
combines a computational strategy with experimental measurements that
are used to restrain the conformational space. These in silico experiments
aim to find all molecular conformations that minimize a pseudo-energy func-
tion composed of two parts: the first defines the physico-chemical properties
of the polypeptide chain in its environment; the second penalizes deviations
from experimentally derived parameters [36, 37]. Biased MD simulations en-
sure, on one hand, that computer generated models are meaningful and, on
the other hand, that they are compatible with experimental measurements.
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A striking example of the described protocol is given by the structure de-
termination of the TSE for acylphosphatase (AcP) by using experimental
φ-values [36]. Assuming that φ-values can be approximated by the fraction
of native interactions formed in the transition state, one can work out a
simple additional energy term to bias the conformational search:
ρ =
1
Nφ
∑
i∈E
(φi − φ
exp
i )
2 , (1.1)
where E is the list of the Nφ available experimental φ-values, φ
exp
i . The
φ-value of amino acid i in the conformation at time t is defined as:
φi(t) =
Ni(t)
Nnati
, (1.2)
where Ni(t) is the number of native contacts of residue i at time t and N
nat
i
the number in the native state. The procedure lets TSE conformations be-
come the most stable states on the potential energy surface, thus allowing
statistically relevant sampling and structure determination of TSE. Interest-
ingly, for AcP it has been shown that using just three specific φ-values, all
the remaining φ-values could be predicted with high precision, thus suggest-
ing that the ensemble of conformations determined by the computational
approach is a faithful representation of the TSE.
Paradigm of the in silico Experiments
The reported examples clearly illustrate the relevance of computational
strategies in structural biology and underline the potential complementar-
ity with in vitro experiments. Different protocols have been successfully
proposed to provide reliable solutions to specific problems. Although the
approaches appear rather diverse, a detailed analysis reveals that they all
share a common basis: the paradigm of the in silico experiments (Fig. 1.4).
Every time molecular biologists are faced with difficult problems that cannot
be addressed by means of standard experimental techniques, novel computa-
tional approaches can be designed to provide alternative solutions. In silico
experiments consist of three stages: (i) methodological development to solve
particular problems; (ii) test-case application and comparison with available
experimental data; and (iii) blind application for real predictions.
Once the biological problem has been carefully analyzed and the limita-
tions of possible experimental methods considered, computational strategies
can be proposed. A big advantage of a computational approach is that the
inherent model is fully under the control of the user who can optimize it
for the specific problem he is dealing with. Hence, before performing the
ultimate experiment, methods are usually tested and validated on problems,
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whose solution is known. This preliminary phase is very important for the
design of a successful protocol: the parameters of the model are fine-tuned,
the range of validity of the method estimated and the procedure customized
to improve its effectiveness (Fig. 1.4, phase I). When the method is reli-
able enough, the procedure is applied to a set of more difficult test cases to
further challenge the strategy, find its weaknesses and suggest beneficial im-
provements. Along the whole stage of refinement, the comparison with the
experiments is mandatory and represents a conditio sine qua non to validate
the simulations results (Fig. 1.4, phase II). If any inconsistency is found,
the procedure must be reviewed in the light of the new data and further
methodological development is required. Through subsequent iterations, in
silico experiments are continuously refined and improved. At each cycle, the
results should become more and more reliable and the description of the bio-
logical process more accurate. Upon validation, the global procedure can be
applied to the biological problem for which it was originally designed (Fig.
1.4, phase III). This time, computational results become real predictions
that can be trusted on the basis of the former testing.
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Fig. 1.4: Paradigm of the in silico experiments
By following the paradigm shown in Fig. 1.4, two in silico experiments
have been designed, performed and reported in this thesis. The biological
problems behind the experiments, i.e., molecular docking and amyloid pep-
tide aggregation, are intrinsically diverse as are the computational methods
developed and used. Nevertheless, both research projects can be included
in the common operational framework of the in silico experiment.
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1.3 Molecular Docking
The identification of molecules that bind the key regions of pharmaco-
logically relevant macromolecules with high affinity and selectivity and alter
or inhibit their biological function is known as “drug discovery”. Drug dis-
covery is a highly multidisciplinary research process which starts with the
identification of a target of therapeutic value through biological studies. In
order to find putative inhibitors, large molecular libraries are screened and
the resulting leads, i,e., ligands with high affinity and low molecular weight,
are optimized in a cycle that includes design, synthesis, biochemical activity
assaying (in vitro experiments) and animal studies (in vivo experiments).
At the lead optimization stage, the determination of the crystal structure
of the target in a complex with some discovered leads is rather important,
if not essential. Structural information, which provides the atomic detail of
the binding modes of actual ligands, contributes to the understanding of the
key elements governing protein-ligand recognition and dramatically speeds
up the rational optimization. Unfortunately, the availability of crystal struc-
tures for protein-ligand complexes is not always timely and this step may
be the “bottleneck” of the entire project. Crystal structure determination is
not the only problem that must be faced with during drug discovery. Many
hurdles and pitfalls must be overcome before a single molecule that ends up
as a drug may be proposed.
At the lead generation stage, experimental high-throughput screening
(HTS) requires a molecular library and a reliable activity assay to identify
a set of hits [38]. A successful hit, which is then called a lead compound,
must display a potency in the low micromolar range, i.e., the concentration
of inhibitor that determines 50% reduction of target activity (IC50) should
be 10 µM or less. As soon as a lead compound has been found, extensive
optimization and development are required to increase its binding affinity
so that the effective concentration gets to the nanomolar range, which is an
essential requisite for further development. Sometimes there are no hits at
all [39] and a new library has to be selected and screened. As a result of
the combination of low hit rates and high costs the large-scale approaches of
the early 90’s are now out of favor [40]. Towards the end of the preclinical
period, i.e., when a series of compounds with adequate potency has finally
been identified, subtle pharmacological concerns relating to bioavailability,
duration of action and toxicity must be addressed. In conclusion, drug
discovery is a very difficult and risky process which involves high costs,
interdisciplinary expertise and extensive human resources.
Computational Approach
To overcome these limitations, more efficient, faster and cheaper approaches
must be pursued. Following the paradigm of the in silico experiment (see
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previous section), a computer-aided strategy designed to discover new leads
from first physico-chemical principles can be proposed. Given the three-
dimensional structure of the biomolecular target, the ultimate goal of the
procedure is to reproduce the correct binding mode of a small molecule in
the binding site of the receptor. the methodology is a valuable help for
medicinal chemists who are aiming to discover novel ligands, since it allows
them to start the long process of drug development from a sensible point.
Computational approaches that mimic the molecular recognition between a
target biomolecule and a small compound on a computer have been inten-
sively studied and developed. In the literature, they are known as “molecular
docking” techniques [41, 42, 43, 44]. The basic strategy of any docking ap-
proach is to generate a conformation of the ligand (conformer), to place
(or dock) it in the active site of the receptor (binding mode) and assign a
score that will be used to produce a ranking. In molecular docking, the
essential prerequisites are the availability of a three-dimensional structure
of the target, a clever search strategy to sample the conformational space of
the ligand and a reliable scoring function to distinguish between active and
non-active binding modes. The proper combination of an effective search
algorithm and an accurate scoring function are the keys for a successful pro-
tocol. When the procedure is applied to a library of available compounds,
the approach takes the name of virtual screening (VS) and represents the
computational analog of HTS. The library is screened against the target,
i.e., each molecule is docked in the receptor’s active site, the compounds are
ranked according to their binding affinities and a subset of virtual “hits” is
suggested for experimental testing. Whereas VS remains less used than HTS
for lead discovery, the increased robustness of search algorithms and scoring
functions, the availability of affordable computational power, and the po-
tential for timely structural determination of target molecules is making it
more practical. Moreover, the speed at which VS can be completed, the low
costs, i.e., no need for robotics, reagent acquisition and compound storage
facilities, and the potential for screening compounds belonging to available
electronic collections make this technique more and more attractive.
In silico Experiment
As for any in silico experiment, the paradigm shown in Fig. 1.4 holds true
for the VS and three phases must be completed. In the first step (the
methodological development), the two components of molecular docking,
i.e., the search strategy and the scoring function, are considered. Dock-
ing procedures belong to the category of global optimization techniques.
The critical element of the search strategy is the amount of time required
to sample the relevant conformational space and find the global minimum
of the scoring function, i.e., the search effectiveness. Most optimization
algorithms for docking fall into one of three classes: (i) gradient-based al-
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gorithms, (ii) combinatorial algorithms and (iii) stochastic algorithms [45].
Gradient-based algorithms are local optimizers and can be used effectively
only in combination with other search strategies, such as cycles of Monte
Carlo (MC) perturbation and gradient minimizations [46]. Combinatorial
algorithms are extremely fast and effective [47, 48, 49, 50, 51] unless the
number of conformational degrees of freedom becomes large and the dimen-
sion of the search space explodes. Stochastic algorithms have the advantage
that irrespective of the dimensionality of the problem, if provided there is
sufficient time, they are able to get arbitrarily close to the global minimum.
However, the amount of CPU time to achieve an acceptable solution may be
relatively large. Although computationally expensive, given the dimension-
ality of the search space and the ruggedness of the binding energy landscape
stochastic algorithms have been shown to be the most suitable optimizers
for flexible docking [52, 53, 42, 54, 55, 44]. Several search algorithms have
been proposed for docking. Up until now, none of them claims to work in all
cases and more effective algorithms are eagerly expected. A brief overview
of published strategies is given in Chapter 2.
In any docking approach, the scoring function represents the model of
protein-ligand interactions. The model should be accurate enough to ef-
fectively distinguish the “active” binding mode from all of the others that
have been explored and simple enough to permit the evaluation of a large
number of potential solutions. Sophisticated energy functions, which ac-
curately describe the thermodynamics of protein-ligand interactions, are
computationally too expensive and therefore cannot be used for docking.
Furthermore, the resulting energy landscape must be smooth to allow the
search to proceed efficiently without becoming trapped in local minima. As
suggested by Verkhivker [53], an “adequate” scoring function should fulfill
both a thermodynamic and a kinetic requirement. The energy related to the
crystallographic structure of the ligand in the complex should be the global
minimum of the binding energy landscape (thermodynamic requirement). At
the same time, this conformation should be accessible during the search (ki-
netic condition). The complexity of a complete and accurate force field that
describes the binding process precisely, thus fulfilling the thermodynamic
requirement, typically results in a highly frustrated energy landscape and
therefore does not meet the kinetic criterion of the docking problem. Hence,
simpler molecular recognition models which fulfill both of the requirements
need to be designed and developed. Molecular recognition models should
at least include both steric and electrostatic terms that account for sur-
face complementarity and hydrogen-bond formation. An intraligand energy
term is also required. The latter largely reduces the conformational space
to be sampled by preventing intraligand steric clashes. In general, the key
elements of a scoring function for robust structural assessment in docking
are: (i) protein-ligand steric interaction terms; (ii) a simple description of
protein-ligand hydrogen-bonding and (iii) an intramolecular self-avoidance
24
term. Other contributions, such as dihedral energy and solvation effects,
might also play a crucial role in specific cases. Hence, provided that both
thermodynamic and kinetic requirements are satisfied, the scoring function
should be developed and adapted on a case by case basis, e.g., by considering
the physico-chemical properties of the binding site of the target or the na-
ture of the library to be screened. Widespread scoring functions for docking
and rationale guidelines for their development are discussed in Chapter 2.
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Fig. 1.5: Comparison between ligand structures with biased geometries
(green carbons) and unbiased geometries (yellow carbons) used as input
for re-docking 1hvr, 1hbv, 1htg and for cross-docking 1htg with the pro-
tease 1hbv. Significant deviations in the covalent angles are marked by
dashed arcs. (The pictures of the ligands were drawn using the program
PyMOL [56]).
In the second stage of the in silico experiment, the docking strategy is
tested on known potent inhibitors with the aim of reproducing their ex-
perimental binding mode. Despite the lack of predictive relevance, redock-
ing experiments represent a very useful tool to challenge the strategy, find
weaknesses and suggest beneficial improvements. A “training set” of protein-
ligand structures representing the target in complex with different inhibitors
is then considered. All ligands are removed from the receptors and mini-
mized when fully solvated, thus removing any bias originating from the crys-
tal structure of the complex. Redocking simulations are carried out and the
predicted solutions are compared with the reference, i.e., the binding mode
in the crystal structure. To evaluate the reliability of the results, the heavy
atom root mean square deviation (RMSD) between the predicted binding
modes and the reference are computed. If the redocking experiments are suc-
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cessful, i.e., the great majority of low-energy conformations of the ligand are
docked within 2.0 A˚ RMSD from the reference, the strategy is further tested
with more difficult training sets, e.g., with more flexible ligands, or more
stringent cases, e.g., cross-docking experiments. In the event that the latter
tests are successfully passed, the docking strategy is validated and the third
phase of the in silico experiment is entered. In contrast, if docking predic-
tions do not match the experimental solutions a new stage of methodological
development is required. Both methodological refinement and test case ap-
plications for the SEED-FFLD strategy [50, 51, 44, 57], the fragment-based
docking procedure developed in house, are presented in Chapter 3. The
SEED-FFLD strategy has been tested on highly flexible inhibitors of human
immunodeficiency virus type 1 protease (HIV-1 PR), human α-thrombin and
the estrogen receptor β. The docking results indicate that it is possible to
correctly reproduce the binding mode of inhibitors with more than ten rotat-
able bonds, except in cases when the strain in the covalent geometry of the
ligand upon binding is large (Fig. 1.5). Hence, automatic approaches that
sample only in dihedral space can give misdocked predictions. For docking
a limited set of compounds, approaches that allow for full flexibility (includ-
ing bond angles and lengths) of the ligands, albeit computationally very
expensive, should be preferred. Finally, a “hybrid search strategy” consist-
ing of local search and genetic algorithm significantly improves the quality
of the SEED-FFLD docking predictions at a moderate additional computa-
tional cost (Fig. 1.6). The results of the docking study suggest that hybrid
search methods, i.e., combinations of global optimization procedures and
local minimization algorithms, should be preferred to global optimization
algorithms alone. Thanks to the methodological improvements described in
Chapter 3, i.e., the introduction of a more efficient and effective search
procedure and replacement of the step functions in the protein-ligand polar
term with continuous bathtub-shaped profiles, the in-house fragment-based
docking strategy could be used in computational screening projects to dis-
cover novel inhibitors against relevant targets. Upon ranking, the top scoring
compounds have been purchased or synthesized and submitted for experi-
mental testing. Numerous successes of this approach are well documented
in the literature [58, 59]. In our laboratory, the SEED-FFLD strategy has
been successfully applied in a VS project against β-secretase, a very difficult
target involved in Alzheimer’s disease [60]. By screening a library of about
300000 molecules (the iResearch library) and a library tailored for proteases,
thirty compounds were predicted to have affinities in the high nanomolar
range. Most of them were phenylurea derivatives. Upon refinement, the
good candidates were purchased and tested in vitro and by two cell-based
assays. Interestingly, three compounds showed low-micromolar activity in
the cell based-assays. Given the the very small size (MW=322) of one of
the three, this compound is a very promising lead candidate for β-secretase
inhibition. In a second screening experiment against the same target eighty-
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Fig. 1.6: Evolution of the best individual of the population averaged over ten
docking runs for two different experiments. Empty and filled bullets indicate
evolutions performed by genetic algorithm and hybrid search procedure,
respectively. Docking of HIV-1 proteinase ligands with 10 and 21 rotatable
bonds are shown in the left- and right-hand plots, respectively. In the right-
hand plot, the vertical bars show the standard deviation computed over ten
docking runs.
eight compounds suggested in silico were tested in vitro, and 10 of them
showed an IC50 value lower than 100 µM in a BACE-1 enzymatic assay.
The 10 active compounds shared a triazine scaffold. Moreover, four of them
were active in an assay with mammalian cells (EC50 ¡ 20 µM), indicating
that they are cell-permeable. Such as the phenylurea compounds, these tri-
azine derivatives are very promising lead candidates for BACE-1 inhibition.
The details of the two VS experiments, the in vitro validation of the com-
putational predictions and the identified active compounds are described in
Chapter 4 and Chapter 5.
1.4 Amyloid Aggregation
The term “amyloid” was originally introduced to describe certain de-
posits found post-mortem in organs and tissues, which gave a positive re-
action when stained with iodine [61]. It was realized only later that the
amyloid material was predominantly proteinaceous. With the increasing
precision in the definition of amyloid due to its characteristic green birifren-
gence when stained with the dye Congo Red [62], its particular appearance
in the electron microscope [63] and its specific X-ray diffraction pattern [64],
it has become evident that amyloid deposits are highly-ordered aggregates
in which the polypeptide units lie in a “non-native” conformation. Thus,
amyloid aggregation is tightly linked to protein misfolding, i.e., the inability
of a protein to fold correctly or remain correctly folded so that under cer-
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tain conditions it assumes a different three-dimensional structure that can
induce the fibril formation.
The major interest in amyloids arises from the evidence that ordered
deposits are associated with a number of severe human disorders (amy-
loidoses) including Alzheimer’s disease, Hungtington’s disease, transmissi-
ble spongiform encephalopathies, i.e., bovine spongiform encephalopathy
(BSE), Creutzfeldt-Jakob disease (CJD) and Kuru, type II diabetes and a
number of systemic polyneuropathies [65]. Presently, more than 20 proteins
are known to be responsible for diverse human amyloidoses. The polypep-
tide chains involved in amyloid diseases include full-length proteins (e.g.
lysozyme or immunoglobulin light chains), biological peptides (amylin, atrial
natriuretic factor) and fragments of larger proteins produced either by spe-
cific processing (e.g. the amyloid-β peptide) or by more general degradation
(e.g. poly-Q stretches cleaved from proteins with poly-Q extensions such
as hungtintin, ataxin and the androgen receptor). In some cases amyloid
deposits involve wild-type sequences and, in other cases, variants resulting
from genetic mutations. This latter group is associated with familial forms
of the disease which are particularly aggressive and usually correspond to
earlier onsets [66]. The soluble precursors of the ordered deposits do not
share any sequence homology or common fold.
Despite the apparent diversity, the presence in tissue of proteinaceous
deposits is a hallmark of amyloidoses, thus suggesting a causative link be-
tween aggregate formation and pathological symptoms (the amyloid hypoth-
esis) [67, 68, 69]. Moreover, X-ray diffraction data indicate a common cross-β
structure for most fibrillar aggregates [70, 71]. The latter finding suggests,
on one hand, that the key steps in aggregation may be common to all amy-
loid proteins and, on the other hand, that fibrillar or pre-fibrillar structures
may be the origin of the disease. Hence, to understand the molecular basis of
the diseases, the structure of the aggregates should be carefully analyzed. In
the last 50 years, a lot of effort has been put into the structural determina-
tion of amyloid aggregates. Initially, these deposits have been characterized
by staining methods, electron microscopy and X-ray diffraction. The early
investigations indicated that amyloids, regardless of the disease, share the
following structural features:
• under electron microscope, amyloid deposits can be seen to be com-
posed of uniform, straight, unbranched fibers, ∼ 100 A˚ in diameter
and of indefinite length [72]; the fibers are usually straight or only
slightly curved suggesting that they have a particularly rigid molecu-
lar structure (Fig. 1.7);
• the molecular structure is such that amyloid fibrils bind Congo Red
dye and interact with this planar bis-diazo dye in such a way that the
bound molecules are spatially ordered with respect to the fibril and
generate a characteristic and diagnostic green birefringence [73];
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• amyloid X-ray diffraction patterns show that the repeating molecu-
lar structure of the fibrils consists of polypeptide chains in extended
β-conformation, hydrogen-bonded together into sheets which run per-
pendicular to the axis of the fibril, the so called “cross-β” conforma-
tion [74, 75].
Fig. 1.7: Electron micrograph of amyloid-β fibrils
The “cross-β” structure unveiled by X-ray studies is rather intriguing be-
cause it incorporates an inherent propensity for propagation. In cross-β con-
formation, polypeptide chains are extended with alternate peptide groups
rotated by 180◦. Each carbonyl and amide group in any β-strand can make
hydrogen bonds with the amide or carbonyl group, respectively, on parallel
or antiparallel adjacent strands. In turn, adjacent strands can make hy-
drogen bonds with other similarly organized strands and, in principle, an
indefinite number of monomeric units can be included. To understand the
mechanism of amyloid formation and the nature of the energetic contribu-
tions that stabilize similar ordered arrangements for such a diverse class
of proteins, atomic resolution structures would be required. However, no
high-resolution three-dimensional structure of an amyloid fibril has been de-
termined yet. Amyloid fibrils are noncristalline solid materials and therefore
highly incompatible with the usual techniques for protein structure deter-
mination, i.e., X-ray crystallography and liquid state NMR.
To obtain structural information at molecular level, more sophisticated
approaches have to be followed. Recent experiments by Lansbury, Griffin
and co-workers [76, 77] and by Linn, Meredith, Botto and co-workers [78, 79]
have demonstrated that structural constraints on amyloid fibrils can be ob-
tained from solid-state NMR, which requires neither crystallinity nor solu-
bility. By appropriate isotopic labelling (e.g., 13C or 15N ), solid state NMR
measurements provide quantitative data on the supramolecular organiza-
tion of the β-sheets in the fibril and describe protein fibrillar conformations
in terms of torsion angles or interatomic distances. Remarkably, measure-
ments of 13C–13C nuclear magnetic dipole-dipole couplings have provided
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experimental evidence of the in-register parallel alignment of the amyloid-β
peptide in the deposits associated with the Alzheimer’s disease [80, 81, 82].
Although these technique are useful, they can supply “only” a certain num-
ber of constraints. Experimental results may be insufficient to define a
unique protein fibrillar conformation and the resulting structural models
may be rather inaccurate, if not incorrect. More importantly, the specific
nature of the pathogens in amyloidoses and the basis of cytotoxicity are still
unclear and the subject of an intense debate [83, 84, 85, 86, 87, 88, 89]. An
increasing quantity of recent experimental data suggest that the early pre-
fibrillar aggregates are the most toxic species [90, 91]. On the hypothesis
that prominent cytotoxicity is exhibited by the soluble precursors of amyloid
fibrils, structural information on mature fibrils cannot be used to prevent
amyloid diseases. Hence, alternative approaches providing structural and
dynamic information should also be pursued in addition to solid state NMR
experiments.
Computational Approach
To study amyloid aggregation at atomic detail, alternative approaches in-
volving computational methods may be invoked. In this case, the ultimate
goal of the in silico experiment would be to monitor the self-assembly of a
certain number of amyloid proteins and determine the complete free-energy
surface of the oligomeric system. This would also provide structural charac-
terization of the early aggregates, which are believed to be cytotoxic. The
nature of the energetic contributions that stabilize ordered aggregates could
be identified and the molecular basis of fibril formation explained. More-
over, by testing the in silico behavior of engineered mutants the sequence
dependence of amyloidogenicity, i.e., the capability of forming amyloid fib-
rils, could be easily investigated.
However, in vitro fibril formation is rather slow and the time taken for
this process ranges from several minutes to days, dependent on which amy-
loid sequence we are dealing with. Such timescales are never accessible by
standard computer simulations. Moreover, the process is intrinsically coop-
erative and several aggregating units must be included in the model. For
these reasons, the size of the system, i.e., the total number of interacting
centers, becomes intractable very rapidly. To keep the complexity and CPU
requirements low, only “small” and “slightly realistic” oligomeric systems
can be investigated. Recent all-atom MD simulations of a three amyloido-
genic heptapeptides GNNQQNY have shown that the effective energy surface
of such a simplistic aggregating system is already highly rugged [92]. The
absence of connections between the peptides results in a large number of
different low-energy states, which increases the frustration of the system
and hinders the sampling. Since current simulation approaches only allow
significant sampling for small oligomers (e.g., typically those with no more
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than six peptide replicas with fewer than ten residues each) larger and “more
relevant” systems cannot be investigated. These limitations strongly reduce
the effectiveness of the computational approach. Indeed, many important
questions about the formation of ordered aggregates have been addressed by
computational studies. Simplified on-lattice models have allowed to investi-
gate the foldability and aggregation propensity [93, 94] and how interaction
potentials affect the properties of aggregation-prone proteins [95]. Other
studies have shown the less stable the protein, the greater the chance that
it will assume an alternative native state as multimer [96]. A minimalist
“Go” model of four peptide strands [97] has been investigated by MD sim-
ulations in a confining sphere and the aggregation process was shown to be
dependent on both sequence and environment [98].
In silico Experiment
Following the paradigm shown in Fig. 1.4, the optimal computational proto-
col is designed to reduce the statistical errors originating from the timescale
of the process and the frustration of the system as much as possible (phase I).
Hence, “simple” amyloid systems can be investigated by applying clever sam-
pling procedures, such as the replica exchange molecular dynamics (REMD)
approach [99, 100], and simplified energy models, such as implicit treat-
ments of the solvent [101, 102, 103, 35]. The former is an efficient way
to simulate complex systems at physiological temperatures, the latter is a
continuum representation of the solvent that drastically reduces the compu-
tational cost of the simulations and allows the investigations to have much
longer timescales (in the µs range).
“Replica exchange” is the simplest form of simulated tempering [99].
Sugita and Okamoto were the first to extend the original formulation of
replica exchange into an MD-based version and they tested it on the pen-
tapeptide Met-enkephalin in vacuo [100]. Several atomistic simulations of
proteins have shown the efficiency of the method [104, 105, 106, 107, 108, 109,
110]. The basic idea of REMD is to simulate different copies (replicas) of the
system at the same time but at different temperatures values. Each replica
evolves independently by MD and, every ttextrmswap time interval, states
i, j which have neighboring temperatures are swapped (by velocity rescal-
ing) with a probability wij = exp(−∆), [100] where ∆ ≡ (βi−βj)(Ej −Ei),
β = 1/kT and E is the effective energy (potential and solvation energy).
The result of this swapping between different temperatures is that high
temperature replicas help the low temperature ones to jump across the en-
ergy barriers of the system. During the simulation, each replica visits all the
temperatures of the set several times, thus undergoing a free random walk in
temperature space [100]. This, in turn, corresponds to a random walk in en-
ergy space that enhances the sampling. Simple protocols to set up a REMD
simulation of amyloid peptide aggregation are described in Chapter 6.
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Fig. 1.8: Temperature dependence of the nematic order parameter 〈P2〉 av-
eraged over the canonical ensembles sampled by REMD for four oligomeric
peptide systems. 〈P2〉 estimates the amyloidogenic propensity of pep-
tide systems and discriminates between amyloidogenic (GNNQQNY and
QQQQQQQ) and non amyloidogenic (SQNGNQQRG and AAAAAAA) se-
quences in agreement with experimental data [112, 113, 114].
Our study showed that REMD samples conformation space and aggregation
transitions more efficiently than constant temperature molecular dynamics
(CTMD) at physiologically relevant temperature values [111]. To simulate
amyloid peptide aggregation, the following protocol can be adopted: each
simulation run is carried out with three peptide replicas starting from ran-
dom conformations, positions, and orientations. In the initial random po-
sitions, there must not be any intermolecular contact, i.e., the peptides are
separated in space. The system is simulated in a cubic box, whose sides are
adjusted to yield the desired sample concentration (∼ 5 mg/ml to be consis-
tent with in vitro experiments), and with periodic boundary conditions. As
soon as some thermodynamic observable which has been selected to monitor
aggregation (e.g., such as the fraction of parallel or antiparallel interstrand
contacts) has reached convergence the simulation is stopped. For the sys-
tems we studied (three 7-residue peptide replicas simulated by REMD), this
corresponded to a 1µs simulation time which requires approximately 2 weeks
on a current processor. Once the simulations are finished, the trajectories
are analyzed and the results compared with available experimental data
(Fig. 1.4, phase II). To describe the aggregation process in terms of free-
energy profiles and surfaces, appropriate progress variables must be chosen.
In the simulation study reported in Chapter 6, two progress variables were
defined: the radius of gyration of the oligomeric system Rg and the nematic
order parameter P2: the former monitors the degree of condensation of the
system, the latter the aggregation process viewed as an order transition.
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The computational results showed that it is possible to simulate with
an atomic model the early steps of aggregation of amyloid forming peptides
and obtain high-resolution structural information (Fig. 1.10). Moreover,
the early steps have been interpreted as a condensation step leading to the
formation of disordered aggregates followed by an order transition, in agree-
ment with experimental evidence [115]. Finally, the nematic P2 averaged
over the canonical ensemble, which is referred to as β-aggregation propen-
sity, can effectively estimate the amyloidogenic propensity of the system and
discriminate amyloidogenic from soluble peptides in agreement with exper-
imental data [113, 112, 114] (Fig. 1.8).
Given the substantial agreement between simulation predictions and ex-
perimental measurements, the phase III of the in silico experiment has been
entered to investigate the aggregation properties of the Alzheimer’s human
amyloid-β peptide (Aβ42). Due to its large size (42 residues), oligomeric
systems of full length amyloid-β peptides cannot be effectively studied by
computer simulations. Hence, a novel method to investigate the aggregating
properties of amyloid proteins has been developed. The strategy consists of
four steps: (i) the amyloid protein is dissected into sets of short overlap-
ping stretches, i.e., 7- or 11-residue long, that encompass the full-length
sequence; (ii) for every stretch, the aggregation process of small oligomeric
systems, i.e., between three and six peptide replicas, is simulated by all-atom
MD; (iii) the β-aggregation propensity is computed and (iv) used to build
the amyloidogenicity profile, i.e., the position dependence of β-aggregation
propensity along the protein sequence. In summary, the amyloidogenicity
profile is obtained by dissecting the whole amyloid protein into short overlap-
ping stretches and computing the aggregation propensity of each segment.
Based on the hypothesis of in-register parallel arrangements, aggregation
MD simulations should reproduce the fibrillar environment experienced by
each segment. The observations made on the stretches can then be extended
to the full-length protein and its aggregating properties deduced with rea-
son. The MD-based amyloidogenicity profile on Aβ42 highlighted the region
from Val12 to Asp22 as the major aggregation hot-spot. Although with a
lower tendency, the C-terminal segment (residues 31-37) was also found to
be aggregation-prone. These findings are in good agreement with radioli-
gand binding experiments [116] and ThT-fluorescence assays [117] and are
rather consistent with the structural model for Aβ40 fibrils derived from
solid state NMR [118]. The enhanced β-aggregation propensity detected
at the N-terminus by the implicit solvent runs is rather surprising and in
disagreement with solid state NMR [118] and EPR measurements [119].
It is likely that the approximations inherent to the solvation model, and
in particular the neutralization of formal charges, were too crude to cor-
rectly reproduce the behavior of polypeptide segments with many charged
side chains. Explicit solvent simulations started from parallel β-sheet con-
formations of segments located at the N-terminus unveiled their marginal
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Fig. 1.9: Results of constant temperature MD simulations of trimeric 7-
residue peptide systems. Values of the β-aggregation propensity along the
Aβ42 sequence at 310 (blue) and 330 K (red) obtained from aggregation
simulations of three 7-residue peptides.
structural stability (see black squares in Fig 1.9), in agreement with ex-
periments. Thanks to the atomic detail provided by the MD simulations,
the β-aggregation profile could be interpreted on a structural basis. A sec-
ondary structural analysis unveiled the presence of four potential β-turn or
bend sites along the amyloid-β sequence: “SG” (res. 8-9), “GS” (res. 25-26),
“GA” (res. 29-30), “GV” (res. 38-39). The four potential β-turns corre-
spond to sudden drops in the β-aggregation profile and are located at the
borders of the identified aggregation-prone regions. The simulation results
suggest that these four potential β-turns play a critical role in determining
the aggregation properties, i.e., the location of the aggregation hot-spots, the
amyloidogenic content, i.e., the capability of forming amyloid fibrils, and the
fibrillar structure of the amyloid-β peptide. A detailed discussion of these
simulation results is reported in Chapter 7. Experimental validation of the
in silico prediction is mandatory and represents a challenge that has been
left to experimentalists.
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Fig. 1.10: (Top) Snapshots of ordered aggregates of three (thick sticks)
and six (thin sticks) amyloidogenic SYVIIE peptides [120] extracted from
CTMD simulations at 330 K. The simulations were performed at a sample
concentration of 5 mg/ml. The overall conformation and twist of the three-
stranded and six-stranded parallel β-sheets are indistinguishable. (Bottom)
The six-stranded β-sheet upon 90◦ rotation to better visualize the twist.
(The pictures were drawn using the program PyMOL [56]).
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Abstract: An improved version of the fragment-based flexible ligand docking approach SEED–FFLD is tested on
inhibitors of human immunodeficiency virus type 1 protease, human -thrombin and the estrogen receptor . The
docking results indicate that it is possible to correctly reproduce the binding mode of inhibitors with more than ten
rotatable bonds if the strain in their covalent geometry upon binding is not large. A high degree of convergence towards
a unique binding mode in multiple runs of the genetic algorithm is proposed as a necessary condition for successful
docking.
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Introduction
Computer-aided approaches for docking small molecules into pro-
teins of known structure are useful tools for drug design.1–4 The
importance of automatic docking procedures keeps growing be-
cause of the ever increasing number of 3D structures of pharma-
cologically relevant enzymes and receptors. Further, combinatorial
and parallel synthesis techniques have generated a significant
number of libraries of compounds with good pharmacological
properties5 and in certain cases tailored for specific targets.6,7
Automatic approaches are available for docking flexible ligands of
up to about 10 rotatable bonds into rigid8–10 and partially flexible
targets,11–17 and several review articles have been pub-
lished.2,18–20 Ligands with a larger amount of rotatable bonds are
much more difficult to dock,13,14 even using a rigid protein.21,22
In this article we present the improvements with respect to the
original version of SEED–FFLD10,23 and evaluate the new version
on difficult test cases. The SEED–FFLD approach is based on the
decomposition of ligands into mainly rigid fragments. First, the
most favorable fragment positions and orientations in the receptor
binding site are determined by the program SEED according to an
accurate binding energy that includes electrostatic solvation ef-
fects.24 The optimal binding modes of the fragments are then used
in FFLD as binding site descriptors to guide the placement of
ligand conformations generated by a genetic algorithm (GA). The
SEED–FFLD approach was tested by docking known nanomolar
inhibitors with about 10 rotatable bonds in the active site of the
uncomplexed and complexed conformations of thrombin and the
human immunodeficiency virus type 1 protease (HIV-1 PR).10
The present work was motivated by two main questions: Is it
possible to dock ligands with more than 10 rotatable bonds into
HIV-1 PR? Are the predicted binding modes affected by the
protein conformation (choice of the crystal structure)? The dock-
ing results show that redocking is almost always successful
whereas cross-docking is problematic mainly because of strain in
the covalent geometry of the ligand. Large and flexible ligands
might be of limited relevance in the context of drug design. Yet,
we think that testing docking programs in cases where the confor-
mational space is very large is useful to find weaknesses and
suggest improvements that will be in any case beneficial also for
smaller and/or more rigid ligands.
Materials and Methods
The docking approach is a three-step strategy based on the decom-
position of a flexible ligand into rigid fragments. First, the program
SEED is used to dock the fragments into the binding site of the
receptor.23,25 Second, the ligand is docked by a genetic algorithm
(FFLD) that uses a fast scoring function.10 The genetic algorithm
perturbations affect only the conformation of the ligand; its place-
ment in the binding site is determined by the SEED anchors and a
least-square fitting method.26 In this way the position and orien-
tation of the ligand in the binding site are determined by the best
binding modes of its fragments previously docked using an accu-
rate energy function with electrostatic solvation.24 The scoring
Correspondence to: A. Caflisch; e-mail: caflisch@bioc.unizh.ch
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function used in FFLD is based on van der Waals and hydrogen
bond terms and does not explicitly include solvation for efficiency
reasons. Solvation effects are implicitly accounted for as the bind-
ing modes of the fragments are determined with continuum elec-
trostatics.
Third, the FFLD results are postprocessed by CHARMM min-
imization. The ligand decomposition into fragments, the choice of
functional groups (preferable large aromatic rings) as anchors, the
identification of rotatable bonds, and the definition of the binding
site have recently been automated (P. Kolb et al., unpublished
results). The other modifications of the SEED–FFLD approach
with respect to the original procedure10 are listed in the next
subsections.
SEED
Fragment Docking
The SEED input parameters used for this application are identical
to those in Table I of the original SEED article23 except for the
following three: (1) The interior dielectric constant is set to 2.0 to
partially account for the electronic polarizability and dipolar re-
orientation effects of the solute. (2) The number of apolar points on
the receptor is increased from 100 to 300 because of the very large
buried binding site of HIV-1 PR. For human -thrombin and the
estrogen receptor  300 and 150 apolar points were used, respec-
tively. (3) To discard polar and apolar receptor vectors that point
outside of the binding site, a selection using an angle criterion is
performed. Initially, the minimal and maximal distances between
the end points of the vectors and a set of points in the binding site
(e.g., the positions of the heavy atoms of the ligand) are evaluated.
A vector is discarded if the angle it spans with the closest point is
larger than a cutoff. This selection uses a permissive cutoff of 100°
for vectors close to the binding site points and a stricter one (70°)
for distant vectors. Using the atoms of a ligand from a known
complex to define the binding site does not introduce a bias in
cross-docking and corresponds to the situation in an advanced drug
design program, where one or more crystal structures of protein–
ligand complexes have already been solved.
Postprocessing of the Optimal Binding Modes of the
Fragments
The fragment binding modes are sorted by binding energy and
clustered in SEED according to their position and orientation in the
binding site using a conservative criterion based on distances
between similar atom types.23,27,28 Cluster representatives are
subsequently grouped according to the coordinates of the geomet-
ric centers using a threshold of 1 Å. The geometric centers of the
first five cluster representatives are removed from the clustering
procedure described in the following and directly used for docking.
For each cluster an average geometric center (rAGC) is calculated
with the following procedure. First, all the positions with a binding
energy greater than 3 kcal/mol with respect to the cluster repre-
sentative are discarded. Then, the rAGC of a given cluster is
evaluated as an energy-weighted mean
rAGC  
i1
N
iri,
i  Eii Ei if Emax  0Ei  Emin  Emax
i
Ei  Emin  Emax if Emin  0
(1)
where Emin and Emax are the minimum and maximum energy
within a cluster, respectively, and the sum runs over the N geo-
metric centers ri of the fragments in the cluster. In the sporadic
case of Emin  0, by subtracting (Emin  Emax) from the fragment
binding energies Ei it is possible to give more weight to positions
with small absolute energy values. For Emin 	 0 	 Emax, average
centers for the subsets of favorable (Ei  0) and unfavorable
(Ei  0) binding modes in a cluster (r and r, respectively) are
computed by eq. (1) and the rAGC is evaluated as
rAGC  0.8r  0.2r (2)
where the multiplicative factors 0.8 and 0.2 are somewhat arbitrary
and were not optimized. The first 15 rAGC are kept for FFLD.
Therefore, the binding site maps used for docking are defined by
20 points, 5 corresponding to geometric centers of fragments
optimally docked by SEED and 15 average geometric centers. In
this way, the final list of geometric centers used for docking is a
compromise between the accuracy of the SEED binding energy
and the diversity derived from the clustering procedure. The post-
processing of the optimal binding modes of the fragments leads to
more heterogeneous binding site maps than using only the most
favorable ones. To store this information for efficient placement of
the ligand in the binding site three hash tables are generated as
described in ref. 10.
FFLD
The following subsections contain the improvements with respect
to the original version of FFLD.10 The FFLD scoring function
consists of an intraligand van der Waals energy, a ligand–protein
soft core van der Waals, and an intermolecular polar energy
term.10 The two latter terms were modified as described below.
Intermolecular Soft Core van der Waals
A soft core van der Waals is used to generate a smooth energy
landscape by reducing the frustration originating from the steep
repulsive part.29 In the present work, the linearization of the
Lennard–Jones potential used to smooth the energy surface was
slightly modified with respect to ref. 10. Originally, upon ligand
placement, for every atom located in the binding site (including a
1-Å layer below the protein surface) a van der Waals energy with
the closest protein atom was evaluated at first. The interaction
energy was linearized if its value was higher than a cutoff; other-
wise, a grid-based interpolated interaction energy including all
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contributions of the receptor atoms was considered. In the original
procedure small atomic interpenetrations with the protein surface
were overpenalized without taking into account the favorable
contributions of the neighboring atoms. In the version used in the
present study, the van der Waals interaction with the closest
protein atom is compared to the grid-based interpolated interaction
energy. If the latter is more favorable, the attractive contributions
of the receptor atoms dominate the interaction and the grid-based
energy is more appropriate. Otherwise, the atomic interpenetration
is significant and the repulsive contribution dominates the interac-
tion. In this case, the linearized interaction with the closest protein
atom is used.
Polar Interactions
The polar term approximates electrostatic interactions between
ligand and protein:
Epolar
inter  
i1
NHB
Ei
HB  
i1
NUP
Ei
UP (3)
where NHB and NUP are the number of hydrogen bonds (HBs) and
unfavorable polar contacts (UPs), respectively. A significant im-
provement with respect to the original version10 is the replacement
of step functions, which allow different binding modes with the
same energy value with smooth functions. Smooth functions allow
the optimization of the hydrogen bonding pattern, avoiding dis-
continuities on the energy surface. A dependence on the distance
and the angle in the polar term of the scoring function was
introduced to reduce the noise arising from the energy degenera-
tion and improve the convergence of the docking runs. The criteria
used for the definition of unfavorable polar contacts and hydrogen
bonds and the smooth functions implemented are described below.
Unfavorable Polar Contacts. An interaction between two H-bond
donors or two H-bond acceptors is an unfavorable polar contact
whose energy is a function of the distance between the interacting
heavy atoms. A sigmoidal function is used
EUPr  Ebad r  ronEbad1  er1 ron 	 r 	 roff
0 r  roff
(4)
where r is the distance between the heavy atoms, Ebad is the
maximal penalty for an unfavorable polar contact,  is the inter-
atomic distance corresponding to the inflection point of the func-
tion, and  is related to the steepness of the sigmoidal. The value
of Ebad  3.0 kcal/mol is the same as used previously.
10 The
values of ron and roff depend on the choice of  and , which were
fixed at 2.8 Å and 15.5 Å1, respectively. The value of ron is
defined as the point where the sigmoidal reaches a value of 0.99
Ebad. For symmetry reasons, roff is fixed by the choice of ron.
Hence, roff,on    4.65/.
Hydrogen Bonds. The hydrogen bonding model of the MAB force
field30
EHBr, 
  WHBRr	D
 (5)
was implemented, where r is the distance between the donor (D)
and the acceptor (A) atoms, 
 is the angle at the H atom (DOH . . .
A), and WH is an atom-type dependent parameter that defines the
strength of the bond. The energy is determined by the parameter
WH, while the distance dependence and the directionality of the
hydrogen bonds follow bathtub-shaped functions:
BRr  1  r  reqwr 
nm (6)
	D
   1  
  
eqw
 
nm (7)
Equations (6) and (7) apply whenever the expression in the outer
brackets is positive; otherwise, BR and 	D vanish. The exponents
n and m determine the curvature of the bathtub-shaped functions
and were chosen as n  2 and m  4. Compared to ref. 30, the
implemented model, while preserving an all-atom description,
does not take into account the angle at the acceptor atom in the
hydrogen bond energy evaluation. Although this could lead to a
loss in accuracy, it avoids the need for additional parameters for
describing the valence state of the atoms involved in the hydrogen
bond. The following parameters were used: the well depth WH and
the optimal distances req were chosen according to the atom types
of the donor and acceptor atoms involved;23,30 
eq was set to 
because of the linearity of optimal hydrogen bonds; wr was 5.0 Å
when r 	 req or 1.25 Å when r  req and w
 was 1.5 radian to
mimic the original stepwise functions.
Local Search
Following a comparative study of several search engines for
AutoDock,31 a hybrid search procedure was implemented in
FFLD. The hybrid search combines a global optimization proce-
dure based on a genetic algorithm to overcome energy barriers
with a local minimization algorithm to explore regions within
energy basins. Local optimization has been shown to dramatically
improve the success rate of the genetic algorithm search without
any loss in efficiency.31 The use of a local optimizer increases the
fitness of the individuals and accelerates convergence. In the
hybrid search, a loop over generations is performed until the
maximum number of generations or the maximum number of
energy evaluations is reached. In a generation, five different stages
follow one another: evolution, mapping, fitness evaluation, local
search, and similarity test. At the beginning of each cycle, the old
population is evolved by means of the genetic operators, one-point
crossing over and mutation, and a new population is generated.
The new genetic material is decoded and the binding energy is
evaluated. For the best 10% of the individuals, the local search is
performed to improve the ligand fitness. Finally, the individuals of
the old population are replaced by new chromosomes, taking into
account both the energy difference and the conformational simi-
larity.32 The latter dramatically improves the efficiency of the
hybrid search because the local search can easily cause the system
to get trapped in local minima. In fact, to avoid premature con-
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vergence it is important to keep structural diversity during the
evolution. As a local optimizer, the Solis and Wets algorithm33
was used with the following parameters: The maximum number of
iterations per search was set to 300; the local search stepsize ()
was 0.1 radian; the maximum number of consecutive successes
before increasing  was 5, while the maximum number of consec-
utive failures before decreasing  was 3; the lower bound on , i.e.,
the termination criterion for the local search, was 0.01.
Postprocessing by CHARMM Minimization
For every docking experiment, 10 genetic algorithm runs were
performed. For each run, the binding mode with the lowest FFLD
energy was postprocessed by CHARMM minimization34 using the
CHARMm22 force field (Accelrys, Inc.). The structure of the
protein, including the critical bridging water, was held fixed. A
distance-dependent dielectric function [(r)  r] was used and
the conjugate gradient minimization was stopped when the root
mean square of the energy gradient reached a value of 0.01 kcal
mol1 Å1. The CHARMM-minimized ligand conformations
were sorted according to their binding energy and the lowest-
energy solution was compared to the reference ligand (see Prepa-
ration of the Ligands section below). The heavy atom root mean
square deviation (RMSD) from the reference was determined as a
quantitative measure of the docking reliability. No least-square
superposition is used in calculating the RMSD because the rigid
protein establishes a fixed frame of reference.
System Setup
Test Cases
To evaluate the performance of the improved version of the
SEED–FFLD procedure, five HIV-1 PR protein–ligand complexes
were considered. Inhibitors of HIV-1 PR are peptidomimetic mol-
ecules with a dozen or more rotatable bonds and, as such, they
present a challenging target for automated docking techniques.
Moreover, a large number of crystallographic structures of HIV-1
PR protein–ligand complexes are available from the Protein Data
Bank (PDB) database.35 The crystal structures used in this study
were 1hvr, 1hbv, 1htg, 1hvs, and 5hvp.36–40 The corresponding set
of ligands is characterized by a wide range of torsional degrees of
freedom (between 10 and 22 rotatable bonds) and contains a
certain amount of diversity due to the different functional groups
(Fig. 1). The ligand 1hvr has the lowest number of rotatable bonds
(10) and is the only nonpeptidic inhibitor of the set. It includes
aromatic fragments suitable as anchors and contains a large central
scaffold, the cyclic urea, which significantly reduces the complex-
ity of its conformational space by decoupling most of the torsional
degrees of freedom. Moreover, the cyclic urea itself strongly
interacts with the protein, forming on one side hydrogen bonds
with the flaps and on the other side hydrogen bonds with the
aspartyl dyad. Therefore, the ligand 1hvr is expected to be the
simplest test case of the set. The ligands 1hbv and 1htg present a
larger amount of flexibility (15 and 17 rotatable bonds, respec-
tively) with respect to 1hvr and therefore represent a test system
having an intermediate level of difficulty. Eventually, the ligands
1hvs and 5hvp (21 and 22 rotatable bonds, respectively) provide
very difficult test cases because of the large conformational space.
In addition, the N-((2-naphthylsulfonyl)glycyl)-DL-p-amidino-
phenylalanyl-piperidine (NAPAP)/human -thrombin complex41 and
the complex between lig15 and the estrogen receptor 42 were inves-
tigated to measure the robustness of the docking method. The former
is a cross-docking experiment in the uncomplexed structure of the
Figure 1. HIV-1 PR inhibitors used in this work. Coordinates for each
complex were obtained from the PDB35 using the accession codes
given in bold. Bonds that were treated as flexible are marked by curly
arrows; gray and black arrows indicate side-chains14 and main-chain,
respectively. Fragments used in SEED are in bold. Experimental free
energies of binding (kcal/mol) are given in parentheses; they were
obtained from the primary reference for each crystallographic struc-
ture.36–40
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human -thrombin (1hgt). The latter is a redocking simulation in the
“native” conformation of the estrogen receptor  (1nde). NAPAP is a
peptidomimetic molecule with eight rotatable bonds. It includes two
large hydrophobic fragments, naphthalene and piperidine, and the
positively charged benzamidine. Lig15 is a 1, 3, 5-triazine-based
molecule with 11 rotatable bonds. The ligand presents a trisubstituted
planar central scaffold (the triazine) with flexible linkers to hydropho-
bic substituents.
Preparation of the HIV-1 PR Structures
The five crystal structures were downloaded from the PDB data-
base.35 The ligand and all water molecules but one were removed.
The water bridging the two flaps was retained except for the
docking runs with either the 1hvr protease structure or the 1hvr
ligand (cyclic urea inhibitor). The side-chains of lysine and argi-
nine residues were protonated, as well as the side-chains of histi-
dine residues because the optimal pH of HIV-1 PR is around 5 and
they are exposed to the solvent. The carboxylate groups of aspartic
and glutamic acid were ionized. Particular attention was addressed
to the ionization state of the cleavage site, which contains the
aspartyl dyad (Asp25/Asp25
). At optimal pH for enzymatic ac-
tivity (5–6), the aspartyl dyad is most probably monoprotonated
in the uncomplexed enzyme. Besides the pH, different inhibitors
can have an effect on the ionization state of the active site because
they can stabilize the neutral dyad or the negatively or dinegatively
charged forms. According to Piana et al.,43 the monoprotonated
state is accompanied by the presence of two strong hydrogen
bonds between the aspartyl dyad and H-bond donors belonging
either to the inhibitor or to an ordered water molecule. Hence, a
monoprotonated state was considered for the proteases 1hvr and
1hvs, while a diprotonated state was chosen for the others. Hy-
drogen atoms were added to the structures and minimized with the
program CHARMM34 and the CHARMm22 force field (Accelrys,
Inc.). Partial charges were assigned using the MPEOE meth-
od.44,45 Finally, the binding site was defined as the smallest zone
that encompasses the HIV-1 PR residues with more than 50% of
the atoms within a distance of 5 Å from any atom of the inhibitor
in the X-ray structure of the complex.
Preparation of Human -Thrombin and the Estrogen
Receptor 
After downloading the crystal structures from the PDB database,35
human -thrombin (1hgt) and the estrogen receptor  (1nde) were
prepared following a procedure similar to the one described above
for HIV-1 PR.
Human -thrombin is a trypsin-like serine protease that fulfills
a central role in both hemostasis and thrombosis.46 Several inhib-
itors are known to bind to the nonprime region of the active site,
i.e., pockets S3–S1. The S3 and S2 pockets are hydrophobic. S3 is
occupied by an aromatic ring in most of the known inhibitors and
by the Phe side-chain in the natural substrate. The S2 pocket is
usually filled by aromatic or aliphatic side-chains. The S1 pocket
is a cylindrical cavity with an Asp at the bottom. It is usually filled
by a positively charged side-chain (Arg, Lys, benzamidine, etc.)
involved in a salt bridge with the Asp. During the preparation of
the protein, particular attention was addressed to the protonation
state of the active site residues (His, Asp, Ser). In particular, the
catalytic His was protonated at the  nitrogen. Its monoprotonated
state is fully compatible with its partially buried position in the
binding site and allows the formation of two intramolecular hy-
drogen bonds between the residues of the catalytic tryad.
The estrogen receptor  is a ligand-activated transcription
factor that plays a key role in the modulation of gene expression.
It binds a wide range of steroidal and nonsteroidal ligands with
moderate to high affinity, with the minimal requirement of at least
one paramonosubstituted phenol as the basic pharmacophore.42
The estrogen receptor  binding site is almost buried and predom-
inantly hydrophobic. Nevertheless, the paramonosubstituted phe-
nol increases the ligand binding affinity because its hydroxyl group
fits optimally into the gap between Arg394 and Glu353, accepting
a hydrogen bond from the guanidinium and donating a hydrogen
bond to the carboxy group.42 In the structure downloaded from the
PDB database,35 the coordinates of 24 residues were missing due
to poor electron density. These incomplete regions were far away
from the binding site and were neglected in the docking experi-
ments.
Preparation of the Ligands
The initial coordinates were downloaded from the PDB database.35
Formal charges were assigned by ionizing carboxylic-acid groups
and protonating amino groups. Hydrogen atoms were added and
partial charges were assigned (see previous subsection). The mo-
lecular structure was minimized in two different ways with the
program CHARMM34 and the CHARMm22 force field (Accelrys,
Inc.).
The first minimization was carried out in the binding site with
the protein fixed. For redocking, the ligand structure optimized
within its own protein conformation is used as reference for the
calculation of the RMSD values. For cross-docking, protein coor-
dinates were first superimposed by fitting the C atoms. The ligand
conformation then optimized in the “non native” protein is used as
the RMSD reference structure. In both cases, the reference struc-
tures used for evaluating docking results differ from the experi-
mental conformation of the bound ligand. Nevertheless, the com-
parison between reference and predicted conformations is more
consistent in this way because both structures correspond to min-
ima of the same energy function (CHARMm22, Accelrys, Inc.).
For redocking, the RMSD between X-ray and reference structures
was 0.4, 0.6, 0.7, 1.0, 1.1, and 1.0 Å for 1hvs, 1htg, 1hvr, 1hbv,
5hvp, and 1nde, respectively. The average RMSD between X-ray
and reference structures for cross-docking was 1.3  0.4 Å, with
a maximum value of 2.4 Å.
The second ligand minimization was performed outside of the
receptor to remove any bias originating from the PDB structure of
the protein–ligand complex [see type (3) docking experiments
below]. Both minimizations were carried out using the same pro-
tocol as described before for the postprocessing.
Results and Discussion
The results on HIV-1 PR are discussed first while the human
-thrombin and estrogen receptor  results are at the end of this
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section. Each of the five HIV-1 PR ligands was docked to each of
the 5 protein structures, yielding a matrix of 25 docking experi-
ments. The complexes along the matrix diagonal correspond to
redocking experiments and are expected to more easily match the
crystallographic structures because any “induced fit” due to the
inhibitor is already present in the protein conformation. To study
the effect of both ligand flexibility and geometry (covalent bond
distances and bond angles in the ligand input structure) on the
docking results three kinds of docking experiments were per-
formed:
1. Biased geometry and partial flexibility. The covalent geometry
of the ligand was minimized with CHARMM in the binding site
of the receptor before running FFLD. The docking experiments
were performed with flexible ligand side-chains and rigid main-
chain (same rotatable bonds as in ref. 14; gray arrows in Fig. 1).
2. Biased geometry and full flexibility. The covalent geometry of
the ligand was the same as in (1) but the experiments were
carried out allowing flexibility to all rotatable bonds (gray and
black arrows in Fig. 1).
3. Unbiased geometry and full flexibility. The ligand structure
was minimized with CHARMM outside of the receptor to
remove any geometric bias. The ligand flexibility was the same
as in (2).
Conformations docked within 2.4 Å heavy-atom RMSD from the
reference structure are considered successes.
Biased Geometry and Partial Flexibility
In docking experiments (1), the SEED–FFLD procedure was able
to correctly dock the five ligands in each of the five protein
structures (Fig. 2, top). Upon CHARMM minimization, the low-
est-energy conformation for each experiment reproduced the crys-
tallographic binding mode very well with a maximal RMSD of 1.1
Å with respect to the reference structure. Moreover, all of the 10
docking runs gave the same binding mode in 23 of 25 cases. Lack
of full convergence for inhibitors 1hbv and 1htg in the 1hvr HIV-1
PR conformation was probably due to the lack of the water
bridging the flaps in the 1hvr structure of the protease. This
structural water plays an important role in the molecular recogni-
tion process, acting as anchor in the active site. Note that the
CHARMm energy of the docking solution can be up to 16 kcal/
mol (1htg in 5hvp) more favorable than the energy of the reference
structure despite RMSD values smaller than 1.2 Å (Fig. 2, top).
This is mainly due to electrostatic contributions coming from a
better placement of the hydroxyl hydrogen interacting with the
catalytic dyad (hydrogens are not considered in the RMSD eval-
uation). Albeit successful, the docking experiments of type (1)
assume the knowledge of the backbone conformation of the bound
ligand and are therefore only marginally useful (e.g., to dock a
library of compounds with the same backbone).
Biased Geometry and Full Flexibility
In docking simulations of fully flexible ligands, such as experi-
ments (2) and (3), the conformational space of the ligand is much
larger than in (1). Nevertheless, in experiments (2) redocking and
cross-docking of inhibitors 1hvr and 1hvs gave good results while
cross-docking of 1hbv, 1htg, and 5hvp was only partially success-
ful.
Cross-docking with the ligand 5hvp and with the protease 1hvr
proved difficult for the SEED–FFLD procedure. In the first case,
the large conformational space of the ligand (22 rotatable bonds)
and the lack of fragments suitable as anchors were crucial for the
poor performance of the simulations. Moreover, the wrong binding
modes have a CHARMm energy more favorable than the reference
structure (Fig. 2, right) and this points to limitations of the energy
model. As an example, the misdocked conformation of the ligand
5hvp in the protease 1hvr (RMSD of 3.8 Å and Epred
CHARMm 
Eref
CHARMm  18.9 kcal/mol) is completely bent in the middle,
folds back onto itself, and occupies only half of the binding site
“cylinder.” Although both inter- and intramolecular van der Waals
interactions are optimized by this binding mode, the negatively
charged terminal carboxy group is buried. This is a clear indication
that solvation is needed for the final ranking of the solutions,
especially for very flexible ligands without anchors.
The lack of the structural water in the protease 1hvr precluded
the reproduction of the experimental results. Although successful,
most of the redocking and cross-docking experiments did not
converge in all cases (Fig. 2, middle). This is due to the large space
accessible to ligands and in particular to the presence of flexibility
in the main-chain. In fact, only the convergence for the ligand
1hvr, which has a rigid central ring rather than a flexible main-
chain, was not affected by the increased number of rotatable
bonds.
Unbiased Geometry and Full Flexibility
As for the docking experiments of type (1), experiments (2) require
the knowledge of the bound complex, at least for determining the
geometry of the input ligand structure. Therefore, to reproduce the
typical high-throughput docking conditions completely unbiased
docking simulations, experiments (3), were performed. Here, re-
docking was successful in three of five cases (1hvr, 1htg, and
1hvs), while cross-docking gave good results only for the highly
flexible ligand 1hvs (Fig. 2, bottom). Experiments of type (3) are
much more prone to fail with respect to experiments of type (2),
even though both deal with the same amount of ligand dihedral
flexibility. With respect to this point, the docking simulations of
the ligands 1hvr and 1hbv are in particular significant. For the 1hvr
inhibitor, while experiments (2) always converged to the reference
structure experiments (3) completely misdocked the ligand in the
majority of the cross-docking simulations. In the case of ligand
1hbv, while partially successful in experiments (2) and (3) did not
reproduce the experimentally determined binding mode.
The explanation for this clear worsening in the performance of
docking calculations is to be searched for in the covalent geometry
of the ligand structures used as input in experiments (2) and (3).
Therefore, for each docking simulation the biased and unbiased
input structures were superimposed and compared. In most cases,
the biased structure, i.e., the geometry of the bound ligand, was far
away from the energy minimum and the CHARMM minimization
performed outside of the receptor yielded geometries not compat-
ible with the binding site (Fig. 3). In the ligand 1hvr, the covalent
angle at the methylene carbons linking the naphthalenes to the
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cyclic urea is stretched to about 120° in the bound conformation to
optimize the van der Waals interactions between the naphthalenes
and the protein. In the minimization outside of the receptor, the
covalent angle at the methylene carbons relaxes to a value of about
113°.
Analogous considerations can be made for the ligand 1hbv
(Fig. 3). Here, the geometry of the nitrogen atom belonging to the
cyclic scaffold is stretched to about 120° in the bound conforma-
tion. Upon minimization outside of the receptor, the geometry at
the nitrogen atom relaxes and moves to a more pronounced tetra-
hedral geometry. In both cases, the CHARMM minimization out-
side of the receptor significantly modifies the covalent geometry of
the ligands so that the SEED–FFLD approach cannot reproduce
the experimental binding mode only by dihedral modifications of
the input structure.
For redocking 1hvr and cross-docking of 1hvr into 1htg, this
problem was overcome by CHARMM postprocessing. The lowest-
energy conformation found by the SEED–FFLD procedure was
Figure 2. Results of the docking simulations. Redocking (boxes along the diagonals) and cross-docking
experiments of types (1), (2), and (3) are presented from top to bottom, respectively. In the left column,
heavy-atom RMSD values between the docked conformation of most favorable energy and the reference
structure are given (Å). For redocking experiments, RMSD values to the unminimized experimentally
determined ligand positions are reported in parentheses. In the middle column, the convergence of docking
experiments are given in terms of percent ratio of successes. Docking predictions within 2.4 Å RMSD of
the reference structure were considered successes. In the right column, the CHARMm energy difference
between the docking solution and the reference structure is reported. Large negative values indicate
limitations in the scoring function whereas positive values may point to uncomplete sampling.
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close to the X-ray structure so that during CHARMM postprocess-
ing the experimental binding mode was reproduced. However, it
has to be mentioned that this was a fortuitous event. In fact,
cross-docking of the 1hvr inhibitor failed in three of four experi-
ments (Fig. 2, bottom). It is important to note that the CHARMm
energy of the docking solution is much poorer than the one of the
reference structure not because the sampling in dihedral space was
incomplete. Rather, the reason is that the optimal covalent geom-
etry (obtained by minimization outside of the binding site) pre-
vents the FFLD docking from reaching the basin of the CHARMm
energy that contains the X-ray structure. Hence, the docking pro-
cedure has no chance to succeed, even after CHARMM postpro-
cessing. This happened also with the ligand 1hbv, where even
redocking was not successful. Here, the apparently small defor-
mation of the central ring (Fig. 3) played a crucial role in docking
and was the main reason for the observed failures.
The ligand 1hvs has similar biased and unbiased input struc-
tures (Fig. 3), i.e., there is not any significant deformation in the
bound conformation. Hence, the unbiased geometry cannot pre-
vent SEED–FFLD from finding a solution close to the correct one
and the performance of experiments (2) and (3) are comparable.
However, the biased and unbiased geometry structures are not
identical and the ligand poses predicted by experiments (3) are
slightly worse than those in (2) (Fig. 2).
Another interesting case is the redocking of the ligand 1htg and
its cross-docking with the protease 1hbv. As shown in Figure 2,
using a biased input structure (middle) both docking simulations
were successful while using an unbiased input structure (bottom)
only redocking succeeded. To understand how the covalent geom-
etry influenced the performance of the simulations, the biased and
unbiased input structures are analyzed. Figure 3 shows that for
redocking the molecular conformations can be well superimposed
and that no important deformation of the covalent geometry occurs
upon binding. On the contrary, for cross-docking the geometry of
the nitrogen in the central ring of the biased conformation is
stretched and the unbiased structure significantly differs from the
one minimized in 1hbv. These deformations can preclude the
finding of the solution and were responsible for the cross-docking
failure in experiments (3).
A careful analysis of the results shown in Figure 2 suggests that
there is a correlation between the quality of the docking prediction
and the convergence of multiple runs of the genetic algorithm. This
is partially due to the fact that it is more difficult to dock highly
flexible ligands for which the lack of convergence is a conse-
quence of the large conformational space. In principle, the lack of
convergence could then be used as a criterion for judging the
quality of a docking prediction and as a valuable indicator in
virtual high-throughput screening projects. To evaluate the reli-
ability of a convergence-based criterion, only the cross-docking
experiments of type (c) were considered, yielding a test sample of
20 docking simulations. The redocking simulations were discarded
because they implicitly contain information of the bound complex.
For each of the 20 docking simulations, convergence toward the
lowest-energy conformation (not necessarily the experimental
structure) in 10 FFLD runs with different random generator seeds
was first determined (Fig. 4, top). The convergence values were
then used to build the density plot shown in Figure 4 (bottom). The
density plot is darker in the top right region, which indicates that
convergence is a necessary condition for reliable predictions. Un-
doubtedly, the sample used for testing the convergence-based
criterion is rather small (only 20 docking simulations) and there-
fore it is difficult to draw general conclusions. Nevertheless, the
density plot shows a clear trend and implies that docking experi-
Figure 3. Comparison between ligand structures with biased geome-
try (green carbons) and unbiased geometry (yellow carbons) used as
input for redocking 1hvr, 1hbv, 1hvs, and 1htg and for cross-docking
1htg with the protease 1hbv (from top to bottom, respectively). Sig-
nificant deviations in the covalent angles are marked by broken arcs.
(The pictures of the ligands were drawn using the program PyMOL.48)
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ments with convergence lower than 60% may have not found the
global minimum of the CHARMm22 energy surface and should be
discarded during the analysis of a library screening project.
Convergence toward a unique binding mode in multiple runs of
the genetic algorithm is a necessary but not sufficient condition for
judging the quality of a prediction. It is not sufficient because an
oversimplified energy function with a funnel-like profile together
with a protein conformation that does not allow the reproduction of
the crystal structure will yield convergence on a wrong binding
mode.
Finally, to completely remove the geometric bias of the crystal
structure a conformational search of the ligand 1hvs was per-
formed by high-temperature molecular dynamics in the absence of
the protein. The simulation was run for 2 ns at 400 K using the
Berendsen thermostat and a distance-dependent dielectric function
[(r)  4r]. The final snapshot was minimized and its RMSD
from the X-ray conformation after optimal overlap is 5.8 Å, which
indicates that all of the information was lost and the initial con-
formation for docking was fully unbiased. Redocking was success-
ful with a RMSD of 1.1 Å and a convergence of 80%. This result
can not be generalized. On the contrary, it is likely that the
majority of experiments (3) would deteriorate by using ligand
covalent geometries without any memory of the crystal structure.
Results on Human -Thrombin and the Estrogen Receptor 
To test the approach on binding sites with different physicochem-
ical properties the same docking procedure was applied to human
-thrombin and the estrogen receptor . Human -thrombin pre-
sents an asymmetrical binding site with two hydrophobic pockets
and a hydrophilic cavity specific for positively charged amino
acids (Lys or Arg). Estrogen receptor  has a predominantly
hydrophobic and almost completely buried binding site (see
above). In both cases, starting from an unbiased and fully flexible
conformation of the ligand [see type (3) docking experiments
above] the SEED–FFLD approach was able to correctly reproduce
the experimentally determined binding modes with RMSD smaller
than 1 Å and convergences larger than 90%.
Judging Search Methods
To evaluate the performance of the hybrid search procedure it was
compared with the GA of the original version of FFLD.10
For this purpose, unbiased redocking experiments were re-
peated without using the local optimizer during the evolution and
with the same amount of energy evaluations. The simulations
clearly show that a hybrid search is more efficient than GA
because it always reaches a lower-energy conformation. The re-
sults of two redocking experiments carried out with both search
methods are presented in Figure 5. For redocking 1hvr, a hybrid
search is more efficient than the GA, especially at the beginning of
the simulation, where the energy gap is large. At about 60% of the
evolution the gap decreases and the performance of the two meth-
ods is comparable. For redocking 1hvs, the hybrid search performs
better during the entire simulation and the energy gap increases
until the end. Moreover, the standard deviation of the hybrid
search evolutions (shown as error bars in Fig. 5) is larger, indi-
cating that it is less prone to premature convergence than the GA.
The comparison shows that the local search accelerates con-
vergence of the simulations and dramatically improves the quality
of the docking predictions in case the conformational space of the
ligand is large and its torsional degrees of freedom are strongly
coupled (main-chain flexibility). This is mainly due to the fact that
random perturbations of binary strings performed by the GA
during the evolution correspond to radical jumps in the energy
landscape and may be too large. On the contrary, the local opti-
mizer is able to refine large perturbations due to crossover and
mutations and leads to a better investigation of the energy land-
scape. The results of the present docking study suggest that hybrid
search methods should be preferred to canonical genetic algo-
rithms.
Figure 4. Evaluation of the convergence-based criterion proposed for
judging the quality of the docking predictions. Top, convergence
toward the lowest energy solution (not necessarily the experimental
structure) in 10 docking runs is shown for the cross-docking experi-
ments of type (3). Bottom, the density plot reports the frequency of
finding a certain RMSD between the lowest-energy ligand pose and
the experimental structure for a given amount of convergence; darker
colors represent higher-frequency values.
420 Cecchini et al. • Vol. 25, No. 3 • Journal of Computational Chemistry
Computational Requirement
All docking simulations were carried out on 1.6-GHz Athlon
processors. For experiments of type (1), because of the limited
amount of ligand flexibility fast docking calculations were per-
formed, having a maximum number of 50 hybrid search cycles per
run. The computational time required for a single docking varied
from 5 to 19 min, yielding an average time of 12 min/run. For
experiments of types (2) and (3), both carried out with full ligand
flexibility, more extensive calculations were performed, using ap-
proximately 1 million energy evaluations per run. The computa-
tional time required for a single docking varied from 123–214 min,
yielding an average time of 168 min/run. In these experiments, the
number of energy evaluations per run was intentionally overesti-
mated to make sure that the stochastic algorithm used for docking
reached convergence in all cases. The computational requirements
given above do not include docking of molecular fragments by
SEED,23 which was performed only once for each protein confor-
mation.
Conclusions
Four main conclusions can be drawn from the docking results.
First, a hybrid approach consisting of a local search and genetic
algorithm significantly improves the quality of the SEED–FFLD
docking predictions at a moderate additional computational cost.
This is not a new finding31 but simply provides further evidence
with more stringent test cases, i.e., cross-docking experiments with
highly flexible ligands.
Second, the quality of docking predictions depends on the
degree of ligand flexibility and we suggest that validation of
docking approaches should be always done with full dihedral
flexibility of the ligands. In this respect, it would be interesting if
the study of O¨sterberg et al.14 could be repeated without holding
the main-chain of the peptidic inhibitors rigid.
Third, automatic approaches that sample only in dihedral space
can give misdocked predictions if the covalent geometry of the
ligand (i.e., its bond angles and lengths) is strained upon binding
to its target. Therefore, a reliable validation of a docking approach
should be performed without using any information on the con-
formation of the bound ligand, i.e., after a conformational search
outside of the receptor. This was not done in previous works by us
and others.10,14,22,29,31,47 For docking a limited set of compounds,
approaches that allow for full flexibility (including bond angles
and lengths) of the ligands, albeit computationally expensive,
should be preferred.11,12
Fourth, the docking results indicate that convergence toward
the same docking solution in multiple runs of the genetic algorithm
is a necessary (but not sufficient) condition for reliable predictions.
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Abstract: A fragment-based docking procedure followed by
substructure search were used to identify active-site â-secre-
tase inhibitors from a composite set of about 300 000 and a
library of nearly 180 000 small molecules, respectively. EC50
values less than 10 µM were measured in at least one of two
different mammalian cell-based assays for 12 of the 72
purchased compounds. In particular, the phenylureathiadia-
zole 2 and the diphenylurea derivative 3 are promising lead
compounds for â-secretase inhibition.
Alzheimer’s disease is the most common neurodegen-
erative disease and accounts for the majority of the
dementia diagnosed after the age of 60.1 Amyloid
plaques, which are found in the post-mortem brain of
Alzheimer’s disease patients,2 consist mainly of fibrillar
aggregates of the Aâ peptide, a proteolytic cleavage
product of the â-amyloid precursor protein (APP). Two
enzymes, γ- and â-secretase (â-site APP cleaving en-
zyme, or BACE-1), are responsible for the sequential
processing of APP.3 Although it is not clear whether the
plaques or oligomeric prefibrillar species are responsible
for neuronal loss and dementia,4 the pepsin-like aspartic
protease BACE-1 has become one of the major Alz-
heimer’s disease targets.1,5 BACE-1 is a very difficult
target as is witnessed by the very small number of
known nonpeptidic inhibitors.1,5-7 Moreover, not a single
BACE-1 inhibitor was found in a library containing
more than 1800 renin inhibitors,8 despite the fact that
both BACE-1 and renin are pepsin-like enzymes. In
addition, a single molecule (1,3,5-trisubstituted benzene)
emerged as a BACE-1 inhibitor from a multimillion
compound library submitted to a high-throughput screen-
ing campaign.9
Here, we report the identification of a dozen BACE-1
inhibitors with a common phenylurea scaffold by our
in silico screening approach that consists of four steps
(details of the methods are in Supporting Information).
First, each molecule is automatically decomposed into
rigid fragments by the program DAIM (decomposition
and identification of molecules; P. Kolb and A. Caflisch,
manuscript in preparation). In a second step the frag-
ments are docked into the rigid binding site by the
program SEED,10,11 which approximates solvation ef-
fects by continuum electrostatics.12 As an improvement
with respect to previous versions of SEED,10,11,13 the
screened electrostatic interaction and fragment desol-
vation energy were evaluated using an empirical cor-
rection of the Coulomb field approximation, i.e., eq 8 of
ref 14. In the third step the optimal SEED binding
modes of the fragments are then used as binding site
descriptors to guide the placement of the flexible
molecules by the docking program FFLD (fragment-
based flexible ligand docking), which is based on a
genetic algorithm.13,15 The most favorable FFLD binding
modes are further minimized in the rigid protein using
the CHARMM program.16
The final step of our approach is the evaluation of the
binding free energy with solvation effects,17 which is an
essential element of the in silico screening procedure.
Computer-aided approaches for docking libraries of
small molecules into proteins of known structure require
fast and accurate methods for the evaluation of binding
free energies.18-22 Rigorous approaches to evaluate
relative binding affinities such as free energy perturba-
tion and thermodynamic integration have sampling and
convergence problems that prevent them from being
used routinely.23 Moreover, it is very difficult to handle
large 2D structural diversity between ligands, e.g., in
the case of completely different core structures.18 Sev-
eral semiempirical methods based on linear approxima-
tions to the free energy have been introduced and used
with success.22 A decade ago A° qvist and co-workers
proposed the LIE (linear interaction energy) method to
calculate free energies of binding by averaging interac-
tion energies from molecular dynamics (MD) simula-
tions of the ligand and the ligand/protein complex.24,25
To improve efficiency, which is essential for evaluating
large libraries of compounds, we have replaced the MD
sampling with a simple energy minimization and com-
bined the LIE method with a rigorous treatment of
continuum electrostatics, i.e., numerical solution of the
Poisson equation by the finite-difference technique.26
The modified LIE approach, termed LIECE where the
last two letters stand for continuum electrostatics, was
shown to have an accuracy in the binding energy
prediction of about 1 kcal/mol for a set of 13 and 29
peptidic inhibitors of BACE-1 and HIV-1 aspartic pro-
tease, respectively.17 It was also shown that a LIECE
model parametrized on HIV-1 aspartic protease is not
transferable to BACE-1 and vice versa.17 Hence, in
general the LIECE approach cannot be used in virtual
screening against a target for which no inhibitor is
known. On the other hand, a recent application to three
different kinases indicates transferability of the LIECE
parameters (Huang, Kolb, and Caflisch, unpublished
results).
Initially, about 300 000 molecules with at least one
hydroxyl group were selected from a collection of chemi-
cal libraries containing about six million compounds.
The in silico screening of these 300 000 molecules, i.e.,
docking and LIECE energy evaluation, took about 10
days on a Beowulf cluster of 100 1.8-GHz Opteron
# This paper is dedicated to Martin Karplus on the occasion of his
75th birthday.
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CPUs. The rigid conformation of BACE-1 from its
complex with the OM00-3 inhibitor (PDB code 1m4h 27)
was used for the docking. Interestingly, only 10 com-
pounds had a LIECE-predicted affinity in the high-
nanomolar range and most of them were phenylurea
derivatives with the two NH groups involved in hydro-
gen bonds with one of the two catalytic aspartates.
Unfortunately, these 10 compounds were no longer
available from the original vendor. Therefore, we de-
cided to select from the six million molecule collection
all of the nearly 32 000 compounds with a phenylurea
moiety, i.e., those with (only 1233 molecules) and
without a hydroxyl group. These nearly 32 000 com-
pounds were docked; the poses with the most favorable
FFLD energy were further minimized by CHARMM,16
and the energetically most favorable 50 000 poses (8558
different molecules) were evaluated by the LIECE
approach.17 The LIECE binding energy evaluation was
performed in two steps using first a grid spacing of 1.0
Å in the finite-difference Poisson calculation followed
by a more accurate calculation with a grid spacing of
0.3 Å for the best 2000 poses. The two-step LIECE
procedure required about 20 h on the Beowulf cluster
of 100 CPUs. Upon visual inspection of the top 200 poses
(131 different molecules), 10 compounds were purchased
and tested in an enzymatic assay with purified BACE-1
and in two cell-based assays. We first tested the cellular
activity of the selected compounds by measuring Aâ
peptide secretion.28 To confirm BACE-1 inhibition in an
additional mammalian cellular assay we established the
so-called SEAP (secreted alkaline phosphatase) system.
For this system, HEK 293 cells were transfected with a
SEAP-APP fusion protein bearing the SEAP enzyme
moiety localized in the topologically extracellular space,
such as ER/Golgi lumen and endosomes, or also at the
cell surface.29 This protein is anchored to cellular
membranes via a portion of APP harboring the Swedish
mutation at the â-site and the K612V mutation at the
R-site. Endogenous â-secretase activity causes liberation
and subsequent secretion of the SEAP enzyme, whose
activity in the supernatant is measured via a chemilu-
minescent read-out. In this way, the diphenylurea
derivative 1 (Table 1) was identified as a low-micromolar
inhibitor of BACE-1. Two of the remaining nine com-
pounds showed low-micromolar activity in at least one
of the two cell-based assays and the enzymatic assay
(data not shown).
An essentially identical screening approach based on
FFLD docking and LIECE postprocessing was applied
to the 2476 compounds in a protease-focused chemical
library. Intriguingly, seven among the 20 compounds
with the most favorable LIECE-predicted affinity had
a phenylurea scaffold. These 20 compounds were pur-
chased and tested. The phenylurea derivative 2 showed
low-micromolar activity in two different mammalian
cell-based assays (Table 1). One of the remaining 19
compounds showed low-micromolar activity in both cell-
based assays and an IC50 of 490 µM in the enzymatic
assay (data not shown).
In a third in silico screening, 391 compounds from a
libary of about 180 000 small molecules were first
selected by similarity search using the phenylurea
scaffold. After the FFLD docking and LIECE postpro-
cessing, 42 compounds were purchased and tested. At
10 µM, 38 of the 42 compounds showed more than 20%
inhibition in at least one of the two cell-based assays.
Moreover, 10 of them have EC50 < 10 µM in the Abeta-
(sw) assay. The two most potent BACE-1 inhibitors
obtained by the similarity search and docking approach
(3 and 4) are shown in Table 1. Despite its smaller size,
3 is as active as 4 in the two cell-based assays and a
factor of about 3 more active in the enzymatic test.
It is interesting to compare 2 with the known non-
peptidic inhibitors of BACE-1 which, as mentioned
above, are rare.1,5 A series of hydroxyethylamine deriva-
Table 1
a The BACE-1 fluorescence resonance energy transfer assay kit was purchased from PanVera (Madison, WI; no. P2985). BACE-1 activity
assays were carried out according to the manufacturer’s instructions. Average value and standard deviation are from three independent
experiments. b Cell-based assay.28 Average value and standard deviation are from three independent experiments. c Cell-based assay.29
Average value and standard deviation are from three independent experiments. d Cytotoxic concentration.33 e See ref 17. f Interference
at concentrations higher than 25 µM. g Percentage inhibition at 3 µM.
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tives of an isophthalamide scaffold have been shown to
have nanomolar affinity by enzymatic30-32 and cell-
based assays.32 The crystal structures of two of these
inhibitors in complex with BACE-1 show that they have
a very similar binding mode despite the different
stereochemistry at the hydroxyl group.31,32 In the cata-
lytic site, the hydroxyl functionality and the protonated
secondary amino group are involved in hydrogen bonds
with the side chain of the catalytic Asp32 and Asp228,
respectively. Moreover, the benzyl functionality close to
the hydroxyl group of the two inhibitors occupies the
S1 pocket in both complexes. The molecular weight of
the hydroxyethylamine compounds (MW ) 531 g mol-1
(ref 30) and MW ) 579 g mol-1 for 3 (ref 32)) is larger
than the one of compound 2 reported here (MW ) 322
g mol-1). Furthermore, the binding mode is different
except for the phenyl group of the inhibitor 2 which
occupies the S1 pocket (Figure 1) and overlaps with the
corresponding ring of the benzyl functionality of the
hydroxyethylamine inhibitors. Because of the small size
and rather symmetric overall shape of 2, we decided to
perform minimization in the flexible binding site (library
docking had been performed in the rigid protein) start-
ing from the two end-to-end flipped orientations ob-
tained by the FFLD docking. An alternative binding
mode of inhibitor 2 is observed upon minimization in
the flexible binding site with protonated Asp32 (instead
of Asp228, which was protonated in all other calcula-
tions). In the alternative binding mode, the two NH
groups of the urea scaffold are involved in hydrogen
bonds with Asp228 (instead of Asp32), but the overall
orientation is flipped end-to-end such that the ethylth-
ioether functionality and the phenyl group occupy the
S1 and S1′ pockets, respectively (Figure 2). It is not
possible to apply LIECE to evaluate the two different
binding modes because the LIECE approach requires a
single protein conformation as reference state. Hence,
the CHARMM in vacuo interaction energy supple-
mented by the finite-difference Poisson solvation was
calculated for both binding modes, but the preferred
orientation cannot be determined because the energy
difference of 2.4 kcal/mol is within the limited accuracy
of the estimation due to the flexible protein treatment.
It is important to note that 2 has only two rotatable
bonds. Its limited flexibility and the marginal loss of
entropy upon binding are consistent with its rather high
binding affinity given the small size.
In conclusion, high-throughput docking into the
BACE-1 active site and continuum electrostatics calcu-
lations were used to select for experimental testing 72
compounds from an initial set of about 500 000. Fifty-
nine of these 72 compounds are phenylurea derivatives.
Twelve of the 72 compounds inhibit BACE-1 in at least
one of two different mammalian cell-based assays at
concentration values less than 10 µM. It is important
to note that for almost all of the 12 compounds, for
which an EC50 value could be measured, the discrep-
ancies between LIECE-predicted affinity and the ex-
perimental value is within the LIECE accuracy of about
1 kcal/mol.17 Given their very small size, the pheny-
lureathiadiazole 2 (MW ) 322 g mol-1) and diphenyl-
urea derivative 3 (MW ) 419 g mol-1) may serve as
starting points for further optimization to evaluate their
therapeutic potential for Alzheimer’s disease.
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Figure 1. Superposition of a known nanomolar inhibitor of
BACE-131 (thin lines and carbon atoms in gray) and 2 (thick
lines with carbon atoms in green) in one of its two possible
orientations obtained by docking in the flexible binding
site. The CR atoms of BACE-1 were used for the structural
alignment.
Figure 2. Two possible binding modes of 2 in the BACE-1
active site. Hydrogen bonds are shown by green dotted lines.
The binding mode in the top picture corresponds to the one of
Figure 1.
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Supporting Information Available: Details on computa-
tion approach and experimental tests. This material is avail-
able free of charge via the Internet at http://pubs.acs.org.
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Abstract: Alzheimer’s disease, the most common amyloid-associated disorder, accounts for the majority
of the dementia diagnosed after the age of 60. The cleavage of the â-amyloid precursor protein is initiated
by â-secretase (BACE-1), a membrane-bound aspartic protease, which has emerged as an important but
difficult protein target. Here, an in silico screening approach consisting of fragment-based docking, ligand
conformational search by a genetic algorithm, and evaluation of free energy of binding was used to identify
low-molecular-weight inhibitors of BACE-1. More than 300 000 small molecules were docked and about
15 000 prioritized according to a linear interaction energy model with evaluation of solvation by continuum
electrostatics. Eighty-eight compounds were tested in vitro, and 10 of them showed an IC50 value lower
than 100 µM in a BACE-1 enzymatic assay. Interestingly, the 10 active compounds shared a triazine scaffold.
Moreover, four of them were active in an assay with mammalian cells (EC50 < 20 µM), indicating that they
are cell-permeable. Therefore, these triazine derivatives are very promising lead candidates for BACE-1
inhibition. The discoveries of this series and two other series of nonpeptidic BACE-1 inhibitors demonstrate
the usefulness of our in silico high-throughput screening approach.
Introduction
Insoluble, extracellular amyloid plaques, a histopathological
hallmark in the post-mortem brain of Alzheimer’s disease
patients,1 consist mainly of fibrillar aggregates of the amyloid-â
(Aâ) peptide, which is a proteolytic cleavage product of the
â-amyloid precursor protein (APP). Two enzymes, γ- and
â-secretase (â-site APP cleaving enzyme, or BACE-1), are
responsible for the sequential processing of APP.2 Genetic
deletion of BACE-1 in mice has been shown to abolish
â-amyloid formation with an otherwise normal, i.e., healthy,
phenotype.3 Although there is no definitive evidence whether
the plaques or oligomeric prefibrillar species are responsible
for neuronal loss and dementia,4 the pepsin-like aspartic protease
BACE-1 is considered an important target for the development
of small-molecule inhibitors to fight Alzheimer’s disease.5,6 The
relatively small number of known nonpeptide inhibitors indicates
that BACE-1 is not an easy target to block.5-8 In fact, not a
single BACE-1 inhibitor was found in a library containing more
than 1800 renin inhibitors,9 despite the fact that both BACE-1
and renin are pepsin-like enzymes. Furthermore, only a single
molecule (1,3,5-trisubstituted benzene) emerged as BACE-1
inhibitor from a multimillion compound library submitted to a
high-throughput in vitro screening campaign.10 It is also
important to note that the recently reported peptidomimetics with
low nanomolar affinity in BACE-1 enzymatic assays are not
active in cell-based assays because of limited penetration across
cell membranes.11 Here, we report the successful application
of our in silico high-throughput docking approach in the
screening of more than 300 000 existing compounds, which has
resulted in the discovery of a series of nonpeptide BACE-1
inhibitors with a common (1,3,5-triazin-2-yl)hydrazone scaffold.
The fragment-based docking procedure, which takes into account
electrostatic solvation, shows a high hit rate and generates few
false positives. Most notably, the combination of in silico
screening with validation by enzymatic and cell-based assays
has led to the identification of several molecules with excellent
potential as lead compounds against BACE-1.
Methods
The essential elements of our in silico screening are a fragment-
based docking procedure and an efficient evaluation of binding free
energy with electrostatic solvation. The latter is presented first because
of its importance for ranking compounds, which is the most challenging
part of the in silico approach.
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Evaluation of Binding Free Energy with LIECE. The linear
interaction energy with continuum electrostatics (LIECE) approach was
recently reported elsewhere.12 Here, only a brief overview of the method
is presented, while the in-depth validation for BACE-1 is given in the
Results and Discussion. The essential aspect of the linear interaction
energy (LIE) method is that the free energy of binding can be calculated
by considering only the end points of the thermodynamic cycle of ligand
binding, i.e., bound and free states. For this purpose, Åqvist and co-
workers proposed to calculate average values of interaction energies
from molecular dynamics (MD) simulations of the isolated ligand and
the ligand/protein complex.13,14 They approximated the free energy of
binding by
where E elec and E vdW are the electrostatic and van der Waals interaction
energies between the ligand and its surroundings. The surroundings
are either the solvent (free) or the solvated ligand/protein complex
(bound). The 〈 〉 denotes an ensemble average sampled over a molecular
dynamics (MD)13 or Monte Carlo15 trajectory, and the parameter R is
determined empirically.13 The LIE method is faster than rigorous free
energy perturbation techniques and has been successfully applied in
the design of a series of inhibitors of the malarial aspartic proteases
Plm I and II.16 Yet, LIE cannot be used for high-throughput docking
because of its computational requirements (about 1 day for each
compound). Therefore, we have replaced the MD sampling with a
simple energy minimization and combined the LIE method with a
rigorous treatment of solvation within the continuum electrostatics (CE)
approximation,12 i.e., the numerical solution of the Poisson equation
by the finite-difference technique.17 The LIECE approach is about 2
orders of magnitude faster than previous LIE methods and shows a
similar precision on the targets tested. In fact, a predictive accuracy of
about 1.0 kcal/mol was observed for 13 and 29 peptidic inhibitors of
BACE-1 and HIV-1 protease, respectively.12
Preparation of the BACE-1 Structure. The X-ray structure of
BACE-1 from its complex with a nanomolar peptidic inhibitor (PDB
code 1M4H18) was used for the in silico screening because BACE-1/
nonpeptide inhibitor structures were not available when this work was
initiated. The side chain of Asp228 was protonated12 (see also below),
while all other Asp and Glu side chains were considered negatively
charged and the Lys and Arg positively charged. Further details on the
protein preparation for docking can be found in the Supporting
Information.
Preparation of the Compound Libraries. Two unrelated libraries
were screened in silico. The first contains about 10 000 molecules with
an average molecular weight of 497.3 ( 42.8 g/mol (Chemdiv Inc.,
2002). The second library is a subset of about 300 000 molecules (424.9
( 71.4 g/mol) selected from a collection of chemical libraries of about
six million compounds (Chemnavigator Inc., 2004). For this selection,
the size and physicochemical character of the substrate binding site
were taken into account by filtering out compounds with molecular
weight smaller than 200 g/mol or larger than 700 g/mol, and molecules
without at least one hydrogen bond donor and acceptor. The 2D-to-3D
conversion was performed using CORINA.19 This step was followed
by the determination of the protonation state and hydrogen coordinates
generation with BABEL,20 the assignment of CHARMm atom types21
and partial charges,22,23 and energy minimization with a distance-
dependent dielectric function.
High-Throughput Fragment-Based Docking. The library-docking
approach consists of four consecutive steps: (1) decomposition of each
molecule of the library into mainly rigid fragments, (2) fragment
docking with evaluation of electrostatic solvation, (3) flexible docking
of each molecule of the library using the position and orientation of its
fragments as anchors, and (4) LIECE evaluation of the binding free
energy for the best poses. The first three steps are performed by in-
house-developed computer programs, while CHARMM24 is used for
the energy minimization and finite-difference Poisson calculations in
the fourth step. The main aspects of the docking approach are illustrated
in the four following subsections, while the details are given in the
Supporting Information.
(1) Decomposition of Library Compounds into Fragments. The
decomposition of a molecule into mainly rigid substructures and
the selection of the three anchor fragments for docking are per-
formed by the program DAIM (Decomposition And Identification of
Molecules, P. Kolb and A. Caflisch, unpublished results). The major
rules are listed in the Supporting Information. The decomposition
generates mainly rigid fragments which can be docked very efficiently
(see below).
(2) Fragment Docking with Evaluation of Electrostatic Solvation.
The docking approach implemented in the program SEED determines
optimal positions and orientations of small to medium-size molecular
fragments in the binding site of a protein.25,26 Apolar fragments are
docked into hydrophobic regions of the receptor, while polar fragments
are positioned such that at least one intermolecular hydrogen bond is
formed. Each fragment is placed at several thousand different positions
with multiple orientations (for a total of in the order of 106 conforma-
tions), and the binding energy is estimated whenever severe clashes
are not present (usually about 105 conformations). The binding energy
is the sum of the van der Waals interaction and the electrostatic energy.
The latter consists of screened receptor-fragment interaction, as well
as values of receptor and fragment desolvation.27
(3) Flexible Docking of Library Compounds. The flexible-ligand
docking approach FFLD uses a genetic algorithm and a very efficient
but approximate scoring function.28,29 FFLD requires three not neces-
sarily different fragments to place a flexible ligand unambiguously in
the binding site, e.g., the fluorobenzene, piperidine, and phenol of
compound 5 (Table 1). Solvation effects are implicitly accounted for
as the binding modes of the fragments are determined with electrostatic
solvation in SEED. Each molecule was docked by three independent
FFLD runs using a population of 100 members for each run and
different initial values for the random number generator.
(4) Clustering and LIECE Binding Energy Evaluation. For each
compound, the best 150 FFLD poses (50 poses from each FFLD run)
were clustered by using a leader algorithm with a similarity cutoff of
0.7.25,30 The representative of each cluster was selected for further
(12) Huang, D.; Caflisch, A. J. Med. Chem. 2004, 47, 5791-5797.
(13) Åqvist, J.; Medina, C.; Samuelsson, J.-E. Protein Eng. 1994, 7, 385-
391.
(14) Hansson, T.; A° qvist, J. Protein Eng. 1995, 8, 1137-1144.
(15) Jones-Hertzog, D. K.; Jorgensen, W. H. J. Med. Chem. 1996, 40, 1539-
1549.
(16) Ersmark, K.; Nervall, M.; Hamelink, E.; Janka, L. K.; Clemente, J. C.;
Dunn, B. M.; Blackman, M. J.; Samuelsson, B.; Åqvist, J.; Hallberg, A. J.
Med. Chem. 2005, 48, 6090-6106.
(17) Warwicker, J.; Watson, H. C. J. Mol. Biol. 1982, 157, 671-679.
(18) Hong, L.; Turner, R. T.; Koelsch, G.; Shin, D.; Ghosh, A. K.; Tang, J.
Biochemistry 2002, 41, 10963-10967.
(19) Sadowski, J.; Gasteiger, J. Chem. ReV. 1993, 93, 2567-2581.
(20) Stahl, M. T. Drug DiscoVery Today 2005, 10, 219-222.
(21) Momany, F.; Rone, R. J. Comput. Chem. 1992, 13, 888-900.
(22) No, K.; Grant, J.; Scheraga, H. J. Phys. Chem. 1990, 94, 4732-4739.
(23) No, K.; Grant, J.; Jhon, M.; Scheraga, H. J. Phys. Chem. 1990, 94, 4740-
4746.
(24) Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan,
S.; Karplus, M. J. Comput. Chem. 1983, 4, 187-217.
(25) Majeux, N.; Scarsi, M.; Apostolakis, J.; Ehrhardt, C.; Caflisch, A.
Proteins: Struct., Funct., Bioinformatics 1999, 37, 88-105.
(26) Majeux, N.; Scarsi, M.; Caflisch, A. Proteins: Struct., Funct., Bioinfor-
matics 2001, 42, 256-268.
(27) Scarsi, M.; Apostolakis, J.; Caflisch, A. J. Phys. Chem. A 1997, 101, 8098-
8106.
(28) Budin, N.; Majeux, N.; Caflisch, A. Biol. Chem. 2001, 382, 1365-
1372.
(29) Cecchini, M.; Kolb, P.; Majeux, N.; Caflisch, A. J. Comput. Chem. 2004,
25, 412-422.
(30) Kearsley, S. K.; Smith, G. M. Tetrahedron Comput. Methodol. 1990, 3,
615-633.
∆Gbind )
1/2 (〈E elec〉bound - 〈E elec〉free) +
R(〈E vdW〉bound - 〈E vdW〉free) (1)
In Silico Discovery of â-Secretase Inhibitors A R T I C L E S
J. AM. CHEM. SOC. 9 VOL. 128, NO. 16, 2006 5437
CHARMM minimization with distance-dependent dielectric function.
During minimization, the protein was kept rigid. In the larger of the
two screening experiments (306 022 compounds, see Results and
Discussion), the minimized poses were re-ranked by the LIECE model
using first a spacing of 1.0 Å for the finite-difference Poisson calculation
as a filter and finally a grid spacing of 0.3 Å for the top 8000 poses,
i.e., 2880 compounds.
Computational Requirements. The LIECE approach requires 26
min (mainly for the finite-difference Poisson calculations with grid
spacing of 0.3 Å) of a CPU of a single Opteron 244 (1.8 GHz) for
each pose in BACE-1. The total CPU time can be further reduced by
first using a coarse grid spacing of 1.0 Å in the finite-difference Poisson
calculation, which takes about half a minute. The in silico screening
of the 306 022 compound library, i.e., docking and LIECE energy
evaluation, took about 10 days on a Beowulf cluster of 100 Opteron
1.8 GHz CPUs.
BACE-1 Enzymatic Assay. The BACE-1 fluorescence resonance
energy transfer (FRET) assay was performed as described by the
manufacturer (PanVera, P2985) with an incubation time of 30 min.
Additional measurements were performed in the presence of detergent
or with an incubation time of only 3 min to check for nonspecific effects
(e.g., compound aggregation31,32). Briefly, fluorescence progress curves
of 30 µL reaction volumes were measured on a Tecan GENios reader
(Ma¨nnedorf, Switzerland) upon excitation at 535 nm and emission at
580 nm in 384-well microtiter plates (Corning, 3654). Linear regression
analysis was calculated with the Magellan 5.0 software (Tecan Austria
GmbH, Salzburg, Austria).
Abeta(sw) (Amyloid â40 ELISA) Cell-Based Assay. Swedish
APP695 transgenic human embryonic kidney 293 cells (HEK 293) were
maintained in Dulbecco’s modified Eagle’s medium (SIGMA) supple-
mented with 10% fetal calf serum (Gibco) and 200 µg/mL G418 (Gibco)
for continued selection of the stably integrated transgene, as described
elsewhere.5 Briefly, a 400× compound stock solution (dissolved in
DMSO) was resuspended in 140 µL of medium lacking G418 and
distributed in poly-L-lysine-precoated 96-well cell culture plates (final
DMSO concentration 0.25%). Immediately thereafter, 50 000 transgenic
HEK 293 cells, resuspended in 20 µL of medium lacking G418, were
added to each well. After 2 days of incubation at 37° C and 5% CO2,
(31) Ryan, A. J.; Gray, N. M.; Lowe, P. N.; Chung, C. W. J. Med. Chem. 2003,
46, 3448-3451.
(32) McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. J. Med. Chem.
2003, 46, 4265-4272.
Table 1. BACE-1 Inhibitors Identified by High-Throughput Fragment-Based Docking
a The BACE-1 fluorescence resonance energy transfer assay kit was purchased from PanVera (Madison, WI; catalog no. P2985). BACE-1 activity assays
were carried out according to the manufacturer’s instructions.Values of average and standard deviation are from three independent experiments. b Cell-
based assay.45 c Cytotoxic concentration in HEK293 cells (not transgenic).47 d See ref 12.
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an ELISA assay to measure Aâ40 in the supernatant was performed
according to the protocol of the manufacturer of the assay kit (The
Genetics Company, Switzerland). In parallel, an XTT assay of the cells
was performed to measure cell viability, thus verifying that a reduction
in the Aâ40 signal is not due to compound toxicity.
Results and Discussion
Validation of the LIECE Model on BACE-1. As in our
previous works,12,33 a two-parameter LIECE model is used
here: ∆Gbind ) 0.2737 ∆E vdW + 0.1795 ∆Gelec, where ∆E vdW
is the ligand/protein van der Waals interaction energy and ∆Gelec
is the sum of the ligand/protein Coulombic energy in vacuo
and the change in solvation energy of ligand and protein upon
binding. Note that the values of the two parameters (R ) 0.2737
and â ) 0.1795) were obtained by using a training set of 13
peptidic inhibitors34 in our previous work12 and have not been
modified since. To further evaluate the predictive power of the
LIECE model for BACE-1, three additional tests were per-
formed.
First, a statistical test based on the randomization of the data
points was used to analyze an eventual chance correlation.35,36
The binding free energies of 13 peptidic inhibitors34 were
randomized within the same range as the experimental values,
i.e., from -14 to -6 kcal/mol, and the two multiplicative
parameters for ∆E vdW and ∆Gelec were determined by fitting
to random “data points”. The randomization and fitting were
repeated 10 000 times, and Figure 1 shows the cross-validated
correlation coefficient (obtained by the leave-one-out procedure)
plotted versus the correlation coefficient. The LIECE model with
the two parameters fitted to the real data points is located in
the top right corner and is significantly separated from the
models generated by the randomization of the binding free
energies. This separation provides further evidence that the
LIECE two-parameter model not only fits the experimental data
but also has very good predictive ability, i.e., chance correlation
is not present.
Second, the recent publication of two X-ray structures of
BACE-1 in the complex with nonpeptide inhibitors (PDB codes
1W5137 and 1TQF10) allowed us to perform additional tests of
the two-parameter model and its robustness with respect to
different protein structures. The LIECE-predicted binding af-
finity of the 1W51 nonpeptide inhibitor was calculated using
two BACE-1 structures, 1W51 and 1M4H.18 Both calculations
gave a LIECE Ki of 0.49 µM, which is close to the experimental
IC50 of 0.2 µM. Furthermore, we tested a series of 12 inhibitors
of BACE-1 based on a 1,3,5-trisubstituted benzene scaffold,10,38
which adopt a nontraditional binding mode with a displacement
of the 10s loop with respect to the 1M4H conformation. These
compounds were manually docked into the binding site of 1TQF
using the 1TQF inhibitor as a template.10 The LIECE binding
free energy values are plotted versus the corresponding experi-
mental values in Figure 2 (see also Table 1 in the Supporting
Information). Remarkably, the root-mean-square of the error
and maximal error are 0.78 and 1.3 kcal/mol, respectively, and
the correlation coefficient is 0.89. In addition, the LIECE model
successfully reproduces the binding energy change between two
compounds which differ only in the stereochemistry at the
R-methyl group pointing toward the P3 pocket (compounds 3
and 4 of ref 10). Therefore, the LIECE two-parameter model
derived from a single structure (1M4H) shows good predictive
ability on a different class of inhibitors, even when the
calculations are based on slightly different BACE-1 conforma-
tions. This result agrees with the previous work on HIV-1
protease inhibitors binding free energy calculation, where the
parameters derived from a single structure were used to
accurately predict the activity of a different series of inhibitors.12
Furthermore, a recent application on 48, 62, and 41 inhibitors
of Lck, CDK2, and p38 kinases, respectively, indicates that the
LIECE model is transferable among enzymes which share a
similar ATP binding site (P. Kolb, D. Huang, F. Dey, and A.
Caflisch, manuscript in preparation). Transferability of LIECE
parameters between slightly different structures of a given
(33) Huang, D.; Lu¨thi, U.; Kolb, P.; Edler, K.; Cecchini, M.; Audetat, S.;
Barberis, A.; Caflisch, A. J. Med. Chem. 2005, 48, 5108-5111.
(34) Ghosh, A. K.; Bilcer, G.; Harwood, C.; Kawahama, R.; Shin, D.; Hussain,
K. A.; Hong, L.; Loy, J. A.; Nguyen, C.; Koelsch, G.; Ermolieff, J.; Tang,
J. J. Med. Chem. 2001, 44, 2865-2868.
(35) Zoete, V.; Michielin, O.; Karplus, M. J. Comput.-Aided Mol. Des. 2003,
17, 861-880.
(36) So, S.; Karplus, M. J. Med. Chem. 1999, 39, 5246-5256.
(37) Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. J. Mol. Biol.
2004, 343, 407-416.
(38) Stachel, S. J.; et al. J. Med. Chem. 2004, 47, 6447-6450.
Figure 1. Statistical test to assess the predictive power of the LIECE two-
parameter model for BACE-1 compared to 10 000 random models (see main
text for details). The fact that the LIECE model data point (red triangle) is
on the right-top indicates that LIECE not only better fits the data than the
random models (black crosses) but has also a better predictive ability.
Figure 2. Cross-validation of the LIECE two-parameter model on 12
BACE-1 inhibitors consisting of a 1,3,5-trisubstituted benzene scaffold.10,38
These 12 BACE-1 inhibitors were not used to derive the LIECE two-
parameter model. The dashed lines emphasize the region corresponding to
a 1 kcal/mol accuracy.
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protein is a useful property, which could be used to take into
account binding site flexibility during in silico screening or hit
explosion. In this context, we have generated a set of low-energy
conformations of BACE-1 using molecular dynamics with
explicit water.39 Because of the transferability of the LIECE
parameters, a virtual screening based on these structures may
find inhibitors with new binding modes.
Third, it is useful to estimate the amount of false positives,
i.e., compounds with good predicted affinity which in reality
do not bind. For this purpose, LIECE binding energies of a
composite set of 37 BACE-1 inhibitors were compared with
those of a library of about 200 000 small molecules (average
value of molecular weight of 407.2 ( 72.2 g/mol; this library
is unrelated to the libraries used for the in silico screening
described here) under the reasonable assumption that very few
of the 200 000 compounds inhibit BACE-1. The compounds
were docked by FFLD, minimized by CHARMM in the rigid
1M4H structure, and the resulting poses were filtered according
to two criteria: the van der Waals intermolecular energy (more
favorable than -40 kcal/mol) and the van der Waals intermo-
lecular energy divided by molecular weight (quotient more
favorable than -0.1 kcal/g). Figure 3 (top) shows a comparison
between the 37 inhibitors (left) and the library of 200 000
compounds (right). Remarkably, 78% and 100% of the known
inhibitors have a LIECE energy in the range of values of the
111 and 1000 library compound poses with the most favorable
LIECE energy, respectively. The 111 and 1000 poses originate
from 100 and 651 different compounds, respectively. In other
words, the large majority of the 200 000 compounds are
predicted to be worse than most of the known inhibitors.
Furthermore, a receiver operating characteristic (ROC) plot40
for the known 37 compounds over the top 1000 poses (Figure
3 bottom) confirms that the LIECE model of BACE-1 does not
generate many false positives.
Effect of Different Protonation States. The protonation state
of the catalytic dyad has been investigated by different groups
recently.41,42 The main observation is that only one of the two
aspartate side chains should be protonated in the presence of
an inhibitor. However, it is still under debate which of the two
side chains should be protonated. All calculations in the present
study and previous works12,33 have been performed with Asp228
protonated and Asp32 negatively charged. To test the robustness
of this choice, docking of the 306 022 compounds of the second
library was repeated using the BACE-1 structure with Asp32
protonated and Asp228 negatively charged. The range of LIECE
energies of the top 500 poses (332 compounds) was -8.40 to
-5.14 kcal/mol, which is comparable to the previous screening
(-8.52 to -5.75 kcal/mol). Importantly, there were 194
compounds in common between the two lists (58%). The four
active compounds (5-8) were ranked in the top 500 list upon
docking with Asp32 protonated, and their LIECE affinities were
18.9, 116.8, 105.5, and 54.7 µM, respectively. These values are
about an order of magnitude less favorable than those obtained
with Asp228 protonated (see below and Table 1).
In Silico Screening and Enzymatic Assay. The DAIM
decomposition of the 10 067 and 306 022 compound libraries
yielded 469 and 4917 unique fragments, respectively. In the
first in silico screening (Figure 4, left), 10 067 compounds were
docked, 1000 poses were further evaluated by LIECE energy
(1000 unique molecules), 64 compounds (19 of which with a
(1,3,5-triazin-2-yl)hydrazone scaffold) were tested in an enzy-
matic assay, and seven (11%) showed an IC50 for BACE-1
smaller than 100 µM. The LIECE ranking of the seven active
compounds was among the first 24 of 1000 molecules. Strik-
ingly, the high hit rate was achieved using solely the LIECE
energy ranking without manual intervention or visual inspection.
In the second in silico screening (Figure 4, right), 306 022
compounds were docked, 58 000 poses were further evaluated
by LIECE (14 085 unique molecules), and 24 compounds (six
of which with a (1,3,5-triazin-2-yl)hydrazone scaffold and a
carboxy group which was negatively charged for docking and
LIECE) were tested in an enzymatic assay. Three of them (12%)
showed an IC50 smaller than 100 µM, and a fourth compound
showed an IC50 of 152 µM. Remarkably, these compounds have
LIECE ranks of first, fourth, seventh, and eighth.
To obtain information on the mechanism of inhibition and
provide evidence against nonspecific effects (e.g., aggrega-
(39) Gorfe, A. A.; Caflisch, A. Structure 2005, 13, 1487-1498.
(40) Zweig, M. H.; Campbell, G. Clin. Chem. 1993, 39, 561-577.
(41) Park, H.; Lee, S. J. Am. Chem. Soc. 2003, 125, 16416-16422.
(42) Rajamani, R.; Reynolds, C. H. J. Med. Chem. 2004, 47, 5159-5166.
Figure 3. (Top) The LIECE two-parameter model does not generate too
many false positives. Comparison between a composite set of 37 known
inhibitors of BACE-1 (left) and the 1000 poses with the most favorable
LIECE energy from a library of 200 000 small molecules (right), the vast
majority of which are not expected to bind to BACE-1. Set1, 13 peptidic
inhibitors developed in Tang’s group;34 Set2, 12 derivatives of a 1,3,5-
trisubstituted benzene scaffold10,38 (see also Supporting Information); Set3,
four phenylurea derivatives;33 Set4, eight compounds listed in Table 1. The
inset on the right plot zooms out on the first 20 000 poses of the library
compounds. (Bottom) Thirty-seven known inhibitors compared to the top
1000 poses as a ROC curve (solid line with triangles). The dashed line of
slope 1 shows the behavior of a random model as a basis of comparison.
The area under the ROC curve is close to the ideal value, which indicates
that the LIECE model generates few false positives.
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tion31,32 or covalent modification), two additional experiments
were performed. First, detergent (0.05% (v/v) Triton X-100)
was added in the enzymatic assay. No significant reduction of
activity was observed. Second, the effect of two different
incubation times, 3 vs 30 min, was investigated for compounds
1 and 5. After the shorter incubation time, the percentage
inhibition at 20 µM concentration of compound 1 is 57%, and
that at 50 µM concentration of compound 5 is 66%. These values
are consistent with the IC50 values measured with 30 min
incubation time (Table 1). Furthermore, two compounds were
tested using another commercially available FRET assay kit
(SIGMA CS0010, which includes Triton X-100 0.08% at final
concentration). With the SIGMA kit, IC50 values of 7 and 32
µM were measured for compounds 7 and 8, respectively.
Compound 7 shows 1 order of magnitude difference in the IC50
value measured with two different kits. This discrepancy is likely
to be a consequence of differences in substrate, protein, and
assay buffer.
Interestingly, the 11 active compounds (10 with IC50 < 100
µM and one with IC50 ) 152 µM) from the two in silico
screenings have a common (1,3,5-triazin-2-yl)hydrazone scaf-
fold. Table 1 shows structure as well as experimental and
predicted affinity of eight compounds, four from each screening.
Compounds 1-3 differ only in the substituents of the ring at
R3, and compounds 5 and 6 are also very similar.
Binding Mode. The predicted binding mode of compound 5
is shown in Figure 5, overlapped with the cycloamide-urethane-
derived peptidic inhibitor 2c of ref 43. The hydrogen atom of
the hydrazone NH group is at a distance of about 4 Å from two
oxygen atoms in the catalytic aspartates. Such distance suggests
Figure 4. Schematic picture of the two applications of the in silico screening approach. FDP stays for finite-difference Poisson calculations.17
Figure 5. Stereoview of the superposition of a known nanomolar inhibitor of BACE-143 (carbon atoms in black) and compound 5 (carbon atoms in green).
The side chains of the catalytic residues Asp32 and Asp228 are shown together with the distances between their oxygen atoms and the hydrazone NH of
compound 5 or the hydroxyl group of the known nanomolar inhibitor (dashed lines). The structural alignment was generated taking into account only the
CR atoms of the two BACE-1 structures 1XS743 and 1M4H,18 which overlap with a deviation of only 0.3 Å. The 1M4H structure was used for the high-
throughput docking.
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the presence of a water-bridged hydrogen bond as observed in
the X-ray structure of BACE-1 in the complex with an oxy-
acetamide compound (IC50 ) 1.4 µM, PDB code 1TQF10) and
in the structure of plasmepsin II complexed with an inhibitor
featuring a tertiary amino group close to the two catalytic aspar-
tates.44 The S2, S2′, and S3′ pockets of BACE-1 are occupied
by the 2-hydroxybenzoic acid, piperidine, and fluorobenzene
substituents of compound 5, respectively. The 2-hydroxybenzoic
acid and piperidine of 5 overlap with part of the macrocycle
and P2′-propyl side chain of 2c, respectively. On the other hand,
the fluorobenzene of 5 has a slightly different orientation
compared to the benzyl group of 2c. The furan and (1,3,5-triazin-
2-yl)hydrazone mimic part of the peptidic backbone of 2c.
The predicted binding mode of compounds 6-8 is essentially
identical to the one of 5, while the R3 substituent of compounds
1-4, which lack the furan linker, points toward the S1 pocket.
Given the small range of measured IC50 values and uncertainties
in the details of the predicted binding mode (determined by
FFLD docking and energy minimization in the rigid BACE-1
structure), it is not possible to obtain a detailed structural
explanation of the measured relative affinities. The rather small
differences in measured affinities is consistent with the fact that
compounds 1-8 are similar among each other and show similar
predicted binding modes.
Cellular Assay. To assess the potential for further develop-
ment, e.g., hit explosion, it is important to verify that the
compounds which are active in the enzymatic assay are also
cell-permeable and able to inhibit BACE-1 in mammalian cells.
For this purpose, 7 and 24 compounds from the first and second
screening, respectively, were submitted to a cell-based test in
which reduction of Aâ peptide secretion was measured as
reported previously by others.45 Table 1 shows that compounds
3 and 5-7 from the first and second screenings are active, with
EC50 < 10 µM and EC50 < 20 µM, respectively.
It is interesting to note that compound 8, with the highest
potency in the enzymatic assay for BACE-1 (IC50 ) 7.1 µM in
the Panvera kit and 32 µM in the SIGMA kit), is not active in
the cell-based assay at a concentration of 25 µM. These data
have to be compared with the corresponding ones for compound
6, which has a very poor activity in the enzymatic assay but a
cell-based EC50 value of 18.0 µM. These discrepancies might
be due to several reasons, including differences in cell perme-
ability, cleavage efficiency of full-length BACE-1 (cell-based
assay) versus the lumenal domain only (enzymatic assay),
different substrates, and assay conditions (e.g., pH 4.5 in the
enzymatic assay).
To provide further evidence that compound 6 inhibits
BACE-1 activity in cells, Western blot analysis was used to
detect differentially cleaved carboxy-terminal fragments (CTFs)
of APP (Figure 6). Compound 6 lowered â-CTF without
affecting R-CTF compared to the dimethyl sulfoxide (DMSO)
negative control. On the other hand, the γ-secretase inhibitor
VII46 caused an accumulation of both â-CTF and R-CTF
compared to DMSO. This result indicates that reduced secretion
of Aâ from cells was caused by â-site cleavage inhibition.
Finally, it is important to note that the peptidic inhibitors
OM99-2 (molecular weight 897.2 g/mol),34 its cycloamide-
urethane derivative 2c (731.1 g/mol),43 and the peptidomimetic
57 (699.4 g/mol) of ref 11 have low-nanomolar affinity for
BACE-1 in enzymatic tests but show only micromolar activity
in cellular assays because of limited ability to cross cell
membranes.11,43 Despite their more than 3 orders of magnitude
worse inhibitory activity in the enzymatic assay, the four triazine
derivatives 3 and 5-7 have cellular activity similar to that of
the three known peptidic inhibitors mentioned above. Given their
smaller size, the triazine derivatives are likely to be more
suitable for further development than the peptidic inhibitors.
Conclusions
High-throughput, fragment-based docking into the BACE-1
active site and LIECE binding free energy evaluation were used
to select 88 compounds for experimental validation from an
initial set of more than 300 000 molecules. Ten of the 88
compounds inhibit BACE-1 activity in an enzymatic assay (IC50
< 100 µM), and four of them are active in a mammalian cell-
based assay (EC50 < 20 µM). Taken together, the discoveries
of three novel series of BACE-1 inhibitors, i.e., phenylurea
derivatives,33 triazine derivatives (this work), and a set of five
cell-permeable, nonpeptide, low-micromolar inhibitors of BACE-1
with a different scaffold (D. Huang and A. Caflisch, unpublished
results), are a proof-of-principle of our in silico high-throughput
screening approach. Furthermore, the present study represents
a successful combination of computational predictions and
experimental validation of inhibitors of a pharmaceutically
relevant enzyme for which few nonpeptidic inhibitors have been
already discovered, despite the availability of the X-ray structure
of BACE-1 for more than 5 years. We are currently applying
high-throughput docking and the LIECE approach to identify
kinase inhibitors from very large collections of low-molecular-
weight compounds. For protein targets of known three-
dimensional structure, the efficient in silico approach presented
in this paper is a cost-effective alternative to high-throughput
in vitro screening campaigns.
Availability of the Software. The software suite of programs
for high-throughput docking (DAIM, SEED, FFLD), including
(43) Ghosh, A.; Devasamudram, T.; Hong, L.; DeZutter, C.; Xu, X.; Weerasena,
V.; Koelsch, G.; Bilcer, G.; Tang, J. Bioorg. Med. Chem. Lett. 2005, 15,
15-20.
(44) Prade, L.; Jones, A. F.; Boss, C.; Richard-Bildstein, S.; Meyer, S.; Binkert,
C.; Bur, D. J. Biol. Chem. 2005, 280, 23837-23843.
(45) Dovey, H. R.; Suomensaari-Chrysler, S.; Lieberburg, L.; Sinha, S.; Keim,
P. S. NeuroReport 1993, 4, 1039-1042.
(46) Durkin, J. T.; Murthy, S.; Husten, E. J.; Trusko, S. P.; Savage, M. J.; Rotella,
D. P.; Greenberg, B. D.; Siman, R. J. Biol. Chem. 1999, 274, 20499-
20504.
(47) Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.;
Nofziger, T. H.; Currens, M. J.; Seni, D.; Boyd, M. R. Cancer Res. 1988,
48, 4827-4833.
Figure 6. Western blot analysis of compound 6, confirming reduction of
the â-site cleavage of APP. (Top) The â-carboxy-terminal fragment (CTF)
and R-CTF bands indicate that cleavage of â-CTF is decreased compared
to DMSO negative control without affecting R-CTF. On the other hand,
the γ-secretase inhibitor VII46 causes an accumulation of both â-CTF and
R-CTF. (Bottom) The actin bands indicate equal loading of the samples in
each lane.
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input files, test cases, and documentation, are available from
the corresponding author (at no expense for not-for-profit
institutions).
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Chapter 6
Replica Exchange Molecular
Dynamics Simulations of
Amyloid Peptide
Aggregation
(Journal of Chemical Physics 121, pp 10748-10756, 2004)
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Replica exchange molecular dynamics simulations of amyloid peptide
aggregation
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The replica exchange molecular dynamics ~REMD! approach is applied to four oligomeric peptide
systems. At physiologically relevant temperature values REMD samples conformation space and
aggregation transitions more efficiently than constant temperature molecular dynamics ~CTMD!.
During the aggregation process the energetic and structural properties are essentially the same in
REMD and CTMD. A condensation stage toward disordered aggregates precedes the b-sheet
formation. Two order parameters, borrowed from anisotropic fluid analysis, are used to monitor the
aggregation process. The order parameters do not depend on the peptide sequence and length and
therefore allow to compare the amyloidogenic propensity of different peptides. © 2004 American
Institute of Physics. @DOI: 10.1063/1.1809588#
I. INTRODUCTION
A thorough sampling of conformational space is required
to describe the thermodynamics of complex systems such as
multiple peptide chains at finite concentrations. Constant
temperature molecular dynamics ~CTMD! techniques often
fail to adequately sample conformational space of frustrated
and minimally frustrated systems which are characterized by
a rugged free-energy landscape where energy barriers be-
tween minima are higher than the thermal energy at physi-
ological temperature. For this reason, a number of ap-
proaches to enhance sampling of phase space have been
introduced.1–4 The parallel tempering technique ~also known
as replica exchange! was developed for dealing with the slow
dynamics of disordered spin systems.5 Sugita and Okamoto
have extended the original formulation of replica exchange
into an MD based version ~REMD! and tested it on the pen-
tapeptide Met-enkephalin in vacuo.6 Although in the context
of fragile liquids De Michele and Sciortino found that paral-
lel tempering does not increase the speed of equilibration of
the ~slow! configurational degrees of freedom,7 in the case of
atomistic simulations of proteins many different applications
have shown the efficiency of the method. Sanbonmatsu and
Garcia have used REMD to investigate the structure of Met-
enkephalin in explicit water,8 and the a-helical stabilization
by the arginine side-chain which was found to originate from
the shielding of main chain hydrogen bonds.9 REMD has
also been applied to investigate the energy landscape of the
C-terminal b-hairpin of protein G10,11 and a three-helix
bundle protein.12 REMD in implicit solvent has been used to
investigate the thermodynamics of designed 20-residue
structured peptides,13,14 and recently to study folding of a
helical transmembrane protein.15
Highly ordered protein aggregates are associated with
severe human disorders including Alzheimer’s disease,
type-II diabetes, systemic amyloidosis, and transmissible
spongiform encephalopathies.16,17 The soluble precursors of
the ordered protein deposits do not share any sequence ho-
mology or common fold. However, x-ray diffraction data in-
dicate a cross-b-structure for most fibrillar aggregates.18,19
These findings suggest that key steps in the aggregation pro-
cess may be common to all amyloidogenic proteins. Despite
the medical relevance of amyloidoses, many important ques-
tions about the formation of ordered aggregates remain un-
answered. There is experimental evidence that cytotoxicity is
more pronounced for the early aggregates than for highly
organized fibrillar structures.20 Moreover, some peptide frag-
ments of amyloidogenic proteins display the same properties
as the full-length protein, including cooperative kinetics of
aggregation, fibril formation, binding of the dye Congo red,
and the cross-b x-ray diffraction pattern.21 Both findings are
particularly interesting because current simulation ap-
proaches allow significant sampling only for oligomeric pep-
tide systems.
There have been several lattice studies on aggregation in
proteins. These simplified models have allowed to investi-
gate the foldability and aggregation propensity22,23 and how
interaction potentials affect the properties of aggregation-
prone proteins.24 Harrison et al. have shown that less stable
proteins have a greater chance of assuming alternative native
states as multimers.25 MD simulations of aggregation have
been performed by using a three-bead backbone and single-
bead side-chain model.26 While this simplified model has
allowed the simulation of the competition between folding
and aggregation for two four-helix bundles it is probably not
possible to extract detailed information on energetics and
sequence dependence. Recently, a minimalist Go model of
four peptide strands27 has been investigated by MD simula-
tions in a confining sphere and the aggregation process was
shown to depend on both sequence and environment.28
Atomic models of amyloidogenic peptides have been simu-
lated by MD with an implicit treatment of the solvent29–31
and explicit water molecules.32–36
Recently, a replica exchange Monte Carlo technique has
a!Author to whom correspondence should be addressed. Fax: 141 1 635 68
62; Electronic mail: caflisch@bioc.unizh.ch
JOURNAL OF CHEMICAL PHYSICS VOLUME 121, NUMBER 21 1 DECEMBER 2004
107480021-9606/2004/121(21)/10748/9/$22.00 © 2004 American Institute of Physics
Downloaded 19 Nov 2004 to 130.60.169.71. Redistribution subject to AIP license or copyright, see http://jcp.aip.org/jcp/copyright.jsp
been applied to a lattice Go model of a minimalist multichain
system to study the interplay between folding and disordered
aggregation23 but atomic model REMD applications to or-
dered aggregation have not been reported yet.
In the present paper, REMD with implicit solvent37 is
used to investigate the thermodynamics of the early steps of
peptide aggregation and comparison is made with CTMD.
The present work was motivated by three questions. Is it
possible to sample the early events of ordered peptide aggre-
gation at physiologically relevant temperatures? Do the ag-
gregation energetics sampled by REMD correspond to those
observed in CTMD simulations? Are the nematic and polar
order parameters, borrowed from liquid crystal theory, useful
to describe aggregation? The simulation results indicate that
all questions can be answered affirmatively. Moreover, the
‘‘liquid crystal’’ order parameters allow to discriminate amy-
loidogenic peptide sequences from those that form only dis-
ordered aggregates.
II. METHODS
A. Model
The MD simulations and part of the analysis of the tra-
jectories were performed with the CHARMM program.38 The
oligomeric peptide systems were modeled by explicitly con-
sidering all heavy atoms and the hydrogen atoms bound to
nitrogen or oxygen atoms ~PARAM19 potential function38,39!.
The remaining hydrogen atoms are considered as part of the
carbon atoms to which they are covalently bound ~extended
atom approximation!. The effective energy, whose negative
gradient corresponds to the force used in the dynamics, is
E~r!5E
vacuo~r!1Gsolv~r! ~1!
for a molecular system with atomic nuclei located at
r5(r1 , . . . ,rN). The PARAM19 vacuo energy function is
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where b is a bond length, u a bond angle, f a dihedral angle,
v an improper dihedral, r i j is the distance between atoms i
and j , q i and q j are partial charges, and d i jmin and « i jmin are the
optimal van der Waals distance and energy, respectively. Pa-
rameters are given in Ref. 39.
An implicit model based on the solvent accessible sur-
face was used to describe the main effects of the aqueous
solvent on the solute.37 In this approximation, the solvation
free energy is given by
Gsolv~r!5(
i51
N
s iA i~r! ~2!
for a molecular system having N heavy atoms with Cartesian
coordinates r5(r1 , . . . ,rN). A i(r) is the solvent-accessible
surface computed by an approximate analytical expression40
and using a 1.4 Å probe radius. The solvation model contains
only two s parameters: one for carbon and sulfur atoms
(sC ,S50.012 kcal/mol Å2), and one for nitrogen and oxy-
gen atoms (sN ,O520.060 kcal/mol Å2).37 Hence, accord-
ing to Eq. ~2! hydrophobic side chains tend to be buried
within the solute whereas hydrophilic side chains and the
polar groups of the backbone prefer to be solvent accessible.
Furthermore, ionic side chains were neutralized41 and a lin-
ear distance-dependent screening function @e(r i j)52r i j#
was used for the electrostatic interactions. The CHARMM
PARAM19 default cutoffs for long range interactions were
used, i.e., a shift function38 was employed with a cutoff at
7.5 Å for both the electrostatic and van der Waals terms. This
cutoff length was chosen to be consistent with the parametri-
zation of the force-field and implicit solvation model. The
model is not biased toward any particular secondary struc-
ture type. In fact, exactly the same force field and implicit
solvent model have been used recently in MD simulations of
aggregation,30,31 folding of structured peptides ~a-helices and
b-sheets! ranging in size from 15 to 31 residues,42–44 and
small proteins of about 60 residues.45,46
B. REMD simulations
The basic idea of REMD is to simulate different copies
~replicas! of the system at the same time but at different
temperatures values. Each replica evolves independently by
MD and every tswap states i , j with neighbor temperatures
are swapped ~by velocity rescaling! with a probability w i j
5exp(2D),6 where D[(b i2b j)(E j2E i), b51/kT , and E
is the effective energy @potential and solvation energy, Eq.
~1!#. A tswap of 10 000 MD steps ~20 ps! was chosen in order
to allow the kinetic and potential energy of the system to
relax. High temperature simulation segments facilitate the
crossing of the energy barriers while the low temperature
ones explore in detail energy minima. The result of this
swapping between different temperatures is that high tem-
perature replicas help the low temperature ones to jump
across the energy barriers of the system.
In this study six replicas were used with temperatures ~in
kelvin! 275, 296, 319, 344, 371, and 400. This range corre-
sponds to a subset of values used in a previous study of
reversible peptide folding with the same force-field and sol-
vation model.14 The acceptance ratios of exchange between
neighbor temperatures ranged between 15% and 24%. Each
trajectory has a length of 2 ms for a total of 12 ms of simu-
lation time ~see Table I!.
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C. Constant temperature MD simulations
A series of control runs were performed at constant tem-
perature: ~i! ten simulations at 330 K ~total of 34 ms! used as
a comparison for the aggregation process between CTMD
and REMD ~see Table I!, ~ii! ten 0.5 ms simulations at 275 K
and ~iii! five 1 ms simulations at 296 K to compare CTMD
and REMD sampling at physiologically relevant conditions,
and ~iv! two 1 ms simulations at 371 K to study the system
near the condensation temperature ~see below!.
For both REMD and CTMD, Langevin dynamics with a
friction value of 0.15 ps21 was used. This friction coefficient
is much smaller than the one of water (43 ps21 at 330 K
computed as 3phd/m ,47 where h is the viscosity of water at
330 K, and d and m are the effective diameter, i.e., 2.8 Å,
and mass of a water molecule, respectively! to allow for
sufficient sampling within the ms time scale of the simula-
tion. The small friction does not influence the thermody-
namic properties of the system.
The SHAKE algorithm48 was used to fix the length of the
covalent bonds involving hydrogen atoms, which allows an
integration time step of 2 fs. Furthermore, the nonbonded
interactions were updated every ten dynamics steps and co-
ordinate frames were saved every 20 ps for a total of 5
3104 conformations/ms. A 1 ms run requires approximately
two weeks on a 1.4 GHz Athlon processor and the REMD
simulations were run in parallel on a Linux Beowulf cluster.
D. Progress variables
Aggregation contacts. In-register parallel and antiparallel
aggregation contacts were defined following the prescription
given in Ref. 30: a contact was considered to be present if
the distance between two Ca atoms placed on different in-
register strands was within 5.5 Å. The fraction of in-register
parallel contacts Qp and in-register antiparallel contacts Qa
were used to monitor the evolution of the aggregation pro-
cess. In-register parallel and antiparallel aggregates, IP and
IA, respectively, were considered formed when Qp and Qa
were larger than 0.75 (Qp ,Qa.11/14) whereas at values
smaller than 0.25 (Qp ,Qa,4/14), the system was consid-
ered disordered. The aggregation time is defined as the tem-
poral interval between the first time point where Qp ,Qa
,0.25 and the following time point where Qp ,Qa.0.75.
Radius of gyration. The radius of gyration of the oligo-
meric system Rg was considered to monitor the degree of
condensation and calculated using the minimum image con-
vention. Large values of Rg indicate conformations with iso-
lated and non-interacting peptides ~uncondensed phase!.
Small values of Rg indicate ordered as well as disordered
aggregated conformations ~condensed phase!.
E. Orientational order parameters
The nematic and polar order parameters, P2 and P1,
respectively, were considered in this study. These order pa-
rameters represent the first and second rank coefficients of
the singlet orientational distribution expanded in a Wigner
series,49,50 i.e., a basis set of the Wigner rotation matrices.
The nematic and polar order parameters are widely used for
studying the properties of anisotropic fluids such as liquid
crystals51–54 and are defined as
P25
1
N (i51
N 3
2 ~ zˆi•d
ˆ !22
1
2 ~3!
and
P15
1
N (i51
N
zˆi•dˆ , ~4!
where dˆ ~the director! is a unit vector defining the preferred
direction of alignment, zˆi is a suitably defined molecular vec-
tor, and N is the number of molecules in the simulation box,
i.e., three peptides in this study. The director is defined as the
eigenvector of the ordering matrix,55 that corresponds to the
largest eigenvalue. Here, the molecular vectors zˆi were de-
fined as unit vectors linking the peptide’s termini ~from the N
to the C terminus, Fig. 1!. To optimally select the zˆi vectors,
other choices were investigated: vectors linking the carbonyl
C to the amide N of each residue ~‘‘amide’’ vectors! as well
as vectors lying along the carbonyl bonds. Similar results
were obtained with the three different choices of zˆi . How-
ever, due to the atomic connectivity along the backbone the
amide vectors are not fully independent; their orientations
are strongly correlated and the description of the ordered
macrostates results less precise. The same is true for the
‘‘carbonyl’’ vectors. Hence, vectors linking peptide’s termini
were preferred.
The order parameters @Eqs. ~3! and ~4!# change value on
going from one order macrostate to the other and should
vanish when the transition to a fully isotropic state takes
place. They describe different orientational properties of the
system and yield useful and complementary information. The
TABLE I. Simulations performed.
Peptide
sequence
Length
~ms!
T
~K! Method
IP aggregation
events
IA aggregation
events
GNNQQNY 1030.5 275 CTMD 0 6 ~19.2!a
GNNQQNY 531.0 296 CTMD 3 ~14.4! 5 ~1.6!
GNNQQNY 1033.4 330 CTMD 54 ~7.6! 43 ~1.4!
GNNQQNY 231.0 371 CTMD 0 0
GNNQQNY 632.0 275–400 REMD 14 ~60.3! 15 ~3.9!
QQQQQQQ 632.0 275–400 REMD 27 ~54.8! 2 ~9.4!
AAAAAAA 631.0 275–400 REMD 4 ~0.8! 12 ~0.9!
SQNGNQQRG 632.0 275–400 REMD 1 ~1.6! 6 ~1.0!
aThe average time ~ns! the three peptides remained aggregated in IP and IA is given in parentheses.
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nematic P2 describes the orientational order of the system
and discriminates between ordered and disordered conforma-
tions. The polar P1 describes the polarity of the system, i.e.,
how much the molecular vectors zˆi point in the same direc-
tion, and discriminates between parallel and antiparallel/
mixed ordered aggregates.
F. Peptides
To evaluate the reliability of amyloidogenic propensity
estimations, four oligomeric peptide systems were consid-
ered in this study: the amyloid-forming heptapeptide
GNNQQNY and the soluble nonapeptide SQNGNQQRG
both from the yeast prion Sup35 ~residues 7–13 and 17–25
with the Gln/Arg mutation at position 24, respectively!,21 the
amyloidogenic poly~L-glutamine! QQQQQQQ ~Ref. 56! and
the nonamyloidogenic poly~L-alanine! AAAAAAA.57 To re-
produce the experimental conditions,21,56,57 the peptide sys-
tems derived from the yeast prion Sup35 were modeled with-
out blocking groups, while the Ala and Gln repeats were both
N-acetylated and C-amidated.
All simulations were performed with three peptide rep-
licas starting from random conformations, positions, and ori-
entations. In the initial random positions there was no inter-
molecular contact, i.e., the peptides were separated in space.
Each system was simulated in a cubic box of 75 Å per side
yielding a sample concentration of 0.012 M. Since the oligo-
meric systems present different molecular weights, the above
reported concentration corresponds to 3.4, 3.9, 5.4, and 3.4
mg/ml for GNNQQNY, SQNGNQQRG, QQQQQQQ, and
AAAAAAA, respectively.
G. Analysis tools
The aggregation contacts, radius of gyration, and order
parameters analysis was carried out with a GPL licensed
program58 developed in house to manipulate and analyze
molecular dynamics ~MD! trajectories. The program is opti-
mized for speed and ease of usage so that it allows extensive
processing of large amounts of data and straightforward ad-
dition of new analysis tools. Compared to other available
programs,38,59 the analysis of MD trajectories is much faster.
III. RESULTS AND DISCUSSION
A. REMD diagnostics
The set of temperatures used in a REMD simulation is
crucial for a correct and efficient sampling.8 Since a simple a
priori protocol for selecting the optimal temperature distri-
bution has not been identified ~yet!, the choice often follows
empirical considerations:8,14,23 the highest temperature of the
set has to be high enough to overcome energy barriers, while
the lowest temperature has to allow the exploration of
minima. However, given a fixed number of replicas the tem-
perature range cannot be too wide. Temperature values need
to be close enough to make the energy histograms overlap
~see Fig. 2! in order to guarantee a high number of tempera-
ture swaps during a simulation run. In this study, a set of six
temperature values ranging from 275 to 400 K has been se-
lected ~see Methods!. The time series of temperature ex-
changes for one of the six replicas is shown in Fig. 3. During
the simulation, each replica visits all the temperatures of the
set several times realizing the desired free random walk in
temperature space.6
Symbols in Fig. 2 show the results from CTMD simula-
tions carried out at 275 ~filled circles!, 296 ~filled triangles!,
330 ~empty circles!, and 371 K ~empty triangles!. At 330 K,
the CTMD effective energy distribution is located between
the REMD distributions extracted at 319 and 344 K and
shows a consistent functional profile. At 371 K, CTMD and
REMD effective energy distributions overlap. Therefore, the
energetic properties of an aggregating system sampled by a
REMD simulation at medium and high temperatures corre-
spond to those observed in CTMD simulations. However,
approaching the physiologically relevant conditions the
CTMD distributions tend to shift toward less favorable ener-
gies ~Fig. 2, filled symbols!. CTMD at low temperature can
get trapped in local energy minima and REMD is superior in
sampling conformational space.6,14
FIG. 1. Pictorial representation of the molecular vectors zˆi ~black arrows!
used to compute the order parameters P1 and P2. zˆi vectors are defined as
full length peptide vectors ~linking the peptide’s termini! and allow to
clearly discriminate between ordered ~left, P250.87) and disordered ~right,
P250.46) conformations of the system. @The pictures were drawn using the
program PYMOL ~Ref. 66!#.
FIG. 2. Probability distribution of the effective energy for the REMD ~solid
lines! and the CTMD control simulations ~filled circles, filled triangles,
empty circles, and triangles for 275, 296, 330, and 371 K, respectively!. The
REMD distributions correspond to the following temperatures ~from left to
right!: 275, 296, 319, 344, 371, and 400 K. The asymmetry of the curves and
the temperature dependence of the distributions indicate the presence of a
phase transition around 371 K ~see text!.
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The time series of the fraction of in-register parallel con-
tacts (Qp) and in-register antiparallel contacts (Qa) have
been monitored along the REMD trajectories ~Fig. 3!. A total
of 14 IP and 15 IA aggregation events have been observed
along the total simulation time of 12 ms ~see Table I!. The
average aggregation time ~see Methods! was 0.74 ms for IP
and 0.75 ms for IA arrangements. The average aggregation
time determined from the REMD simulation is similar to the
values obtained from 34 ms CTMD simulations at 330 K. It
is worth noting that in a preliminary REMD run with higher
temperatures values (631 ms, 319–465 K; data not shown!
only 3 IP and 4 IA aggregation events were sampled. The
temperature range is crucial in REMD and it has to be care-
fully chosen in order to speed up the conformational search
of relevant states,60 i.e., the ordered states when studying
aggregation. To bias the search toward conditions where or-
dered states are more probable, the temperature was set to
lower values ~275–400 K, as mentioned above! and the sam-
pling of aggregation events turned out substantially im-
proved.
Figure 4 shows the projections of the free energy surface
along Qp and Qa for both REMD and CTMD trajectories.
The profiles indicate that the structural properties of the ag-
gregating system sampled by a REMD simulation corre-
spond to those observed in CTMD simulations only at high
and medium temperatures. At 371 K, CTMD and REMD free
energy projections overlap. At 330 K, the CTMD free-energy
profiles ~empty circles! are correctly placed between REMD
projections at 319 and 344 K ~dashed lines! and show pat-
terns characterized by a well-defined local minimum at Qp
.0.7 and a monotonic uphill trend along Qa , fully consis-
tent with the profiles extracted from the REMD simulation.
However, at low temperature ~275 and 296 K! the free en-
ergy profiles extracted from CTMD and REMD trajectories
are not consistent any more and the most ‘‘relevant’’ confor-
mations, which correspond to in-register parallel and antipar-
allel arrangements (Qp ,Qa.0.7), are not correctly sampled
by CTMD ~Fig. 4, filled symbols!.
B. Temperature dependence of ordered amyloid
peptide aggregation
Since the energetic and structural properties of the sys-
tem are not artificially altered ~see preceding section!, the
REMD approach allows to evaluate thermodynamic quanti-
ties as a function of temperature in the chosen range.6 From
the REMD simulation performed for this study, the proper-
ties of interest have been extracted at any temperature of the
set and the aggregation of the amyloid-forming peptide
GNNQQNY has been monitored in temperature space ~275–
400 K!. This analysis gives interesting insights into the amy-
loid aggregation process.
The effective energy histograms shown in Fig. 2 are not
symmetrically distributed around their mean value and their
shape varies with temperature. The distributions, in fact,
broaden toward higher energy values at low temperature
~275–344 K! and toward lower energy values at high tem-
perature ~371–400 K!. Moreover, by increasing temperature
they progressively become lower and broader till the value of
371 K is reached. Mitsutake et al. have interpreted such a
behavior as the evidence of a phase transition.61 To charac-
terize the transition, the radius of gyration Rg of the oligo-
meric system was considered and free-energy projections
along Rg were plotted ~see Fig. 5!. Conformations of the
system producing non-interacting peptides, namely, confor-
FIG. 3. Time series of ~from top to bottom! the temperature T , the fraction
of in-register parallel contacts Qp , and the fraction of in-register antiparallel
contacts Qa for a REMD replica. Along the trajectory, replicas realize the
desired free random walk in temperature space ~top! so that an efficient
sampling of the ordered aggregates is allowed ~peaks in Qp and Qa plots!.
Horizontal lines in the time series of the fraction of aggregation contacts
indicate the upper/lower thresholds used to define the ordered aggregation/
disaggregation events.
FIG. 4. Free-energy projections along the fraction of in-register parallel
contacts Qp ~left! and in-register antiparallel contacts Qa ~right!. Conforma-
tions with zero in-register contacts were chosen as reference states. DG (n20)
was computed as 2kBT ln(Nn /N0), where Nn indicates the number of con-
formations with n contacts and kB is the Boltzmann constant. REMD data
are shown in solid lines for all the temperature values except for 319 and
344 K which are in dashed lines. CTMD data are shown with symbols ~filled
circles, filled triangles, empty circles, and triangles for 275, 296, 330, and
371 K, respectively!.
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mations where all interpeptide atomic distances are larger
than the long-range interactions cutoffs ~7.5 Å in this case!,
were used to determine Rg
C
, i.e., the lowest detected radius
of gyration for isolated peptides ~see Fig. 5!. The existence
of two macrostates in equilibrium has been revealed: the
first, named uncondensed state, includes high energy confor-
mations with one or more isolated peptides (Rg.RgC); the
second, named condensed state, consists of low energy con-
formations with aggregated peptides (Rg,RgC). For entropic
reasons, the uncondensed state is preferred at high tempera-
ture. By cooling down, the condensed state is increasingly
stabilized, and around 371 K the fluctuations of Rg show a
well-defined peak highlighting the presence of the condensa-
tion transition ~see Fig. 5!. The equilibrium between the con-
densed and the uncondensed macrostates is clearly concen-
tration dependent. If the concentration of amyloid-forming
units increases, the equilibrium is moved toward the con-
densed state and the aggregation process is favored.
The free-energy profiles along Qp and Qa at various
temperatures help in understanding how the nucleation pro-
cess evolves upon peptides condensation. At values of 400,
371, and 344 K both projections show steep uphill patterns
with a single free-energy minimum at Qp'Qa'0 ~see Fig.
4!. This means that upon condensation the peptides are still
more likely to form disordered aggregates characterized by
nonspecific interactions than amyloid-forming nuclei. In this
range of temperatures, the enthalpic contribution due to in-
register backbone or side-chain interactions does not domi-
nate the entropic one and the growth of ordered nuclei is
forbidden. However, when the temperature decreases the en-
tropic contribution becomes less important and ordered in-
register aggregates start forming. As shown in Fig. 4 in fact,
below 330 K two and one additional free-energy minima
appear in the projection along Qp and Qa , respectively. The
observed minima correspond to in-register parallel (Qp
.0.7) and in-register mixed or out-of-register (0.3<Qp
<0.7 and 0.4<Qa<0.7) arrangements and strongly suggest
that the three-peptide system moves toward a higher degree
of order when approaching the physiologically relevant con-
ditions.
The simulation results indicate that in the early steps of
amyloid aggregation a condensation stage toward disordered
aggregates precedes the nucleation process and the disorder-
order transition, in agreement with experimental evidence.62
C. Disorder-order transition
In the early steps of aggregation, amyloidogenic peptides
assemble into highly ordered b-sheet structures.21,30 During
the assembly, the peptides tend to align adopting an extended
b-strand conformation and a remarkable change in the local
orientational order occurs. The aggregation of amyloid-
forming peptides may then be interpreted as an order transi-
tion and orientational order parameters are suitable to moni-
tor the time evolution of the process. Two orientational order
parameters were employed and free-energy projections are
shown in Fig. 6. Along P2, the free-energy profiles show a
first broad minimum at P2'0.5 for any temperature of the
set and a second narrower one at P2'0.9 for T values below
FIG. 5. ~Top! Free-energy projections along the radius of gyration of the
oligomeric system Rg computed from REMD trajectories. Solid lines corre-
spond to temperature values below the condensation temperature ~275–344
K!; dashed lines correspond to temperature values above the transition tem-
perature ~371 and 400 K!. The lowest radius of gyration for the uncondensed
state is shown as a vertical line (RgC511.9 Å). ~Bottom! Temperature de-
pendence of the average radius of gyration ^Rg& ~filled circles! and its fluc-
tuations s ~empty circles!. The behavior of ^Rg& and s indicates the pres-
ence of a phase transition around 371 K between a condensed ~low T) and
an uncondensed phase ~high T). Fluctuations of the radius of gyration s are
computed as ^Rg2&2^Rg&2. Data at 431 and 465 K were obtained from a
preliminary REMD run carried out in a higher temperature range
(631 ms, 319, 344, 371, 400, 431, and 465 K!.
FIG. 6. Free-energy projections along the nematic (P2, left! and the polar
(P1, right! order parameters. REMD data are shown in solid lines for all the
temperature values except for 319 and 344 K which are in dashed lines.
CTMD data are shown with symbols ~filled circles, filled triangles, empty
circles, and triangles for 275, 296, 330, and 371 K, respectively!. Schematic
representations of the aggregates ~black arrows! are depicted to show that
order parameters yield complementary information: P2 discriminates be-
tween ordered and disordered conformations while P1 discriminates be-
tween parallel and antiparallel/mixed ordered aggregates.
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330 K. The first corresponds to a large free-energy basin
where orientational order is absent, while the second corre-
sponds to a smaller and well-defined basin with a high ori-
entational degree of order. Although the order parameters
should vanish when order is absent, Fig. 6 shows that this is
not the case when the number of vectors is small. Since only
three peptides were simulated, a ‘‘background’’ order was
always detected and the free energy minimum describing the
disordered state is placed at P2'0.5, which is consistent
with the value of A81/40pN expected for a completely ran-
domly oriented array of N molecules.63 The order parameter
P2 shows the existence of two macrostates in equilibrium:
the disordered state with a high entropy content, which cor-
responds to the global minimum of the free energy surface at
high temperature, and the ordered state which becomes the
global free energy minimum at low temperature. Interest-
ingly, the free-energy profiles along Qp and Qa do not lead
to the same conclusion and the observed in-register arrange-
ments correspond to local minima of the free-energy surface
~see Fig. 4!.
Along P1, two narrow and well-distinct minima corre-
sponding to ordered macrostates at different polarity appear
on the free-energy projections ~Fig. 6!. The first, displayed at
P1'0.35, describes a free-energy basin with a high-order
and low-polarity content. Conversely, the second, displayed
at P1'0.95, corresponds to a basin with a high-order and
high-polarity content. The order parameter P1 discriminates
between parallel and antiparallel/mixed ordered conforma-
tions and provides complementary information since it al-
lows to further characterize the ordered state.
Symbols in Fig. 6 show the free-energy projections
along the order parameters from CTMD simulations. Once
again, the comparison with REMD profiles indicates that iso-
thermal MD ~filled symbols! does not sample the ordered
aggregates with their correct statistical weight close to the
physiological temperature range.
The REMD free energy profiles along P1 show that at
low temperature ~275 and 296 K! both polar macrostates are
highly populated. In the investigated temperature range, the
system does not show an overall polar degree and frequent
jumps between ordered states characterized by different po-
larity are observed. This suggests that below the order tran-
sition the equilibrium between polar macrostates might help
amyloidogenic systems overcoming the entropy loss occur-
ring during nucleation. In other words the growth of
amyloid-forming nuclei might have an entropically favorable
component due to the multiple ordered macrostates.
D. Sequence dependence of amyloidogenic
propensity
Free-energy projections along the nematic order param-
eter P2 show how the equilibrium between the ordered and
disordered state changes in temperature space ~Fig. 6!. Upon
cooling, the statistical weight of the ordered state increases
and the mean of the P2 distribution moves toward higher
values. The value of ^P2&, where ^¯& indicates the average
over the canonical ensemble, is then related to the thermo-
dynamic stability of the ordered state and could be used to
measure the amyloidogenic propensity of the system.
^P2& values computed at different temperatures from REMD
trajectories of the amyloid-forming peptide GNNQQNY are
shown in Fig. 7 with filled circles. At high temperature, the
^P2& values are close to 0.5 because no orientational order is
present, and the system does not show amyloidogenicity. By
decreasing temperature, the amyloidogenic propensity grows
and becomes increasingly larger until the order transition is
completed. At physiologically relevant conditions, ^P2&
'0.65 and the system is highly amyloidogenic in agreement
with experimental data.21
Since the orientational order parameters do not depend
on the peptide sequence and length, the reliability of the
predictions could be further tested in sequence space. The
REMD protocol was then applied to three additional oligo-
meric peptide systems ~see Methods! and ^P2& values were
evaluated to measure and compare amyloidogenic propensi-
ties. The testing set comprises a nonapeptide from the yeast
prion Sup35 ~SQNGNQQRG! experimentally studied by
Balbirnie et al.21 and two heptapeptides ~QQQQQQQ and
AAAAAAA!. Glutamine and alanine homopolymers flanked
by basic residues to improve solubility have been investi-
gated by Perutz et al.56,57
Experimentally, the nonapeptide SQNGNQQRG shows
solubility in vivo and in vitro and no formation of amyloid
fibrils.21 In agreement with these findings, ^P2& is smaller
than 0.55 in the whole temperature range ~Fig. 7, empty
squares! and the system is considered as nonamyloidogenic.
The number of aggregation events and the average lifetime
of aggregation extracted from REMD trajectories are re-
ported in Table I. Remarkably, these quantities show that
nonamyloidogenic sequences, i.e, SQNGNQQRG and
AAAAAAA, do transiently assemble in a b-sheet conforma-
tion but still remain soluble because their ordered aggregates
do not correspond to well-defined free-energy minima.
Circular dichroism ~CD! spectra, electron micrographs,
and x-ray diffraction photographs showed that poly~L-
FIG. 7. Temperature dependence of the nematic order parameter ^P2& av-
eraged over the canonical ensembles sampled by REMD for four oligomeric
peptide systems. ^P2& estimates the amyloidogenic propensity of peptide
systems and discriminates between amyloidogenic ~GNNQQNY and
QQQQQQQ! and nonamyloidogenic ~SQNGNQQRG and AAAAAAA! se-
quences in agreement with experimental data ~Refs. 21, 56, and 57!.
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glutamine! peptides aggregate in solution at both pH 7.0 and
3.0 forming tightly linked b-sheet structures.56 In particular,
the x-ray diffraction picture exhibits a fiber diagram of the
cross-b type distinctive of amyloid fibrils. On the other hand,
poly~L-alanine! does not display amyloidogenicity and CD
spectra showed a-helical structures at all pHs.57 Again, the
^P2& patterns shown in Fig. 7 ~filled squares and empty
circles! are consistent with experimental findings and cor-
rectly indicate amyloidogenicity only for QQQQQQQ.
Interestingly, Fig. 7 allows also to compare between
amyloidogenic sequences. In fact, according to the ^P2& pat-
terns the glutamine repeat is more amyloidogenic than
GNNQQNY at physiologically relevant conditions. To our
knowledge, no experimental data are available to verify this
finding. Testing of this prediction is a challenge for experi-
mentalists.
IV. CONCLUSIONS
The present study shows that atomistic REMD simula-
tions with implicit solvent allow to sample the early steps of
ordered aggregation of amyloidogenic peptides at physi-
ologically relevant temperatures. The free-energy profiles
projected along structural and orientational progress vari-
ables are essentially the same in REMD and CTMD. The
discrepancies at temperature values below 330 K are due to
the limitations in sampling in CTMD simulations which in-
dicates that REMD is a more efficient approach in the physi-
ological range.
The early steps of amyloidosis can be interpreted as a
condensation followed by an order transition. Therefore, the
REMD simulation results were analyzed with two order pa-
rameters originally introduced to study liquid crystals. Inter-
estingly, the nematic order parameter averaged over a ca-
nonical ensemble is able to discriminate amyloidogenic from
soluble peptides in agreement with experimental data.
Although the present study was performed with three
peptides for reasons of computational efficiency, the descrip-
tion of the ordered aggregates is likely to be independent of
the size of system, i.e., the number of simulated peptide rep-
licas. Very recent MD simulations of the amyloidogenic
SYVIIE peptide,64 which has been experimentally investi-
gated by de la Paz and Serrano,65 have shown ordered aggre-
gates of six peptides. Interestingly, the parallel b-sheet con-
sisting of six peptides has the same overall conformation and
twist as the three-peptide aggregate ~Fig. 8!.
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A novel computational approach to the structural analysis of ordered
b-aggregation is presented and validated on three known amyloidogenic
polypeptides. The strategy is based on the decomposition of the sequence
into overlapping stretches and equilibrium implicit solvent molecular
dynamics (MD) simulations of an oligomeric system for each stretch. The
structural stability of the in-register parallel aggregates sampled in the
implicit solvent runs is further evaluated using explicit water simulations
for a subset of the stretches. The b-aggregation propensity along the
sequence of the Alzheimer’s amyloid-b peptide (Ab42) is found to be highly
heterogeneous with a maximum in the segment V12HHQKLVFFAE22 and
minima at S8G9, G25S26, G29A30, and G38V39, which are turn-like segments.
The simulation results suggest that these sites may play a crucial role in
determining the aggregation tendency and the fibrillar structure of Ab42.
Similar findings are obtained for the human amylin, a 37-residue peptide
that displays a maximal b-aggregation propensity at Q10-
RLANFLVHSSNN22 and two turn-like sites at G24A25 and G33S34. In the
third application, the MD approach is used to identify b-aggregation “hot-
spots” within the N-terminal domain of the yeast prion Ure2p (Ure2p1–94)
and to design a double-point mutant (Ure2p-N4748S1–94) with lower
b-aggregation propensity. The change in the aggregation propensity of
Ure2p-N4748S1–94 is verified in vitro using the thioflavin T binding assay.
q 2006 Elsevier Ltd. All rights reserved.
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Introduction
Protein folding and unfolding are the most
sophisticated and specific ways of promoting and
abolishing cellular activity. Failure to fold correctly,
or to remain folded correctly, results in a plethora of
diseases.1–3 Some of these diseases originate from
amyloidogenic polypeptides that have a high
propensity to form ordered aggregates in the
extracellular space,4 e.g. Alzheimer’s and Parkin-
son’s diseases, type II diabetes, systemic amyloi-
dosis, and transmissible spongiform
encephalopathies.5,6 Understanding the molecular
determinants that cause soluble proteins to aggre-
gate into insoluble fibrils and plaques is therefore
an important challenge.
The soluble precursors of amyloid deposits do
not share any sequence homology or common fold.
However, amyloid aggregates have common struc-
tural features: (i) they show the same optical
behavior (such as birefringence) on binding certain
dye molecules such as Congo red; (ii) present very
similar morphologies (long, unbranched and often
twisted fibrillar structures a few nanometers in
diameter); and (iii) display the characteristic cross-b
X-ray diffraction pattern,7,8 which indicates that the
“core” structure is composed of b-sheets running
perpendicular to the fibril axis.9 Hence, regardless
of the sequence, the key steps in the aggregation
process may be common to all amyloidogenic
polypeptides. The ability of a polypeptide chain to
self-assemble is not restricted to disease-related
proteins. A large number of non-pathogenic pep-
tides and proteins have been shown to form
amyloid fibrils under particular solvent, pH and
temperature conditions.10–12 Taken together, these
0022-2836/$ - see front matter q 2006 Elsevier Ltd. All rights reserved.
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observations indicate that amyloid propensity is a
general property of the polypeptide backbone,13
thus suggesting that under certain conditions any
protein above a critical concentration will even-
tually assemble into ordered aggregates. On the
other hand, several studies have shown that the
aggregation propensity depends dramatically on
amino acid composition and that side-chains
influence the kinetics and stability of amyloid fibrils
enormously.14–17 To shed light into the molecular
mechanism of amyloid formation and the nature of
the energetic contributions that stabilize these
structures for an extremely diverse class of poly-
peptides, atomic-resolution three-dimensional
structures are required. As non-crystalline solid
material, amyloid aggregates are strongly incompa-
tible with high-resolution techniques for protein
structure determination, i.e. X-ray crystallography
and liquid state NMR, and, with the exception of
the amyloid-like spine formed by a seven-residue
peptide,18 no structure of an amyloid fibril has yet
been determined at an atomic level of detail. To
obtain structural information, more sophisticated
approaches such as solid state NMR,19–24 site-
directed spin labeling,25–27 cryo-electron
microscopy28,29 and proline-scanning mutagen-
esis30 have been used.
Given the difficulty of obtaining high-resolution
structures, alternative theoretical and compu-
tational approaches have been followed to ration-
alize the physico-chemical principles of
amyloidogenesis and understand the role of the
sequence. Very efficient theoretical models to
predict protein aggregation propensities from
primary structures have been proposed.31–33 At
minimal computational cost, some of these
models32,33 determine putative aggregation-prone
regions (“hot-spots“) within a protein sequence.
Despite remarkable correlation with experimental
data, these methods do not provide detailed
structural information. Experimental approaches
on simplified amyloid systems have also been
reported.17 Remarkably, the full positional scanning
mutagenesis of the amyloidogenic peptide STVIIE
highlighted both sequence and position depen-
dence of amyloid propensity, even for such a small
peptide system. However, the lack of structural
detail for the fibrils formed by these peptides has
precluded a rational explanation for the origin of
the observed mutational effects. Hence, to shed
some light into the “hidden” link between protein
sequence and amyloid propensity, computational
studies providing structural information are
required.34,35
Here, a novel approach to structurally character-
ize the propensity towards ordered aggregation of
amyloid polypeptides is presented. The procedure
is based on the decomposition of a polypeptide
chain into overlapping segments and equilibrium
molecular dynamics (MD) simulations of a small
number of copies of each segment. An efficient
implicit solvent model (based on the solvent-
accessible surface area36) is used to obtain
a statistically significant sampling for the trimeric
and hexameric systems of each peptide segment.
It is important to note in this context that the in-
register parallel packing of a seven-residue peptide
from the yeast prion protein Sup35 determined by
this implicit solvent model16 is in remarkable
agreement with the X-ray microcrystal structure of
the cross-b spine (see Materials and Methods).18
The computational strategy has been designed to
predict the position dependence of b-aggregation
propensity along the sequence, i.e. the amyloido-
genicity profile. From the shape of the profile,
amyloidogenic stretches can be discriminated from
regions with scarce b-aggregation propensity. More-
over, the atomic detail provided by the MD
simulations allows us to interpret the shape of the
profile on a structural basis. The method has been
tested on three amyloid sequences: the amyloid-b
peptide (Ab42), the human amylin and the
N-terminal domain of the yeast prion protein Ure2
(Ure2p1–94). Ab42 is a product of the proteolytic
cleavage of the 695-residue amyloid precursor
protein (APP) accomplished by the b and g-secre-
tases.37 Amyloid fibrils and plaques formed by full-
length Ab are associated with Alzheimer’s disease,
which is the most common neurodegenerative
disease and accounts for the majority of the
dementia diagnosed after the age of 60.38
Human amylin, also known as islet amyloid
polypeptide (hIAPP), is the major component of
pancreatic amyloid deposits found in w90% of
patients with non-insulin-dependent (type 2) dia-
betes mellitus39 of which there are about 150 million
worldwide.40 hIAPP is a peptide hormone of 37
amino acid residues produced by cleavage from a
pro-amylin precursor protein. It has been shown by
X-ray and electron diffraction that hIAPP fibrils are
well-ordered cross-b structures.41 However, a
detailed understanding of the fibrillar structure
and aggregation properties of full-length hIAPP
(hIAPP1–37) has yet to be achieved.
Ure2p is a prion from the yeast Saccharomyces
cerevisiae42 that acts as a negative regulator of
nitrogen metabolism.43 In its prion state, Ure2p is
at the origin of the [URE3] phenotype.44 In vitro,
Ure2p aggregates into long, straight filaments that
bind Congo red, show green-yellow birefringence
and have an increased resistance to proteolysis.45,46
The prion domain (residues 1–90)46 is involved in
filament formation47 and contains an unusually
high number of Asn, Gln, and Ser residues, i.e. 35%,
12%, and 10% of its 90 residues, respectively. The
prion domain of Ure2p is protease-sensitive and
poorly structured.46 However, synthetic Ure2p1–65
was shown to readily form fibrils with more than
60% b-sheet.47
The agreement between the amyloidogenicity
profile obtained by MD simulations and exper-
imental data on Ab42 and hIAPP1–37 indicates that
the computational approach is descriptive and can
be applied to predict the aggregation properties of a
polypeptide sequence. The b-aggregation profile
highlights critical segments for b-sheet formation
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and can be used to guide site-directed mutations
that modulate the aggregation tendency. The
predictive power of the computational approach is
validated experimentally by a double-point mutant
of Ure2p1–94.
Results
Polypeptide decomposition into segments
Here, the aggregation properties of three amyloid
sequences are investigated by theMD computational
approach: thehumanAb42, hIAPP1–37, and the central
part of the N-terminal domain of the yeast prion
protein Ure2 (Ure2p20–70). Due to the large size of the
polypeptide chains (42, 37 and 51 residues, respect-
ively) their oligomeric systems cannot be effectively
studied by all-atom MD simulations. Therefore, the
polypeptide sequence was decomposed into over-
lapping stretches. By systematically applying a two-
residue shift along the sequence, 18 seven-residue
and 16 11-residue peptide segments span the 1–41
region of Ab42 (Tables 1 and S2), 16 seven-residue
peptide segments span hIAPP1–37 (Table S3), and 23
seven-residue peptide segments cover the 20–70
region of Ure2p (Table S4). Each peptide segment
was both N-acetylated and C-amidated to reproduce
the original context in the full-length sequence. The
considerable overlap between neighboring segments
allows us to extrapolate the simulation results from
the stretches to the polypeptides.
Human amyloid-b peptide (Ab42)
b-Aggregation propensity
The b-aggregation profile of Ab42 was deter-
mined by first performing implicit solvent MD
simulations of a trimeric system for each of the
seven-residue peptide segments (see Table 1). For
each segment, the b-aggregation propensity was
obtained by averaging the time series of the nematic
order parameter P2 along the trajectory (see
Materials and Methods). At both temperatures of
310 K and 330 K the average value of P2 reaches
convergence, on a time-scale faster than 1 ms, as
indicated by the small standard deviations from
three independent runs at 310 K (Figure 1, top). At
330 K, b-aggregation propensity values ranged
from 0.51 to 0.89. According to our previous
analysis of the amyloid-forming peptides
GNNQQNY and QQQQQQQ and nonamyloido-
genic peptides SQNGNQQRG and AAAAAAA,48
these P2 values indicate the presence of both
aggregation-prone and non aggregation-prone
stretches along the Ab42 sequence. Interestingly,
the most aggregation-prone segments are not
distributed uniformly along the Ab42 sequence but
tend to cluster in the region 12–22. The heterogen-
eity in the aggregation properties of the Ab42
segments is reflected in the free-energy projections
along P2 (Figure 1, bottom left). Two main scenarios
emerge: the first, described by a free-energy profile
with a broad minimum at P2w0:5 (broken line),
Table 1. Ab42: seven-residue stretches simulations
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indicates scarce propensity for b-aggregation; the
second, described by a steep downhill profile
toward a minimum with high orientational order
(thick line), highlights amyloid-like sequences.
To obtain insights into the relatively weak
b-aggregation propensity detected at the C
terminus, the radius of gyration of the oligomeric
system Rg was monitored along the implicit solvent
trajectories. Again, the free-energy projections
along Rg (Figure 1, bottom right) show two different
scenarios. The first scenario, described by
a free-energy profile with a unique and narrow
minimum at Rg!R
C
g (see Materials and Methods),
indicates that the simulated peptides are very likely
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Figure 1. Ab42. Results of constant temperature MD simulations of trimeric seven-residue peptide systems. Top: b-
aggregation propensity averaged along the implicit solvent simulations at 310 K (blue), 330 K (red), and the explicit
solvent runs (black squares). The data points represent the values of the nematic order parameter P2 averaged over the
canonical ensemble. The continuous and broken lines are drawn to help the eye for the wild-type and single-point
mutants, respectively. The segment identification number corresponds to the position of the central residue in the Ab42
full-length sequence (see Table 1). Error bars on the data points at 310 K represent standard deviations of average b-
propensities computed over three independent runs. For some data points at 310 K, e.g. 32 and 36, the error bar is smaller
than the symbol. Pink and cyan open circles show the effect of the single-point mutations, F19S51 and A21G,52
respectively. Bottom: free-energy projections along P2 (left) and the radius of gyration (right) of the oligomeric system at
330 K. Thick and broken lines for segments 16 and 34, respectively, show the emergence of two distinct scenarios in both
aggregation (left) and condensation (right) properties. Thin continuous lines represent the 16 remaining segments.
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to aggregate. The second scenario, which shows a
prominent broad minimum at Rg!R
C
g on the free-
energy profile (broken line), reports that confor-
mations characterized by isolated peptides are
favored and the occurrence of condensed states of
the system (either ordered or disordered) is rather
low. Remarkably, all the stretches compatible with
the second scenario belong to the C-terminal part of
the amyloid-b peptide (from Ab21–27 to Ab35–41).
Since at elevated temperature entropic effects favor
the uncondensed state, three additional 1 ms
implicit solvent simulations were performed at
310 K for each segment. Interestingly, an aggrega-
tion-prone region in the C-terminal part of Ab42
(residues 32–36) emerges at 310 K (Figure 1, blue
circles). These simulation results suggest that the
condensation propensity, though not sufficient to
describe amyloidogenicity, is a necessary condition
for the formation of amyloid nuclei. It is not
sufficient because amyloidogenic sequences must
also have b-sheet propensity, which promotes the
assembly into highly ordered structures (see also
Supplementary Data).
A comparison of the b-aggregation propensity
calculated from the implicit and explicit solvent
simulations shows a good agreement except for the
N-terminal segment D1AEFRHD7 (Figure 1, top). The
much larger P2 value in the implicit solvent runs is a
consequence of the approximations inherent to the
treatment of charged groups,36 which are neutral-
ized to prevent vacuum-like artifacts like the
excessive formation of salt-bridges. In the implicit
solvent simulations of D1AEFRHD7, the lack of
strong Coulombic repulsion between side-chains
with the same charge does not prevent formation of
in-register parallel b-sheets. The first two
N-terminal segments D1AEFRHD7 and E3-
FRHDSG9 contain four and three charged side-
chains, respectively, whereas the remaining seven-
residue segments have between zero and two
formal charges. For this reason, the implicit solvent
b-aggregation profiles are more reliable for the 8–42
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Figure 2. Comparison between b-
aggregation propensities from MD
simulations and experimental data.
See the legend to Figure 1 for the
meaning of data points and connect-
ing lines. Top: 11-residue peptide
segments of the amyloid-b peptide.
Thepinkbarsquantify thebindingof
the full-length Ab40 to each of 31
overlapping decapeptides (corre-
sponding to residues 1–10 up to 31–
40) as measured by radioligand
experiments.49 Bottom: seven-resi-
due peptide segments of the human
amylin. The pink bars quantify the
binding of the full-length hIAPP1–37
to each of 28 over lapping decap
peptides (corresponding to residues
1–10 up to 28–37) as measured by
immunoblotting experiments.55
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region of the Ab42 peptide, where they also show
good agreement with the explicit solvent simulation
results.
Implicit solvent replica exchange MD (REMD)48
simulations of 11-residue segments were also used
to derive the Ab42 amyloidogenicity profile
(Figure 2, top). At 306 K and 330 K, the profiles
look similar with higher propensity for the lower
temperature. For all the aggregation-prone seg-
ments (8, 14, 16, 18, 20 and 22), the analysis of the
trajectories by a polar order parameter ( P1; see
Cecchini et al.48) revealed a statistically relevant
predominance of in-register parallel b-sheets and,
with the exception of stretch 22, negligible anti-
parallel arrangements (data not shown). The high-
propensity region encompasses residues 14–22.
Interestingly, the same region was identified by
means of radioligand experiments49 as the most
prone to bind full-length Ab42 (pink bars in
Figure 2). The radioligand experiments were
carried out with overlapping ten-residue stretches,
which is very close to the simulation systems.
A second region located at the C terminus, which is
missing from the 11-residue segments aggregation
profile, was detected by the experiments. However,
the binding of Ab42 to the C-terminal decapeptides
was considerably less prominent and probably
mediated by hydrophobic rather than specific
interactions.
An in-depth comparison of the amyloidogenicity
profiles obtained from seven and 11-residue peptide
simulations (Figures 1 and 2, respectively) provides
additional information. The profiles are qualitat-
ively similar and display a prominent high-
propensity region located in the central part of the
sequence. However, the effect of the increased
peptide length is not negligible; a considerably
lower b-aggregation propensity is detected at the N
terminus (residues 1–6). When the peptide length is
increased, the resulting stretches are more likely to
include both aggregation-prone and non-aggrega-
tion-prone segments. Therefore, the b-aggregation
propensity decreases in regions of the sequence
with mixed properties. To verify that the length of
the segments identified on the Ab42 sequence had
no impact on the results, the b-aggregation
propensity profile was recalculated by considering
seven-residue substretches along the 11-residue
simulation trajectories (e.g. D1AEFRHD7, E3-
FRHDSG9 and R5HDSGYE11 from D1-
AEFRHDSGYE11). Both b-aggregation propensity
and secondary structure profiles are in good
agreement with those obtained from seven-residue
peptide simulations (Figure S4 in Supplementary
Data). Thus, the simulation results are robust with
respect to the choice of the segment length.
Secondary structure analysis
To interpret the amyloidogenic trend in the
central zone (stretches 14, 16, 18, 20 and 22),
a secondary structure analysis of the conformations
saved along the trajectories was performed. The
analysis showed that b-aggregation propensity
correlates with b-strand content, anticorrelates
with a-helical content, and seems very sensitive to
b-turn or bend propensity (Figure 3 and Figure S5 in
Supplementary Data). The b-aggregation profile in
the segment 14–22 is influenced by the location of a
turn-like segment (G25S26) and the a-helical/
b-strand equilibrium. The latter is consistent with
NMR studies that highlighted a trend to helical
structures for the segment 16–24 in aqueous
solution.50 The identification of four turn-like
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Figure 3. Secondary structure profiles. Single-residue
secondary structure propensities have been extracted
from REMD trajectory segments at 306 K of trimeric 11-
residue systems for Ab42 (top) and from constant
temperature MD trajectories at 330 K of trimeric seven-
residue systems for hIAPP1–37 (bottom). To obtain the
propensity value of residue i, averages were taken over all
stretches containing residue i. Green, blue, red, and cyan
lines correspond to a-helical, b-strand, turn or bend, and
random coil content, respectively. The simulation results
indicate the presence of turn-like segments (red letters),
which play a key role in determining amyloid aggrega-
tion properties. The vertical broken lines mark the
borders of the regions identified by the specific location
of the turns along the sequence.
MD Characterization of Amyloid-fibril Propensity 1311
peaks (S8G9, G25S26, G29A30, and G38V39) helps to
interpret the shape of both seven and 11-residue
profiles as well as the differences between the two.
When Ab42 is dissected into 11-residue segments,
the stretches at the N terminus always include the
first potential turn (S8G9) in the middle of the
sequence and therefore the amyloidogenic content
is low. In contrast, the heptamer Ab3–9 has the S8G9
turn at the C terminus and shows a high
b-aggregation propensity. Similar considerations
explain the low propensity of the 11-residue profile
in the C-terminal region of Ab42. With longer
segments, either the third (G29A30) or the fourth
(G38V39) turn-like site is always included in the
stretches and the b-aggregation propensity is
suppressed. On the other hand, the seven-residue
stretches between G29A30 and G38V39 are respon-
sible for the peak at residues 31–37 (Figure 1 and
Figure S2 in Supplementary Data). Taken together,
the simulation results show that the b-aggregation
profile of Ab42 is strongly modulated by the
position of four turn-like sites along the sequence.
Single-point mutants of Ab42
The aggregation properties of four familial
disease-related variants of Ab42, i.e., the Arctic
(E22G), Dutch (E22Q), Italian (E22K) and Flemish
(A21G) mutants, and one non-pathological variant
obtained by random mutation51 (F19S) were inves-
tigated. In vitro studies51–53 have shown that the
E22G, E22Q and E22K mutations accelerate fibril
formation while A21G and F19S decrease the
fibrillogenesis rate with respect to wild-type Ab42.
Starting from the b-aggregation profile of the wild-
type sequence (Figure 1), mutational effects can be
predicted at moderate computational cost, i.e. by
repeating only the implicit solvent simulations of
the seven-residue stretches affected by the mutation
(Table S1 in Supplementary Data). Seven-residue
segments are preferred to 11-residue segments
because of the lower computational cost, which
allows us to investigate a larger number of mutants.
As shown in Figure 1, the lower aggregation
propensity of the F19S and A21G variants is
reproduced correctly. Interestingly, the disease-
related mutant E22G has a profile (data not
shown) similar to that of wild-type Ab42, indicating
that the simulation-based approach is able to
distinguish the subtle difference between A21G
and E22G. On the other hand, the fact that three
disease-related variants E22G, E22Q and E22K have
profiles similar to wild-type (data not shown)
suggests that the approach is less sensitive in the
very-high propensity region, which could be a
consequence of the reduced dimensionality of the
simulation system, i.e. number of peptides smaller
than in the nucleus and/or short segment length. In
this context it is important to note that previously
published explicit water simulations of the mono-
meric Ab10–35 peptide and its E22Q mutant do not
support the hypothesis that the Dutch E22Q variant
leads to a higher b-structure propensity,54 in
agreement with the present implicit solvent results.
Human amylin (hIAPP1–37)
The b-aggregation profile of hIAPP1–37 was
determined using the same approach as for Ab42.
Sixteen implicit solvent MD simulations of three
seven-residue peptide segments were performed
(Table S3 in Supplementary Data). At 330 K,
b-aggregation propensity values ranged from 0.52
to 0.81 (Figure 2, bottom). The resulting profile
highlights two well-defined hot-spots along the
hIAPP1–37 sequence, with the first (residues 10–22)
more prominent than the second (residues 28–30).
A systematic mapping of the hIAPP1–37 sequence
for the identification of domains that can potentially
mediate molecular recognition and lead to amyloid
fibril formation has been performed by Gazit and
co-workers.55 Their in vitro immunoblotting exper-
iments showed that the region most prone to bind
the full-length hIAPP1–37, i.e. the recognition
domain, is located at the center of the sequence
(residues 7–21). The simulation results are in good
agreement with in vitro findings (Figure 2, bottom).
In particular, the NFVLH pentapeptide suggested
as the “core” of the recognition motif55 is included
in the seven-residue stretch hIAPP13–19 (central
residue 16) that showed the highest b-aggregation
propensity in silico. The largest discrepancy is
located at the region 24–26, which was not
identified by the simulation-based approach. How-
ever, the immunoblotting signal is very weak in this
region and likely to originate from hydrophobic
rather than specific interactions.
The structural analysis performed on Ab42 was
repeated on the hIAPP1–37 sequence. Average
single-residue secondary structure propensities
were extracted from simulation trajectories and
used to draw the profiles shown in Figure 3, which
highlights two short turn-like segments (G24A25 and
G33S34) corresponding to regions of reduced
b-aggregation propensity. Again, the simulation
results suggest that turn-like sites strongly modu-
late the aggregation propensity of amyloid poly-
peptides. It is worth noting, though that a third
b-aggregation propensity minimum observed
around Thr6 is due to a strong a-helical propensity
(green line in Figure 3 bottom) and not to a turn- or
bend-site. As mentioned above, the a-helical/b-
strand equilibrium can modulate the b-aggregation
propensity of a polypeptide chain.
N-terminal domain of the prion protein Ure2
(Ure2p1–94)
As for Ab42 and hIAPP1–37, the b-aggregation
profile of Ure2p20–70was determined by performing
implicit solvent MD simulations of a trimeric
system for each of the seven-residue peptide
segments (Table S4 in Supplementary Data). At
330 K, b-aggregation propensity values ranged
from 0.51 to 0.76 (Figure 4, top). Three aggrega-
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tion-prone regions intercalated with short non
aggregation-prone segments are highlighted: resi-
dues 33–39, 45–49, and 55–61. It is worth noting that
one of the two central regions with low b-aggre-
gation propensity corresponds to three consecutive
serine residues located at positions 51–53. Appar-
ently, these serine residues reduce the local
aggregation tendency by splitting a poly (N) stretch
in two segments. To further investigate the role of
serine residues, six variants of the stretch Ure2p44–50
(NNNNNNN) were modeled by considering all
possible single and double-point N-to-S mutants at
positions 47, 48 and 49 (Table S5 in Supplementary
Data). Six additional simulations were run at 330 K
and b-aggregation propensities computed. As
shown in Figure 4 (top, blue triangles), a strong
position dependence on mutation is observed in
agreement with recent experimental findings.17
Furthermore, the central positions (residues 47
and 48) are more sensitive than the lateral ones
(residue 49). The N-to-S mutations reduce the
aggregation propensity of Ure2p44–50 with the
lowest tendency for the double mutant Ure2p-
N4748S44–50. To study the effect of this double-point
mutation on Ure2p1–94, aggregation simulations of
all stretches affected by themutations, i.e. Ure2p42–48,
Ure2p44–50, Ure2p46–52 and Ure2p48–54, were carried
out. The N4748S double-point mutation is respon-
sible for the disappearance of the hot-spot at
residues 45–49 (empty circles in Figure 4 top) and
therefore is predicted to strongly affect the assembly
behavior of the whole prion domain. To validate the
in silico prediction, the assembly kinetics of the
N-terminal domain of wild-type Ure2p (Ure2p1–94)
and double-point mutant (Ure2p-N4748S1–94) were
compared using the thioflavin T (ThT) binding
assay. For the latter, a pronounced increase in the
lag phase of the assembly reaction and a lower level
of ThT fluorescence at steady state were observed
(Figure 4, bottom). From this observation, we
conclude that the substitution of asparagine by
serine residues at position 47 and 48 hinders the
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Figure 4. N-terminal domain of
the prion protein Ure2: MD simu-
lations and in vitro validation. Top:
values of the b-aggregation pro-
pensity from 330 K constant tem-
peratureMD trajectories of trimeric
seven-residue peptide systems are
shown by filled circles. The seg-
ment identification number corre-
sponds to the position of the central
residue in full-length Ure2p (Table
S4 in Supplementary Data). Blue
triangles indicate b-aggregation
propensities of single and double-
point N-to-S mutants at positions
47, 48 and 49 of the stretch Ure2p44–
50 (segment 47). Open circles con-
nected by a broken line highlight
the mutational effect of the double
mutation N4748S on the aggrega-
tion properties of Ure2p1–94. Bot-
tom: assembly kinetics of wild-type
(Ure2p1–94, red circles) and Ure2p1–
94 N4748S variant (blue triangles)
monitored by ThT binding. The
N4748S substitutions have a dra-
matic effect on the lag phase preced-
ing assembly and validate the
simulation results. Ure2p1–94 fibrils
are 4 nmwide and are shown in the
electron micrograph (inset; the scale
bar represent 100 nm).
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aggregation process of the N-terminal domain as
predicted by the implicit solvent simulations.
Concluding Discussion
A “divide-and-conquer” approach to investigate
the aggregation properties of amyloid polypeptides
is presented. The amino acid sequence is first
decomposed in overlapping segments. Then,
implicit solvent MD simulations of oligomeric
systems are performed for each segment. The use
of an implicit model of the solvent36 allows for
equilibrium sampling (total simulation time of
hundreds of microseconds) starting from peptides
well separated in space, i.e. without intermolecular
contacts. To validate the structural stability of the
ordered aggregates observed in the implicit solvent
runs, 50 ns control simulations with explicit water
are carried out for a subset of the segments.
The MD procedure is used here to determine the
position dependence of the b-aggregation propen-
sity along the polypeptide sequence, i.e. the
b-aggregation profile. Despite higher compu-
tational demand with respect to analytical models
recently developed to predict b-aggregation pro-
pensities,31–33 the present method provides a
structural interpretation of the b-aggregation pro-
file, which is essential to rationalize the sequence
dependence and predict mutational effects on
amyloid aggregation. The use of segments to
investigate the b-aggregation properties of a full-
length sequence is justified, especially for parallel
in-register aggregates. The dissected stretches are
N-acetylated and C-amidated to reproduce their
original context in the full-length sequence. Assum-
ing in-register parallel arrangements, aggregation
MD simulations of short stretches are a good
approximation of the fibrillar environment and the
observations made on the stretches can be extended
to full-length polypeptides.
Up to now, the details of the amyloid structure
and the extent to which it is uniquely defined are
unclear. Initially, structural models with antiparallel
b-sheets were favored.56,57 However, solid state
NMR measurements revealed that amyloid fibrils
formed by Ab10–35
58 and by full-length Ab40
59,60
contain parallel b-strands exactly in register. More-
over, electron paramagnetic resonance (EPR)
studies26 and very recent vibrational dipolar
coupling measurements61 on fibrils formed by
spin-labeled and isotope-labeled Ab40, respectively,
have provided further evidence for the parallel in-
register arrangement. Also, spin labeling exper-
iments on hIAPP1–37 fibrils have indicated an in-
register parallel organization of the b-strands.27 The
compelling experimental17,62–65 and compu-
tational16,66 evidence that side-chains strongly
influence amyloid aggregation suggests that a
parallel organization of the strands in the fibrils
should be, in general, preferred to antiparallel. By
construction, in-register parallel arrangements
favor the interactions of hydrophobic/aromatic
side-chains. Hence, a preference for parallel aggre-
gates is expected for polypeptide sequences with
few charged residues. Short stretches with charged
groups at the termini might prefer the antiparallel
arrangement.34
The aggregation properties of the Alzheimer’s
amyloid-b peptide have been investigated by
applying a two-residue shift: 18 seven-residue and
16 11-residue peptide segments were defined along
the Ab42 sequence. Although the stretches of the
two sets are rather diverse in both amino acid
composition and length, the resulting amyloido-
genicity profiles highlight the same region (from
Val12 to Asp22) as the major hot-spot. Interestingly,
this central zone is also the most prone to bind the
radiolabeled full-length Ab40 peptide, as quantified
by densitometry.49 Since the autoradiography
experiments were carried out with short
(ten-residue) overlapping stretches, the comparison
between in vitro and in silico results is appropriate
and the former validates the latter. Furthermore, the
central region includes the K16LVFF20 pentapeptide
that was shown to be essential for amyloid fibril
formation.49 Although with a lower tendency, the
C-terminal segment (residues 31–37) is also found
to be aggregation-prone. In agreement with this in
silico result, ThT fluorescence assays have shown
that residues 30–35 (AIIGLM) promote the self-
assembly by accelerating the aggregation process.67
The enhanced b-aggregation propensity detected at
the N terminus by the implicit solvent runs is rather
surprising and in disagreement with solid state
NMR23 and EPR measurements.26 It is likely that
the approximations inherent to the solvation model
and, in particular, the neutralization of formal
charges, are too crude to correctly reproduce the
behavior of polypeptide segments with many
charged side-chains. Explicit solvent simulations
started from parallel b-sheet conformations of
segments located at the N terminus unveiled their
marginal structural stability, in agreement with
experiments. The structural details emerging from
the simulations are consistent with the model for
Ab40 fibrils derived from solid state NMR spec-
troscopy.23 In the NMR model, the amyloid-b
peptide bends to generate double-layered sheets
that can pack in a parallel arrangement. Interest-
ingly, the segments 12–24 and 31–37 correspond to
the b-strands of the NMR model.
Thanks to the atomic detail provided by the MD
simulations, the b-aggregation profile could be
structurally characterized. Secondary structure
analysis of the MD trajectories unveiled the
presence of four turn-like sites along the amyloid-
b sequence: S8G9, G25S26, G29A30, and G38V39.
Interestingly, the location of the first three turns
had been suggested by solution NMR,68 solid state
NMR23 and proline scanning mutagenesis,30
respectively. Although the four sites with turn
propensity could have been detected by algorithms
for secondary structure prediction, the conse-
quences of such propensity within the context of
an oligomeric system can be determined only by the
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MD-simulation approach. The identified turn-like
segments correspond to large drops in b-strand
propensity and are located at the borders of
aggregation-prone regions (Figure 3, top). Hence,
their specific position on the sequence determines
the location and width of the aggregation hot-spots,
which are supposed to drive amyloid fibril for-
mation and to have an influence on the fibrillar
conformation of Ab42. In this regard, it is worth
noting that although the structural model proposed
by Tycko and co-workers23 has a single turn located
at residues 25–26, the original solid state NMR
chemical shifts are fully compatible with the
presence of a second turn located at residues
29–30, as suggested by the MD simulation results.
An alternative structural model including a second
turn and a different intramolecular register between
the strands cannot be excluded because of the lack
of experimental data in that region of the sequence
and the usage of a minimization protocol by
Petkova et al.23 unable to investigate the whole
conformational space compatible with experimen-
tal constraints.
The simulation-based approach has been
further tested on the human amylin polypeptide
(hIAPP1–37) and the N-terminal domain of the yeast
prion protein Ure2 (Ure2p20–70). Unlike Ab42, these
two polypeptide sequences contain very few
charged side-chains (i.e. 2/37 and 4/51 in hIAPP1–
37 and Ure2p20–70, respectively). Moreover, these
charges are separated along the sequence (Lys1 and
Arg11 in hIAPP1–37; Arg24, Asp31, Glu38, and
Arg65 in Ure2p20–70) so that each blocked heptapep-
tide contains a maximum of one charge. Hence,
explicit water runs were not deemed necessary. Two
aggregation-prone regions have been identified
along the hIAPP1–37 sequence: a major hot-spot
from Gln10 to Asn22, and a minor one from Ser28 to
Val32. In contrast with experimental data obtained
without blocking groups at the peptide termini,69
the present simulation analysis indicates that the
blocked NNFGAIL segment does not show high
b-aggregation propensity. Interestingly, recent
explicit water simulations of an octameric system
of blocked NFGAIL peptides have also reported
low aggregation tendency.70 In fact, despite the
usage of ad hoc conformational restraints, i.e. the
main chains were completely restrained to ideal
b-sheet conformations, only 8% of the sampled
octamers were well ordered. The apparent dis-
agreement between the simulation results (this
work and work done by Wu et al.70) and the
experiments suggests that short peptide stretches
may show different aggregation properties if
unblocked. Hence, it is more appropriate to
consider blocked peptides to infer the aggregation
properties of a polypeptide sequence from its
segments.
The structural characterization of the b-aggre-
gation profile of hIAPP1–37 unveils the presence of
two specific turn-like segments (G24A25 and G33S34).
Similarly to what was found for Ab42, these two
sites determine the overall shape of the aggregation
profile, i.e., the location and extension of the hot-
spots. It is worth noting that the Ab42 and hIAPP1–37
aggregation profiles are strikingly similar (Figures 1
and 2). Both share a major aggregation hot-spot in
the middle of the sequence, a less aggregation-
prone region in the hydrophobic tail and a turn-like
segment between them. Despite the rather low level
of sequence identity (w21%) and similarity
(w36%), the b-aggregation profiles suggest that
Ab42 and hIAPP1–37 might have similar fibrillar
structures. In accord with these considerations, it
has been found that Ab42 fibrils can act as efficient
seeds for hIAPP1–37 aggregation,
71 thus implying
that at least under certain conditions hIAPP1–37 can
adopt a structure similar to that of Ab42 in the fibrillar
form.
Taken together, the MD-simulation results of
Ab42 and hIAPP1–37 provide further evidence that
alternating b-strands and turn (or bend) segments
might be a general feature of amyloid polypeptides,
as suggested by Kajava et al.72,73 Assemblies with
completely elongated peptide backbones are likely
to be less favorable than partially folded arrange-
ments of b-strands because of entropic effects as
well as the tighter packing and minimal solvent
exposure of hydrophobic residues in the latter.23 In
this view, the identified turn-like segments are
expected to be very sensible to mutation and
therefore optimal targets for reducing amyloid
propensity.
When removed from its natural environment,
Ure2p1–94assembles into 4 nmwidefibrils of amyloid
nature (Figure 4). Three aggregation-prone
regions have been identified along the sequence of
Ure2p20–70: residues 33–39, 45–49, and 55–61. Again,
the presence of aggregation hot-spots intercalated
with non-aggregation-prone segments has been
observed. The simulation-based approach has been
successfully applied to guide site-directed mutagen-
esis for reducing the amyloidogenic tendency of
Ure2p1–94. The double-point mutation N4748S
designed in silico to reduce aggregation propensity
has been verified experimentally (Figure 4).
In conclusion, the MD simulation approach
yields the amyloidogenicity profile along a poly-
peptide sequence and the secondary structure
propensity of its overlapping segments in the
context of an ordered aggregate. The combination
of both types of information is very helpful for the
understanding of the sequence and structure
determinants of amyloid fibril formation. The
computational strategy may be ultimately used to
guide the rational design of synthetic peptidic and
non-peptidic molecules that hinder or prevent
amyloid aggregation.
Materials and Methods
Implicit solvent simulations of aggregation
To simulate peptide aggregation, a strategy similar to
that described by Gsponer et al.16 was followed. Implicit
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solvent simulations of aggregation were performed with
the program CHARMM.74 The oligomeric peptide
systems were modeled by explicitly considering all
heavy atoms and the hydrogen atoms bound to nitrogen
or oxygen atoms (PARAM19 potential function74,75). The
remaining hydrogen atoms are considered as part of the
carbon atoms to which they are covalently bound
(extended atom approximation). An implicit model
based on the solvent-accessible surface was used to
describe the main effects of the aqueous solvent on the
solute.36 The CHARMM PARAM19 default cutoffs for
long range interactions were used, i.e., a shift function74
was employed with a cutoff at 7.5 A˚ for both the
electrostatic and van der Waals terms. The model is not
biased toward any particular secondary structure type. In
fact, the same force field and implicit solvent model have
been recently used in MD simulations of aggregation,16,48
folding of structured peptides (a-helices and b-sheets)
ranging in size from 15 to 31 residues,76–78 and small
proteins of about 60 residues.79,80 Moreover, the in-
register parallel packing of three GNNQQNY peptides
predicted by this model16 has been recently validated by
the X-ray microcrystal structure of the cross-b spine:18 the
b-strand alignment, the stacking interactions of the
tyrosine rings and the hydrogen bonds between amide
groups are essentially identical (compare Figure 2 of
Gsponer et al.16 with Figure 2(e) of Nelson et al.18). The
same force field, solvation model and simulation protocol
have been applied to polypeptide segments experimen-
tally known not to form amyloid structures, i.e. the
nonapeptide SQNGNQQRG (corresponding to Sup35
residues 17–25 with the Gln/Arg mutation at position
24, which showed solubility in vivo and in vitro81) and the
alanine heptapeptide.82 No ordered b-aggregate was
observed in these control simulations,16,48 which is
particularly remarkable for the SQNGNQQRG sequence
given its similarity to the amyloidogenic GNNQQNY
peptide.
In the case of Ab42, the following constant tempera-
ture MD runs were performed: (i) 18 simulations of
three seven-residue peptide copies at 330 K to monitor
b-aggregation propensity along the sequence and
highlight possible aggregation hot-spots; (ii) 18 simu-
lations of three seven-residue peptide copies at 310 K
to investigate the temperature effect on the aggregation
properties of the overlapping stretches; (iii) 18 simu-
lations of six seven-residue peptide copies at 330 K to
investigate the effect of the system size, i.e. the number
of molecules in the simulation box, on both b-aggre-
gation propensity and structural properties of the
aggregates; (iv) 13 310 K and four 330 K runs of three
seven-residue peptide copies to predict mutational
effects on the aggregation properties of Ab42; and (v)
16 simulations with three 11-residue peptide copies at
330 K to study the dependency of b-aggregation
propensity on the length of the overlapping segments.
To guarantee the correct sampling of peptide confor-
mational space in physiological conditions,48 the self-
assembly of long segments (11-residue) was investi-
gated by replica exchange molecular dynamics (REMD)
simulations. In an REMD run, different copies of the
system (“replicas”) are simulated at the same time but
at different temperature values. Each replica evolves
independently by MD and every tswap states i,j with
neighbor temperatures are swapped (by velocity
rescaling) with a probability wijZexp(KD),
83 where
Dh(biKbj)(EjKEi), bZ1/kT and E is the effective
energy (potential and solvation energy). During the
simulation, each replica visits all temperatures of
the set and realizes a free random walk in temperature
space. High-temperature simulation segments facilitate
the crossing of the energy barriers while low tempera-
ture ones explore energy minima in detail. Thus, the
temperature swapping determines a random walk in
energy space, which improves sampling efficiency. In
this study, ten replicas were used with temperatures (in
K): 294, 306, 318, 330, 343, 356, 369, 383, 397, 413. By
using fixed value of DtswapZ10,000 MD steps (20 ps),
48
temperature values were adjusted by trial and error
until the acceptance ratios of exchange between
neighbor temperatures converged to values between
40% and 50%.
In a similar fashion, to determine the b-aggregation
profile and identify the aggregation hot-spots along both
hIAPP1–37 and Ure2p20–70, 16 and 23 simulations of three
seven-residue peptide copies at 330 K were carried out,
respectively. Finally, ten simulations of three seven-
residue peptide copies were performed at 330 K to
investigate mutational effects on Ure2p1–94 aggregation
properties.
All implicit solvent simulations were performed
starting from random conformations, positions, and
orientations of the peptide copies. In the initial random
positions there was no intermolecular contact, i.e. the
peptides were separated in space. Each system was
simulated in a cubic box whose side was adjusted to yield
a sample concentration of 5 mg/ml. Langevin dynamics
with a friction value of 0.15 psK1 was used. This friction
coefficient is much smaller than that of water (43 psK1 at
330 K) to allow for sufficient sampling within the
microsecond time-scale of the simulation. The small
friction does not influence the thermodynamic properties
of the system. The SHAKE algorithm84was used to fix the
length of the covalent bonds involving hydrogen atoms,
which allows an integration time-step of 2 fs. Further-
more, the non-bonded interactions were updated every
ten dynamics steps and coordinate frames were saved
every 20 ps for a total of 5!104 conformations/ms. On a
2.1 GHz Athlon processor, a 1 ms run requires approxi-
mately 10.4 days, 25.2 days and 22.3 days for three, seven-
residue peptides, six, seven-residue peptides, and three
11-residue peptides, respectively. Simulations were run
on a Beowulf cluster for a total simulation time of 0.35 ms,
0.02 ms and 0.05 ms for Ab42, hIAPP1–37 and Ure2p20–70,
respectively.
Explicit solvent simulations started from ordered
aggregates
For a subset of four Ab42 seven-residue stretches
(Ab1–7, Ab5–11, Ab13–19 and Ab29–35), explicit solvent
MD simulations were carried out starting from in-
register parallel b-sheet conformations. The starting
structure of each run was selected among the implicit
solvent conformations with a fraction of parallel
contacts larger than 0.85 (these contacts were defined
following the procedure described by Gsponer et al.16).
Explicit solvent simulations were performed with the
program NAMD285 using the CHARMM all-hydrogen
force field (PARAM22 potential function86) along with
the TIP3P model for water molecules.87 Non-polar
hydrogen atoms were added by CHARMM (HBUILD
module) and their position was optimized in vacuo. The
resulting structure was solvated in a water box of
appropriate dimensions so that the distance between
periodic images was not smaller than 25 A˚. Chloride
and sodium ions were added to neutralize the systems,
yielding a salt concentration of 150 mM. Long-range
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electrostatic forces were accounted for by using
the particle mesh Ewald summation method88 with
real space cutoff distance of 10 A˚ and a grid width of
0.93 A˚. The simulations were run at constant tempera-
ture (310 K) and pressure (1 atm) by applying the
Berendsen thermostat89 with a coupling decay time of
1 ps and the hybrid Nose–Hoover Langevin pressure
control.90 The SHAKE algorithm84 was used to allow
for an integration time-step of 2 fs. Solvent molecules
and counterions were equilibrated at 310 K while
holding the peptide system rigid for 1 ns. Two 0.5 ns
equilibration cycles were then performed applying a
harmonic constraint to all peptide atoms with force
constants of 1.0 and 0.1 kcal/mol A˚2, respectively. Upon
releasing the constraints, 50 ns production runs were
performed for each peptide system.
Order parameters and b-aggregation propensity
The nematic order parameter P2 was considered to
monitor the aggregation process as described by Cecchini
et al.48 This order parameter is widely used for studying
the properties of anisotropic fluids such as liquid
crystals91–93 and is defined as:
P2Z
1
N
XN
iZ1
3
2
ðz^i$d^Þ
2
K
1
2
(1)
where d^ (the director) is a unit vector defining the
preferred direction of alignment, z^i is a suitably defined
molecular vector, andN is the number of molecules in the
simulation box, i.e., three or six peptides in this study. The
director is defined as the eigenvector of the ordering
matrix94 that corresponds to the largest positive eigen-
value. Here, the molecular vectors z^i were defined as unit
vectors linking the peptide’s termini (from the N to the C
terminus). The nematic P2 describes the orientational
order of the system and discriminates between ordered
and disordered conformations.
As it has been recently shown,48 the average over the
canonical ensemble of P2 is descriptive of the thermo-
dynamic stability of the ordered state of oligomeric
peptide systems. This scalar value, which ranges from 0
(complete disorder) to 1 (perfect order), can then be used
to estimate and compare the amyloidogenic propensity of
different peptide sequences. Here, the value of P2
averaged over the MD trajectory, referred to as b-aggre-
gation propensity, is used to determine the b-aggregation
profiles.
Progress variables
Radius of gyration
The radius of gyration of the oligomeric system Rg was
considered to monitor the “condensation” equilibrium
along the simulation trajectories. Conformations of the
system producing non-interacting peptides, namely
conformations where all inter-peptide atomic distances
are larger than the long-range interactions cutoffs (7.5 A˚
in this case), were used to determine RCg . In other words,
RCg is the lowest value of the radius of gyration measured
for the snapshots when the three peptides are far apart
from each other. Conformations with one or more isolated
peptides ðRgOR
C
g Þ describe the “uncondensed state” of
the system.
Secondary structure
Strings of secondary structure (SS) were considered to
monitor peptide conformational changes along the
trajectory. For each oligomeric snapshot (Cartesian
coordinates of the atomic nuclei) the SS of each chain
was calculated.95 The resulting strings of SS elements (one
element per residue) were used to describe peptide
conformations and monitor the aggregation process.
The SS alphabet includes four possible letters: “H”, “E”,
“T” and “–”, which stand for a-helix, extended (b-strand),
b-turn or bend, and random coil, respectively. Terminal
caps as well as N and C-terminal residues are always
assigned a “–”. Albeit devoid of the atomic detail, SS
strings are useful because they provide an intuitive
description of the shape of the peptide backbone.
However, these strings are suitable to monitor peptide
conformational changes only at a coarse-grained level. In
fact, in a perfect in-register arrangement a capped
hendecapeptide would present the following SS string
“–EEEEEEEEE–” independently of the polarity of the
assembly, i.e. the number of parallel and antiparallel
b-strands.
Mutagenesis
The N-terminal domain of Ure2p (Ure2p1–94) is highly
insoluble and forms inclusion bodies inE. coli. In contrast, it
is soluble when attached to the C-terminal domain of the
protein. We therefore engineered a specific cleavage site
between the two domains in order to generate soluble
Ure2p1–94 at the onset of the assembly reaction by cleavage
with the specific protease Factor Xa as described byBousset
et al.96 The variant Ure2p-N4748S expression vector was
obtained by site-directed mutagenesis. Mutagenesis was
achieved using theQuickChange site-directedmutagenesis
kit (Stratagene Europe, Amsterdam, The Netherlands) and
the primers 5 0-CAGGTGTAAATAATAATAGTAGTAA-
CAATAGCAGTAGTAATAAC-3 0 and 5 0-GTTATTAC-
TACTGCTATTGTTACTACTATTATTATTTACACCTG-3 0.
Protein purification, generation of soluble Ure2p1–94
and assembly of Ure2p1–94 into fibrils
Recombinant Ure2p-I91EGR94 and Ure2p-N4748S-
I91EGR94 were over expressed as soluble proteins in
E. coli and purified as described.46 The Ure2p1–94 frag-
ment was generated as described by Bousset et al.96 The
assembly reactions were monitored using thioflavin T
binding ,97 using a Quantamaster QM 2000-4 spectro-
fluorimeter (Photon Technology International, Inc. NJ).
Ure2p1–94 fibrils were also examined following negative
staining with 1% uranyl acetate on carbon-coated grids
(200-mesh) in a Philips EM 410 electron microscope
(Philips Inc., The Netherlands).
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1. Single-peptide cluster analysis
A single-peptide cluster analysis was performed to investigate the conformations visited
by each peptide segment in the perturbation field of its oligomeric system and to determine
the statistical relevance of the conformations sampled. The simulation trajectory of the
oligomeric system was first split into n single-peptide trajectories, where n is the number
of peptide copies in the simulation box. For each snapshot, the Cartesian coordinates of
single peptides were extracted and collected according to their identification number, i.e.,
coordinates of copy 1 were gathered in the first trajectory, coordinates of copy 2 in the second
and so on. Single-peptide trajectories were then merged one after the other. The resulting
trajectory, which is made of a number of snapshots n times larger than the original trajectory,
underwent a cluster analysis based on structural similarity1. Single-peptide conformations
were grouped according to the Cα–Cβ root-mean-square deviation (RMSD) for each pairs
of structures after optimal superposition2. A 1.5 A˚ RMSD cutoff was used to determine
the cluster centers. The clustering algorithm proceeded iteratively until each structure was
assigned to a cluster center.
2. Role of condensation in amyloid peptide aggregation
To further investigate the role of the condensation equilibrium in amyloid peptide ag-
gregation, the simulation trajectories of two non aggregation-prone stretches (Aβ25−31 and
Aβ29−35) were analyzed in detail. Unlike the free-energy profiles along P2 and Rg, a single-
peptide cluster analysis (see above) revealed that the two oligomeric systems have intrin-
sically different β-aggregation propensities. For both systems, the most populated clusters
sampled along the whole trajectory are shown in Fig. S1 (top). For Aβ29−35, already the
third most populated cluster (4.1%) is the extended conformation which favors β-sheet for-
mation. Moreover, if one considers only the fraction of condensed conformations sampled
along the trajectory (Rg < Rg
C) the statistical weight of the cluster increases substantially
and the extended conformation becomes the most populated cluster (6.3%). Hence, Aβ29−35
does have a certain β-sheet propensity, which due to the condensation equilibrium remains
hidden at 330 K and cannot be detected by the order parameter analysis. For Aβ25−31, the
situation is different: the cluster producing the extended conformation ranks 19th (statistical
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weight of only 0.7%). However, even considering the condensed fraction, its ranking does
not improve. Irrespective of the degree of condensation Aβ25−31 does not show any β-sheet
propensity. Thus, the condensation propensity, though not sufficient to describe amyloido-
genicity, is a necessary condition to promote the growth of ordered amyloid nuclei. It is not
sufficient because amyloidogenic sequences must also contain β-sheet propensity.
3. Effect of the number of peptides on β-aggregation
To investigate the effect of the dimensionality of the system on the Aβ42 β-aggregation
profile, the self-assembly process of hexamers was considered. Eighteen MD simulations
of six peptides were performed (see Table I) and each trajectory was analyzed by means
of the order parameters. At 330 K, β-aggregation propensities ranged between 0.28 and
0.71, thus confirming a strong heterogeneity in aggregation tendencies. A direct comparison
with β-aggregation propensities measured from trimeric simulations is however not possible.
Although by definition the order parameters do not depend on the number of molecules (n)
in the simulation box, when this number is rather small a n-dependent “background” order3
is detected4. β-aggregation propensities obtained from hexameric and trimeric trajectories
are therefore not directly comparable. Nonetheless, if one considers only triplets of peptides
from each hexameric snapshot, the order information becomes homogeneous and different
oligomeric systems can be compared. To guarantee a fair comparison, only triplets of non-
isolated peptides, i.e., triplets where each chain forms at least a Cα contact (Cα – Cα < 5.5 A˚)
with another chain, were considered. Hexameric and trimeric amyloidogenicity profiles are
shown in Fig. S2 (blue and red circles, respectively). Remarkably, the correlation between
the two is quantitative and the grey bars, which show β-aggregation differences (∆β) along
the profile, are rather small (below 0.05) almost everywhere. For both systems three hot-
spots separated by non aggregation-prone regions have been identified. Interestingly, the
C-terminal hot-spot in the trimeric profile (red spots) was not originally observed (see Fig.
1). Here, the third aggregation-prone region originates from the restriction of the order
analysis to non-isolated peptide triplets and gives further evidence of the role played by the
condensation equilibrium in amyloid aggregation (see previous section). Free energy profiles
along Rg, used to monitor the condensation propensity of the hexameric system, were also
measured (data not shown); in agreement with previous findings, the C-terminal stretches
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(from Aβ27−33 to Aβ35−41) showed little condensation propensity.
The structural properties of the aggregates sampled by the MD simulations were also
analyzed. By cluster analysis, the trajectories of the stretches located in the hot-spots
revealed the existence of fully ordered states. The majority of these low-energy states were
structurally diverse six-stranded β-sheets characterized by different register alignment, twist
and polarity content. Although a statistically relevant preference for in-register parallel
arrangements was observed, no hexameric system exhibited a single dominating free energy
minimum. This finding is consistent with the very recent discovery that the well-known
amyloid-fibril polymorphism results from significant variations in the molecular structure
at the protofilament level5. The observed “fibril-like” aggregates are fully consistent with
the ordered arrangements sampled along the trimeric trajectories and can be thought as
their logic extension. The emergence of multiple and competitive low free-energy states
suggests, on one hand, that the critical nucleus size has not been reached yet and, on the
other hand, that kinetically trapped states might be involved in the structural evolution of
ordered oligomers6.
4. Effect of the segment length on β-aggregation
The robustness of the simulation results with respect to the length of the segments that
are identified along the polypeptide sequence was also investigated. The Aβ42 primary struc-
ture was decomposed into overlapping hendecamers (Table S2) and the trimeric systems of
individual segments were studied by implicit solvent MD simulations. The increasing com-
plexity arising from the presence of longer peptide chains resulted in insufficient sampling of
the conformational space by constant temperature MD. In fact, a few preliminary runs at
330 K produced trajectories where the system remained trapped in a single free-energy mini-
mum for the whole length of the simulation (∼ 2µs, data not shown). Thus, replica exchange
MD (REMD)4 was preferred to investigate the aggregation process of 11-residue stretches.
Profiles of β-aggregation propensity as a function of temperature are shown in Fig. S3. At
elevated temperature, the profiles converge to 0.5, which indicates that no orientational
order is present and different stretches are indistinguishable. Close to the physiological tem-
perature, a strong heterogeneity becomes apparent: (i) the stretches centered at residues 14
and 16 show a steep sigmoidal profile which means large β-aggregation propensity over a
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wide range of temperatures; (ii) stretches 6, 12, 18 and 20 display a maximum indicating the
existence of an equilibrium that disfavors ordered states at low temperature; (iii) stretches
8 and 22 show monotonically growing profiles which resemble the behavior of highly amy-
loidogenic sequences, though shifted to lower temperatures; and (iv) the remaining eight
stretches (10, 24, 26, 28, 30, 32, 34 and 36) do not show any β-aggregation propensity over
the range investigated. Whereas both monotonically growing and non-amyloidogenic pro-
files have been already observed for 7-residue peptides4, trends characterized by a maximum
are detected here for the first time. Secondary structure analysis (data not shown) revealed
that the competition between self (intramolecular) and cross (intermolecular) interactions
is responsible for such behavior. By lowering the temperature the self interactions (e.g.,
α-helical and loop conformations) of certain segments are favored at the expenses of the
extended conformations and the β-aggregation propensity drops.
The values of β-aggregation propensity from implicit solvent REMD trajectories were
used to draw the Aβ42 amyloidodgenicity profile at 330 K. However, to compare the re-
sults obtained from different segment decompositions (i.e., 7- and 11-residue peptide seg-
ments) the profile was re-derived by considering 7-residue substretches on the 11-residue
segments. For each hendecapeptide three substretches were identified (e.g., D1AEFRHD7,
E3FRHDSG9 and R5HDSGYE11 from D1AEFRHDSGYE11; E3FRHDSG9, R5HDSGYE11 and D7SGYEVH13
from E3FRHDSGYEVH13; and so on) and the time series of the nematic order parameter was
computed for each of them along the trajectory. β-Aggregation profiles obtained from 7- and
11-residue segment simulations are comparable (Fig. S4, top); the trends are very similar and
display a maximum in the region 10-22 and two minima at S8G9 and the C-terminus. Due to
the errors inherent to the implicit solvation model, the N-terminus is more aggregation-prone
than the C-terminus in both cases. Similar conclusions can be drawn from the comparison
of the β-sheet structure profiles (Fig. S4, bottom). Again, maxima and minima are similarly
located along the Aβ42 sequence. The analysis shows that the segment length does not affect
the simulation results.
5. Structural interpretation of the Aβ42 aggregation profile
The Aβ42 β-aggregation profile from simulations of three 11-residue peptides (Table S2)
shows a high propensity region encompassing residues 14-22 (Fig. 2, top). Interestingly,
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β-aggregation propensities indicate the following ranking 14 ≈ 16  18 > 20  22. To
structurally characterize the amyloidogenic trend in this central hot-spot, a secondary struc-
ture analysis of the conformations saved along the trajectories was performed. Secondary
structure histograms plotted along the sequence are shown in Fig. S5. A α-helical/β-strand
equilibrium, consistent with NMR studies that highlighted a trend to helical structures for
the segment 16-24 in aqueous solution7, accounts for the shape of the profile. On the left
edge of the central hot-spot (stretch 12), α-helical conformations are dominating and very low
β-aggregation propensity is observed. In stretches 14 and 16 the β-strand content increases
dramatically, the α-helical propensity vanishes and the sequences are highly amyloidogenic.
In stretches 18 and 20 the α/β equilibrium restores and although β-strand conformations
are still preferred at this stage, α-helical structures become more stable. Finally, in stretch
22 a turn-like motif (G25S26) shows up and a second large drop in the profile occurs. Hence,
β-aggregation propensity correlates with β-strand content, anticorrelates with α-helical con-
tent and seems very sensitive to β-turn or bend propensity. The simulation results indicate
that both α-helical/β-strand and β-turn/β-strand equilibria modulate the aggregation prop-
erties of this region.
6. Structure stability from explicit water runs
For a subset of four Aβ42 7-residue stretches (Aβ1−7, Aβ5−11, Aβ13−19, and Aβ29−35)
explicit solvent MD simulations were started from in-register parallel β-sheet conformations
observed in implicit solvent runs to evaluate their structural stability. For each peptide
system, 50-ns explicit water production runs were performed and the time series of P2 were
computed along the trajectories. Average values taken at time intervals of increasing length
(0.002, 1, 2, 5, 10, 20, 30, and 50 ns) are shown in Fig. S6. The quick drop of the average P2
in the case of the Aβ1−7 and Aβ5−11 segments indicates marginal structural stability of the
in-register parallel β-sheet arrangements. On the contrary, segments Aβ13−19 and Aβ29−35
show rather stable β-sheet conformations in agreement with experimental observations8–10.
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TABLE S1: Aβ42: 7-Residue stretches simulations of four disease-related and one non-pathological
variants
Segment Variant Peptide Sequence Central 3 peptides (µs)
Residue 310 K 330 K
Aβ15−21 A21G DAEFRHDSGYEVHHQKLVFFGEDVGSNKGAIIGLMVGGVVIA 18 3× 1.0
Aβ17−23 A21G DAEFRHDSGYEVHHQKLVFFGEDVGSNKGAIIGLMVGGVVIA 20 3× 1.0
Aβ19−25 A21G DAEFRHDSGYEVHHQKLVFFGEDVGSNKGAIIGLMVGGVVIA 22 3× 1.0
Aβ21−27 A21G DAEFRHDSGYEVHHQKLVFFGEDVGSNKGAIIGLMVGGVVIA 24 3× 1.0
Aβ17−23 E22G DAEFRHDSGYEVHHQKLVFFAGDVGSNKGAIIGLMVGGVVIA 20 3× 1.0
Aβ19−25 E22G DAEFRHDSGYEVHHQKLVFFAGDVGSNKGAIIGLMVGGVVIA 22 3× 1.0
Aβ21−27 E22G DAEFRHDSGYEVHHQKLVFFAGDVGSNKGAIIGLMVGGVVIA 24 3× 1.0
Aβ17−23 E22K DAEFRHDSGYEVHHQKLVFFAKDVGSNKGAIIGLMVGGVVIA 20 3× 1.0
Aβ19−25 E22K DAEFRHDSGYEVHHQKLVFFAKDVGSNKGAIIGLMVGGVVIA 22 3× 1.0
Aβ21−27 E22K DAEFRHDSGYEVHHQKLVFFAKDVGSNKGAIIGLMVGGVVIA 24 3× 1.0
Aβ17−23 E22Q DAEFRHDSGYEVHHQKLVFFAQDVGSNKGAIIGLMVGGVVIA 20 3× 1.0
Aβ19−25 E22Q DAEFRHDSGYEVHHQKLVFFAQDVGSNKGAIIGLMVGGVVIA 22 3× 1.0
Aβ21−27 E22Q DAEFRHDSGYEVHHQKLVFFAQDVGSNKGAIIGLMVGGVVIA 24 3× 1.0
Aβ13−19 F19S DAEFRHDSGYEVHHQKLVSFAEDVGSNKGAIIGLMVGGVVIA 16 1× 1.9
Aβ15−21 F19S DAEFRHDSGYEVHHQKLVSFAEDVGSNKGAIIGLMVGGVVIA 18 1× 1.7
Aβ17−23 F19S DAEFRHDSGYEVHHQKLVSFAEDVGSNKGAIIGLMVGGVVIA 20 1× 1.3
Aβ19−25 F19S DAEFRHDSGYEVHHQKLVSFAEDVGSNKGAIIGLMVGGVVIA 22 1× 1.3
S-8
TABLE S2: Aβ42: 11-Residue stretches simulations
Segment Peptide Sequence Central 3 peptides (µs) 3 peptides (µs)
Residue CTMD 330 K REMD 294-413 K
Aβ1−11 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 6 1× 1.5 10× 1.0
Aβ3−13 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 8 1× 1.4 10× 1.0
Aβ5−15 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 10 1× 1.3 10× 1.0
Aβ7−17 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 12 1× 1.5 10× 1.0
Aβ9−19 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 14 1× 1.5 10× 1.0
Aβ11−21 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 16 1× 1.5 10× 1.0
Aβ13−23 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 18 1× 1.5 10× 1.0
Aβ15−25 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 20 1× 1.7 10× 1.0
Aβ17−27 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 22 1× 1.8 10× 1.0
Aβ19−29 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 24 1× 1.7 10× 1.0
Aβ21−31 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 26 1× 1.9 10× 1.0
Aβ23−33 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 28 1× 2.0 10× 1.0
Aβ25−35 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 30 1× 2.0 10× 1.0
Aβ27−37 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 32 1× 2.1 10× 1.0
Aβ29−39 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 34 1× 3.0 10× 1.0
Aβ31−41 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 36 1× 2.3 10× 1.0
TABLE S3: hIAPP1−37: 7-Residue stretches simulations
Segment Peptide Sequence Central 3 peptides (µs)
Residue 330 K
hIAPP1−7 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 4 1× 1.1
hIAPP3−9 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 6 1× 1.1
hIAPP5−11 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 8 1× 1.1
hIAPP7−13 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 10 1× 1.1
hIAPP9−15 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 12 1× 1.1
hIAPP11−17 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 14 1× 1.1
hIAPP13−19 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 16 1× 1.1
hIAPP15−21 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 18 1× 1.1
hIAPP17−23 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 20 1× 1.1
hIAPP19−25 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 22 1× 1.1
hIAPP21−27 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 24 1× 1.1
hIAPP23−29 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 26 1× 1.1
hIAPP25−31 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 28 1× 1.1
hIAPP27−33 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 30 1× 1.1
hIAPP29−35 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 32 1× 1.1
hIAPP31−37 KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 34 1× 1.1
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TABLE S4: Ure2p20−70: 7-Residue stretches simulations
Segment Peptide Sequence Central 3 peptides (µs)
Residue 330 K
Ure2p20−26 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 23 1× 1.8
Ure2p22−28 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 25 1× 1.8
Ure2p24−30 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 27 1× 1.7
Ure2p26−32 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 29 1× 2.0
Ure2p28−34 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 31 1× 2.1
Ure2p30−36 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 33 1× 1.8
Ure2p32−38 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 35 1× 1.7
Ure2p34−40 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 37 1× 1.6
Ure2p36−42 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 39 1× 1.8
Ure2p38−44 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 41 1× 2.0
Ure2p40−46 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 43 1× 2.3
Ure2p42−48 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 45 1× 1.8
Ure2p44−50 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 47 1× 1.6
Ure2p46−52 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 49 1× 1.8
Ure2p48−54 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 51 1× 2.1
Ure2p50−56 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 53 1× 2.1
Ure2p52−58 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 55 1× 1.9
Ure2p54−60 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 57 1× 1.7
Ure2p56−62 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 59 1× 1.7
Ure2p58−64 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 61 1× 1.7
Ure2p60−66 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 63 1× 1.1
Ure2p62−68 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 65 1× 2.1
Ure2p64−70 NIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQN 67 1× 2.0
TABLE S5: Ure2p20−70: 7-Residue stretches simulations of single- and double-point N-to-S sub-
stitutions at positions 47, 48 and 49.
Segment Variant Peptide Sequence Central 3 peptides (µs)
Residue 330 K
Ure2p44−50 N47S NIGNRNSNTTTDQSNINFEFSTGVNNNSNNNSSSNNNNVQNNNSGRNGSQN 47 1× 1.5
Ure2p44−50 N48S NIGNRNSNTTTDQSNINFEFSTGVNNNNSNNSSSNNNNVQNNNSGRNGSQN 47 1× 1.5
Ure2p44−50 N49S NIGNRNSNTTTDQSNINFEFSTGVNNNNNSNSSSNNNNVQNNNSGRNGSQN 47 1× 0.9
Ure2p44−50 N4748S NIGNRNSNTTTDQSNINFEFSTGVNNNSSNNSSSNNNNVQNNNSGRNGSQN 47 1× 1.0
Ure2p44−50 N4749S NIGNRNSNTTTDQSNINFEFSTGVNNNSNSNSSSNNNNVQNNNSGRNGSQN 47 1× 1.0
Ure2p44−50 N4849S NIGNRNSNTTTDQSNINFEFSTGVNNNNSSNSSSNNNNVQNNNSGRNGSQN 47 1× 1.0
Ure2p42−48 N4748S NIGNRNSNTTTDQSNINFEFSTGVNNNSSNNSSSNNNNVQNNNSGRNGSQN 45 1× 1.4
Ure2p44−50 N4748S NIGNRNSNTTTDQSNINFEFSTGVNNNSSNNSSSNNNNVQNNNSGRNGSQN 47 1× 1.0
Ure2p46−52 N4748S NIGNRNSNTTTDQSNINFEFSTGVNNNSSNNSSSNNNNVQNNNSGRNGSQN 49 1× 1.4
Ure2p48−54 N4748S NIGNRNSNTTTDQSNINFEFSTGVNNNNSNNSSSNNNNVQNNNSGRNGSQN 51 1× 1.5
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FIG. S1: Analysis of the non aggregation-prone 7-residue stretches Aβ25−31 (red) and Aβ29−35
(blue). (Top) Single-peptide cluster analysis on the whole trajectory. (Bottom, inset) Cluster
analysis for fraction of conformations with Rg < Rg
C . Rg
C corresponds to the lowest radius
of gyration detected for conformations where all inter-peptide atomic distances are larger than
the long-range interactions cutoffs (7.5 A˚ in this case). For both fractions (the whole and the
condensed), the most populated clusters are represented with their statistical weight. (Bottom,
main plot), free-energy projection along the radius of gyration of the trimeric system. Unlike the
free-energy profiles on Rg, the single-peptide cluster analysis shows that the two trimeric systems
are distinguishable and reveals the role played by the condensation equilibrium in β-aggregation.
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FIG. S2: Analysis of dependence on the size of the simulation system. Values of the β-aggregation
propensity from 330 K constant temperature MD simulations of trimeric (red) and hexameric
(blue) 7-residue peptide systems. To compare the different oligomeric systems, only triplets where
any chain forms at least one Cα contact (Cα – Cα < 5.5 A˚) with another chain were considered.
β-Aggregation propensity differences (∆β = ‖β3rep−β6rep‖ ) shown as gray bars with y-axis legend
on the right highlight the largest discrepancies.
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FIG. S3: Aβ42: β-Aggregation propensity profiles as a function of temperature from REMD sim-
ulations of trimeric systems (11-residue peptide segments, Table S2 in Supplementary Material).
Stretches with high β-aggregation propensity at physiological temperature values are highlighted
by solid lines. The segment identification numbers, which are reported in the vertical panel on the
left, correspond to the position of the central residue in the Aβ42 full-length sequence.
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FIG. S4: Analysis of dependence on the length of the segments considered along the Aβ42 se-
quence. β-Aggregation (top) and β-sheet structure (bottom) propensities have been extracted
from 330 K MD trajectories of trimeric 7-residue (red) and 11-residue (blue) peptide systems. To
allow for a direct comparison, β-aggregation and β-sheet structure propensities extracted from
the 11-residue segment simulations have been computed by considering only 7-residue substretches
(e.g., D1AEFRHD7, E3FRHDSG9 and R5HDSGYE11 from D1AEFRHDSGYE11).
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FIG. S5: Secondary structure histograms over REMD trajectory segments at 306 K for six Aβ42
11-residue central stretches. Green, blue, red and cyan dots correspond to α-helical, β-strand, β-
turn or bend and random coil content, respectively. The histograms highlight an α-helical/β-strand
competition in the central region of the Aβ42 sequence.
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FIG. S6: Average P2 values computed from explicit solvent trajectories started from parallel β-
sheet conformations observed in implicit solvent runs for four Aβ42 7-residue stretches: Aβ1−7
(red), Aβ5−11 (magenta), Aβ13−19 (green), and Aβ29−35 (blue). From left to right, the data points
represent average values taken at time intervals of growing length: 0.002, 1, 2, 5, 10, 20, 30, and
50 ns.
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Chapter 8
Conclusions
The relevance of computational studies in structural biology and their com-
plementarity to in vitro biochemical experiments are today unquestionable.
Although limited by non negligible statistical and systematic errors, com-
puter simulations provide the ultimate detail concerning individual atom
motion as a function of time, which are not accessible from a sample in
a test tube. This detail can be used to describe the complete free-energy
surface of individual proteins, which in the “new view” of protein folding
represents the link between protein sequence and biological activity. In
spite of continuous experimental progress this information is not available
for any protein yet. Only the synergy between experimental and computa-
tional strategies can supply the description at the desired level of resolution.
Computational approaches to simulate the behavior of model proteins at
atomic resolution, called in silico experiments, must then be invoked. In
silico experiments consist of three stages: (i) methodological development
to solve particular problems; (ii) test-case application and comparison with
available experimental data; and (iii) blind application for biological pre-
dictions. Following this paradigm, effective protocols can be designed to
investigate difficult biological problems. In this thesis two in silico experi-
ments have been presented: molecular docking for drug discovery and amy-
loid peptide aggregation. In the former, the in-house automatic approach
for molecular docking has been improved, validated and successfully applied
in a virtual screening project against β-secretase. In the latter, a novel
molecular dynamics approach to investigate the aggregation properties of
amyloid proteins has been developed. In agreement with experimental data,
the strategy predicted the position dependence of β-aggregation propensity
along the Alzheimer’s peptide sequence.
The results reported in the thesis claim that in silico experiments for
difficult problems, such as docking and amyloid peptide aggregation, can
be successfully designed. An increasing role of computational studies in
the understanding of complex biological processes is expected in the near
future. Following the paradigm of the in silico experiment, molecular details
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of abnormal processes associated to severe pathologies can be elucidated and
efficient strategies for treating or even preventing such pathologies rationally
developed.
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